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 Abstract 
During mitosis, accurate chromosome segregation is essential: gain or loss of genetic 
information can be detrimental to cell viability, or promote tumourigenesis.  The mitotic 
checkpoint (also known as the spindle assembly checkpoint or SAC) ensures accurate 
chromosome segregation by delaying cell cycle progression until accuracy can be 
guaranteed.  Mps1 is a protein kinase that is crucial for mitotic checkpoint signalling and 
also for proper chromosome alignment at metaphase.  However, the precise role of Mps1’s 
catalytic activity is still unclear.  Here, I present AZ3146, a novel small molecule inhibitor 
of Mps1.  AZ3146 inhibits recombinant Mps1 in vitro with an IC50 of ~35 nM, and has low 
activity against a panel of 50 kinases, suggesting a good degree of selectivity.  As 
predicted for an Mps1 inhibitor, AZ1346 treatment led to spindle checkpoint malfunction 
in cells, accelerated mitotic timing, and perturbed the kinetochore localisation of the 
checkpoint effector Mad2.  AZ3146 has a negative effect on cell viability, suggesting it 
leads to detrimental missegregations.  Thus, the cellular effects of AZ3146 are consistent 
with Mps1 inhibition, and I was able to use the compound confidently as a tool to further 
probe the role of Mps1 activity in cells. 
Strikingly, levels of Mps1 increased at unattached kinetochores following inhibition 
of its kinase activity, suggesting Mps1’s kinetochore localisation is regulated by its own 
activity.  A kinase-dead GFP-Mps1 fusion protein only accumulated at kinetochores in the 
absence of endogenous, active Mps1, implicating intra-molecular interactions in regulation 
of Mps1’s kinetochore localisation.  I confirm a role for Mps1 in the mechanism of 
chromosome alignment, but in contrast to previous reports I did not detect a decrease in 
Aurora B activity following Mps1 inhibition.  On the contrary, both Mps1’s 
phosphorylation status and its kinetochore localisation were affected by treatment with the 
Aurora B inhibitor ZM447439, placing Mps1 downstream of Aurora B.  As an alternative 
explanation for the alignment defect in cells with reduced Mps1 activity, I found that levels 
of the plus-end directed kinesin Cenp-E were markedly decreased at unaligned 
kinetochores.  I propose a model in which catalytically active Mps1’s auto-release from 
kinetochores simultaneously promotes both mitotic checkpoint signalling and chromosome 
alignment by facilitating Mad2 dimerisation and Cenp-E binding at unattached 
kinetochores. 
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 1 | Introduction 
Successful progression through the cell cycle requires control mechanisms.  Protein 
phosphorylation controls many aspects of cell biology, and some 518 protein kinases are 
present in the human kinome (Manning et al., 2002).  Many of these are implicated in 
control of cell cycle progression.  This thesis focuses one of these kinases: Mps1 
(Monopolar Spindle 1) (Weiss and Winey, 1996).  Mps1 is involved in regulation of the 
mitotic checkpoint (otherwise known as the spindle assembly checkpoint or SAC), a 
critical control mechanism that ensures the genome is partitioned equally between the two 
new daughter cells during cell division.  This introduction will firstly place Mps1’s role in 
context by describing mitosis and its control, focusing on the mitotic checkpoint (otherwise 
known as the spindle assembly checkpoint), which controls anaphase onset, and the 
relationship between the mitotic checkpoint, aneuploidy and cancer.  I will also outline the 
mechanism of chromosome alignment, the roles that kinases play in regulating all of these 
processes, and our current understanding of Mps1’s role in mitosis. 
1.1 | Mitosis – a brief synopsis 
Mitosis, during which the cell divides to produce two new, genetically identical 
daughter cells, is the final stage of the mammalian cell cycle (see Figure 1.1), and could be 
called the most visually spectacular.  Perhaps partly for this reason, it has been a source of 
intense fascination for scientists since the advent of microscopy allowed it to be observed.  
The term mitosis was coined by Walther Flemming (Flemming, 1882), an important figure 
in the newly emerging field of cell biology (reviewed in Paweletz, 2001).  Flemming made 
detailed drawings and classified cells as they progressed through mitosis, identified the 
‘chromatin’ by its propensity to take up dyes, and noted the formation of ‘thread-like’ 
structures which were divided between the two daughter cells; these were later individually 
called ‘chromosomes’ by Heinrich Waldeyer in 1888.  These observations eclipsed the 
theory of de novo ‘free cell formation’ that had previously found favour among his 
contemporaries, and formed the basis for the study of mitosis as we know it today. 
Thanks to more than 120 years of research, we now have a much fuller 
understanding of the process of mitosis.  However, mitosis is still commonly split into six 
distinct phases based largely on cell morphology visible to the early cell biologists  
10
The Cell Cycle
G1
S
G2
M
Figure 1.1 The eukaryotic cell cycle
In somatic cells, the cell cycle comprises 4 distinct stages: Gap phase 1 (G1), DNA synthesis phase (S) dur-
ing which the genome is replicated, Gap phase 2 (G2) and mitosis (M), when the cell divides and the
genome is partitioned between two daughter cells. Phases G1, S and G2 are also collectively known as
interphase.
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 (reviewed in Pines and Rieder, 2001; Scholey et al., 2003), which are illustrated in Figure 
1.2.  After duplicating that genetic material and centrosomes (microtubule organising 
centres that will become the poles of the mitotic spindle; called spindle pole bodies [SPBs] 
in yeast) in the preceding DNA synthesis phase (S phase), a cell proceeds through Gap 
Phase 2 (G2) and, if the DNA is properly replicated, enters the first stage of mitosis, 
prophase.  In prophase, the chromosomes (consisting of two identical chromatids) 
condense, the centrosomes begin to separate and move towards opposite ends of the cell, 
and the nuclear envelope fragments.  It is during mid-prophase that the cell becomes 
irreversibly committed to mitosis (Pines and Rieder, 2001).  Higher eukaryotes undergo an 
open mitosis, in which the nuclear envelope disintegrates early in mitosis, whereas in fungi 
the nuclear envelope remains intact throughout (De Souza and Osmani, 2007).  In higher 
eukaryotes, nuclear envelope breakdown signals the beginning of prometaphase.  The 
bipolar spindle forms, and chromosomes can now make contact with its microtubules.  
Stable attachments form between the microtubules and the kinetochore, a specialised 
proteinaceous structure that forms adjacent to the centromeric DNA on each paired 
chromatid.  When all chromosomes have become stably attached, via the kinetochore, to 
microtubules emanating from both spindle poles (biorientation), and aligned at the cell 
equator forming a so-called ‘plate’ of DNA, metaphase is reached.  After a brief delay, 
anaphase is initiated, and the sister chromatids are pulled apart towards opposite spindle 
poles, which also move further apart.  In telophase, the nuclear envelope reforms around 
the decondensing segregated chromatids, and the cleavage furrow begins to ingress, 
constricting the spindle midzone.  After telophase, as mitosis ends, cytokinesis occurs.  
This process enables partitioning of the cytoplasm into two daughters and their subsequent 
physical separation. 
1.2 | Regulation of mitosis: Cdk1 as the master regulator 
Progression through the cell cycle must be controlled to ensure the correct event 
sequence.  To achieve this, eukaryotic cells have evolved molecular control mechanisms 
involving posttranslational modification and targeted degradation.  The master regulators 
of the eukaryotic cell cycle are the cyclin-dependent kinases (Cdks), whose activity 
oscillates during the cell cycle due to a dependence upon association with their regulatory 
subunits, cyclins.  Cyclin levels are regulated by transcription and proteasome-dependent 
degradation throughout the cell cycle, so that different cyclin/Cdk pairings are active at 
specific points.  Phosphorylation of cyclin/Cdk substrates regulates the major events in, 
and passage through, mitosis and interphase (Vermeulen et al., 2003).  In budding yeast, 
only one Cdk binds to all types of cyclin, whereas in vertebrate cells, there are 4 Cdks 
involved in cell cycle regulation. 
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Interphase (G2)
1.Prophase
2.Prometa-
phase
3.Metaphase 4.Anaphase
5.Telophase
6.Cytokinesis
Interphase (G1)
S phase
Figure 1.2 Mitosis in a higher eukaryotic cell
This schematic depicts the phases of mitosis in the context of the metazoan cell cycle. The 6 phases of mito-
sis, as determined by cell morphology, are labelled in red. A G2 cell enters mitosis having replicated its
genome (giving it a 4N complement of chromosomes) and its centrosome. In prophase, the first phase of
mitosis, the chromatin condenses, the kinetochores mature adjacent to the centromeres, the nuclear envelope
begins to break down, and the two centrosomes, which will become the poles of the mitotic spindle, move
apart. Prometaphase begins after nuclear envelope breakdown (NEB). The bipolar mitotic spindle forms,
and its dynamic microtubules capture the chromosomes through a stochastic process. Metaphase is reached
when all chromosomes are attached, via the kinetochores, to microtubules emanating from both poles of the
spindle (biorientation). Chromosomes form a metaphase plate at the cell equator. After a brief metaphase
delay, anaphase is initiated. Sister chromatids are separated by the action of the mitotic spindle and move
toward opposite spindle poles. The spindle poles themselves also move further apart. In telophase, the
nuclear envelope reforms around the decondensing segregated chromatin. The cleavage furrow begins to
ingress through contraction of the actomyosin contractile ring, constricting the spindle mid-zone. In
cytokinesis, the cytoplasm is partitioned into the two new daughter cells, which then separate completely.
After mitosis, cells enter G1 phase of the next cell cycle. Cycling cells will then replicate their DNA and re-
enter G2, before dividing again.
Cytoplasm
Nuclear membrane
Nucleus
Plasma membrane
Centrosome
Microtubule
Chromosome
Kinetochore region
2N4N
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In vertebrate cells, the initiation of mitosis is thought to be triggered by Cdk2/cyclin 
A activity (De Boer et al., 2008; Furuno et al., 1999).  Cdk2/cyclin A activity declines as 
cyclin A is degraded after nuclear envelope breakdown (NEBD) (den Elzen and Pines, 
2001; Wolthuis et al., 2008).  During late G2/early mitosis, Cdk2/cyclin A promotes the 
accumulation and activity of Cdk1/cyclin B, the major mitotic cyclin/Cdk pairing 
(Lindqvist et al., 2009).  The activity of Cdk1/cyclin B is essential for mitotic progression: 
a substantial increase in its activity represents a point-of-no-return for the cell (Pines and 
Rieder, 2001).  Cdk1 is active from prophase until metaphase, at which point the mitotic 
checkpoint is silenced and cyclin B is targeted for destruction by the proteasome (see 
Section 1.4).  Multiple feedback loops govern Cdk1/cyclin B activity, ensuring its rapid 
activation in early mitosis, and subsequent deactivation (reviewed in Lindqvist et al., 
2009), which is necessary for anaphase onset and mitotic exit.  Using a Förster resonance 
energy transfer  (FRET) sensor to monitor the net amount of Cdk1/cyclinB substrate 
phosphorylation in living cells, Gavet and colleagues (2010b) showed that Cdk1/cyclin B 
is activated in prophase, and reaches maximal activity shortly after NEBD.  Its substrates 
remain maximally phosphorylated through prometaphase and metaphase until anaphase 
onset, when they are rapidly dephosphorylated (Gavet and Pines, 2010b).  In anaphase, 
phosphatase activity is critical to remove phosphates from Cdk1/cyclin B’s substrates and 
facilitate mitotic exit: in yeast, this function is carried out by Cdc14 (Amon, 2008), and in 
human cells, a probable candidate for the job is protein phosphatase 1 (PP1) (Gavet and 
Pines, 2010b; reviewed in Queralt and Uhlmann, 2008; Wu et al., 2009), which itself is 
phosphorylated and kept inactive by Cdk1 before anaphase onset (Dohadwala et al., 1994; 
Kwon et al., 1997; Wu et al., 2009). 
Cdk1/cyclin B activity is both temporally and spatially regulated: just prior to 
nuclear envelope breakdown (NEBD) it is transported from the cytoplasm into the nucleus 
(Pines and Hunter, 1991).  The increase in the rate of Cdk1/cyclin B import into the 
nucleus is dependent upon its continual activity, which is thought to mediate an increase in 
the rate of nuclear import, by an as yet undetermined mechanism (Gavet and Pines, 2010a).  
Cdk1/cyclin B phosphorylates numerous substrates in mitotic cells, both cytoplasmic and 
nuclear.  Some of Cdk1/cyclin B’s substrates are involved in orchestrating the massive 
cellular rearrangements seen in mitosis.  For example, in prophase, Cdk1/cyclin B 
activation triggers cell rounding and centrosome separation, likely by phosphorylation of 
cytoskeletal components (Gavet and Pines, 2010b).  As well as the cytoskeleton, 
Cdk1/cyclin B is known to phosphorylate components of the Golgi apparatus (e.g. Lowe et 
al., 1998), the nucleolus (Peter et al., 1990a; Sirri et al., 2002), nuclear lamins (Peter et al., 
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 1990b; Ward and Kirschner, 1990) caspases (Allan and Clarke, 2007), and amongst many 
others.  Numerous mitotic Cdk1 substrates have been identified on purified mitotic 
spindles (Nousiainen et al., 2006), in whole cell lysates (Dephoure et al., 2008) or by 
covalent capture of labelled substrates (Blethrow et al., 2008).  Many of these substrates 
are uncharacterised candidates, and suggest many as-yet unknown roles for Cdk1 
phosphorylation in the coordination of mitotic events. 
To drive human cells into and through mitosis, Cdk1/cyclin B functions in 
combination with several other mitotic kinases, including Aurora A and Plk1.  Aurora A, a 
centrosomal serine/threonine kinase, promotes centrosome maturation and timely 
progression of early mitosis by contributing to Cdk1/cyclin B localisation and its full 
activity, and also promotes formation of a functional, bipolar mitotic spindle (reviewed in 
Barr and Gergely, 2007).  Polo-like kinase 1 (Plk1), a serine/threonine kinase with multiple 
mitotic functions, also promotes progression through early mitosis, perhaps by 
participating in Cdk1/Cyclin B activation feedback loops (Lindqvist et al., 2009), or, as has 
been recently suggested, by promoting mitotic entry upstream of Cdk1/cyclin B activation 
(Gavet and Pines, 2010b).  Plk1 also has a role in centrosome maturation and participates 
in cytokinesis, promoting contraction of the actomyosin contractile ring by activating Rho 
GTPase (reviewed in Archambault and Glover, 2009; Petronczki et al., 2008).  The role of 
Plk1 at the kinetochore is discussed in Section 1.7. 
1.3 | Ubiquitin-mediated proteolysis: regulating the regulators 
The rapid, targeted proteolysis of mitotic regulators including cyclin A, cyclin B, 
Aurora A and Plk1 is critical to drive the orderly progression of events from prometaphase 
to mitotic exit (Pines, 2006).  This targeted proteolysis is achieved by the ubiquitin-
proteasome system (Hershko and Ciechanover, 1998).  Proteins tagged with polyubiquitin 
chains (covalently linked molecules of a small protein, ubiquitin) are recognised and 
selectively degraded by the constitutively active 26S proteasome, a multisubunit protease.  
Ubiquitinylation requires a chain of 3 enzymes: a ubiquitin-activating enzyme (E1); a 
ubiquitin-conjugating enzyme (E2) and finally a ubiquitin ligase (E3), which is responsible 
for targeting of specific proteins for degradation.  The E3 enzyme active in mitosis is 
called the anaphase-promoting complex/cyclosome (APC/C).  The APC/C is a very large, 
megadalton multisubunit complex that requires a co-activator to simultaneously activate 
the enzyme and convey substrate specificity (Peters, 2006).  APC/C substrates are 
recruited to the complex via the co-activator subunit if they contain either a destruction-
box (D-box) or a KEN-box motif.  In mitosis, the APC/C associates with 2 different co-
activators, Cdc20 and Cdh1.  Pre-anaphase degradation depends upon APC/CCdc20, since 
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 Cdk1 phosphorylation stimulates Cdc20 binding to the APC/C (Kraft et al., 2003), and also 
prevents Cdh1 and APC/C from interacting (Crasta et al., 2008; Zachariae et al., 1998).   
Recent advances have explained a previously puzzling paradox concerning pre-
anaphase, APC/CCdc20-mediated degradation of cyclin A.  It is well accepted that primary 
target of the mitotic checkpoint is the APC/CCdc20.  The checkpoint delays anaphase onset 
by preventing APC/CCdc20-mediated degradation of securin and cyclin B during 
prometaphase (for detail of the checkpoint mechanism, see below).  The Cdc20-dependent, 
but not mitotic checkpoint-dependent, degradation of cyclin A from NEBD has now been 
explained by the discovery of a novel, checkpoint-independent mode of APC/CCdc20 
substrate recognition.  Cyclin A is degraded through interaction of cyclin A, Cdc20 and a 
Cdk1/cyclin B accessory unit, Cks, and is recruited to the APC/C before checkpoint 
activation (Wolthuis et al., 2008).  Thus, though the APC/CCdc20 is kept inactive in 
prometaphase towards specific substrates by the mitotic checkpoint, it is still active 
towards cyclin A, the degradation of which is necessary for mitotic progression.   
1.4 | Control of anaphase onset 
1.4.1 | The mitotic checkpoint 
Regulation of the APC/CCdc20 is critical to ensure the correct timing of anaphase.  In 
prometaphase, each pair of sister chromatids must become attached, via the kinetochore, to 
microtubules emanating from both spindle poles.  Biorientation ensures that at anaphase, 
the chromatids are evenly split between the two daughters.  The process of kinetochore-
microtubule attachment is stochastic: it depends upon random chance encounters between 
the dynamic microtubules of the mitotic spindle and the kinetochore, and while cells have 
evolved ways of increasing the likelihood of stable kinetochore-microtubule attachment 
formation (see Section 1.6), the nature of the process means that the duration of 
prometaphase can vary from cell to cell (Rieder et al., 1994).  In order to prevent 
chromosome loss or gain due to the premature initiation of anaphase before all 
chromosomes are properly aligned and bioriented on a metaphase plate, cells employ the 
mitotic checkpoint.  The checkpoint is a surveillance mechanism that is active from 
prometaphase until the last chromosome is correctly attached and aligned at the metaphase 
plate (Rieder et al., 1995).  The target of checkpoint signalling is widely accepted to be the 
APC/CCdc20: more specifically, its ubiquitination of cyclin B and securin (for review, see 
Musacchio and Salmon, 2007; Zich and Hardwick, 2010).  The active mitotic checkpoint 
prevents the polyubiquitination and subsequent proteasome-dependent degradation of 
cyclin B and securin (see Figure 1.3). 
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Figure 1.3 The Mitotic Checkpoint
During prometaphase, checkpoint proteins concentrate at the kinetochores (red circles), and unattached kine-
tochores produce a ‘wait anaphase’ signal. This results in inhibition of the E3 ubiquitin ligase activity of the
APC/C towards cyclin B and securin, and therefore maintains high Cdk1 activity, and inhibits separase’s pro-
tease activity. Only when all chromosomes are bioriented and aligned at the metaphase plate is the mitotic
checkpoint satisfied. The ‘wait anaphase’ signal is silenced, allowing the APC/CCdc20 to target both cyclin B
and securin for proteasome-mediated degradation. Active separase cleaves the cohesins holding sister
chromatids together, and Cdk1 is inactivated, triggering anaphase onset and mitotic exit.
An
ap
ha
se
Cd
k1 CycB
Active Cdk1
Separase
Securin
Inactive Separase
Inactive APC/CCdc20
Mad1, Mad2,
Bub1, BubR1,
Bub3, Mps1,
Cenp-E
Checkpoint
satisfied APC/C
Active APC/CCdc20
Securin
Cyc
B
Ub
Ub
Ub
Ub
Ub
Ub
Protea
-some
Separase
Active Separase
Inactive Cdk1
(+ active
phosphatases)
Cohesin
cleavage
Mitotic
exit
Cdc20
17
  
1.4.2 | The checkpoint prevents destruction of cyclin B and securin 
Cyclin B is the activating partner of Cdk1.  High Cdk1 activity facilitates progression 
through prophase and prometaphase, and its targets must be dephosphorylated to promote 
anaphase, telophase, cytokinesis and mitotic exit.  Seminal work in Xenopus egg extracts 
pointed to the importance of the fall in cyclin levels in regulating mitotic exit in the 
embryonic cell cycle (Murray and Kirschner, 1989); moreover, Murray and colleagues 
showed that a proteolysis-resistant mutant form of cyclin B (CYCΔ90) prevented mitotic 
exit in cycling egg extracts and intact eggs (Glotzer et al., 1991; Murray et al., 1989).  
Later, Holloway et al (1993) discovered that non-destructible cyclin B did not prevent the 
chromatids from separating, though they did not decondense: this, along with the discovery 
that inhibition of ubiquitin-mediated proteolysis could stop chromatid disjunction, clearly 
indicated that at least one other protein, in addition to cyclin B, must be degraded to allow 
chromatids to separate at anaphase.  Studies in yeast identified Securin as an inhibitor of a 
protease called separase, which is required to cleave the mediators of chromatid cohesion, 
cohesins (reviewed in Nasmyth, 2002).  During prophase, cohesion dissolves along the 
length of the chromosome arms via a mechanism thought to involve phosphorylation by 
Plk1 (Hauf et al., 2005; Sumara et al., 2002), but centromeric cohesion is resistant to 
prophase removal.  Separase-mediated cohesin cleavage is necessary for resolution of the 
sister chromatids at anaphase.  By targeting both Cyclin B and securin, the checkpoint 
maintains the early mitotic environment until all chromosomes are aligned, and ensures 
anaphase spindle behaviour and chromatid disjunction are perfectly synchronised, thereby 
promoting accurate DNA segregation and the production of viable, genetically identical 
diploid daughters.   
1.4.3 | Components of the checkpoint 
Several decades before the molecular targets of the mitotic checkpoint were 
discovered, microtubule disruption by treatment with drugs such as colcemid (which 
depolymerises tubulin) was understood to block cells in mitosis through damage to the 
mitotic spindle (reviewed in Rieder and Palazzo, 1992).  Checkpoint mechanisms, which 
were thought to govern progression through mitosis (e.g. Hartwell and Weinert, 1989), 
were considered likely to mediate this mitotic block.  In the early 1990s, genetic analysis 
of mutant budding yeast strains that failed to arrest in mitosis after treatment with 
benzimidizole (another microtubule depolymerising agent) identified three genes, named 
the budding uninhibited by benzimidizole (BUB1-3) genes (Hoyt et al., 1991; Roberts et 
al., 1994).  A parallel study identified three mitotic arrest deficient (MAD1-3) genes by 
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 similar methods (Li and Murray, 1991).  It later became evident that Bub2 was part of the 
budding yeast mitotic exit network (MEN, Wang et al., 2000), but Bub1, Bub3, Mad1, 
Mad2 and Mad3 (or BubR1 in humans), along with Mps1 (Weiss and Winey, 1996), are 
considered core components of the checkpoint (e.g. May and Hardwick, 2006; Taylor et 
al., 2004).  Both Bub1 and Mps1 are protein kinases in lower and higher eukaryotes 
(Abrieu et al., 2001; Lauze et al., 1995; Mills et al., 1992; Roberts et al., 1994; Taylor et 
al., 1998; Taylor and McKeon, 1997), whereas Mad1 and Mad2 do not possess enzymatic 
activity (Li and Murray, 1991).  In human cells, Mad3 has no known homologue.  
However, human cells contain BubR1, a kinase related to both Saccharomyces cerevisiae 
Bub1 and Mad3, which requires binding to non-enzymatic Bub3 to localise it to 
kinetochores (Taylor et al., 1998).   
In addition to these original checkpoint proteins, several new regulators of the 
checkpoint have been identified.  Some of these have no obvious homologues in yeast, 
pointing to the additional complexity of the mitotic checkpoint in higher eukaryotes.  Such 
proteins include Rod and Zeste-white 10 (ZW-10), part of the Rod-ZW10-Zwilch (RZZ) 
complex, which was first described in Drosophila melanogaster and is conserved in 
humans (Basto et al., 2000; Chan et al., 2000; reviewed in Karess, 2005; Williams et al., 
2003).  The RZZ complex is required for Mad1 and Mad2 to localise to kinetochores 
(Buffin et al., 2005; Kops et al., 2005) and is therefore important for checkpoint function 
(see below).  In addition, the kinetochore microtubule motor Cenp-E may play a role in 
checkpoint signalling in vertebrates (Mao et al., 2003).  Aurora B, a mitotic kinase, may 
also have a direct role in the mitotic checkpoint in yeast and higher eukaryotes (see Section 
1.4.8). 
1.4.4 | The kinetochore and checkpoint signalling 
Kinetochores are specialised proteinaceous structures which assemble at the 
beginning of mitosis adjacent to the centromeric DNA.  Kinetochores form the point of 
attachment for microtubules of the mitotic spindle, and their ultrastructure has long been 
the subject of study (e.g. Jokelainen, 1967).  Electron microscopy on samples from cells 
treated with a microtubule-depolymerising drug showed that unattached kinetochores have 
a fibrous outer corona region extending away from the outer plate (Dong et al., 2007; 
McEwen et al., 1998).  The outer plate undergoes rearrangement on contact with 
microtubules, and is directly connected to an inner kinetochore region, which contacts the 
chromatin (see Figure 1.4). 
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Figure 1.4 The vertebrate centromere and kinetochore region.
On the left is a mitotic chromosome, with one unattached kinetochore (left) and one attached kinetochore
(right). When visualised by electron microscopy, the centromere and kinetochore region appears as illustrat-
ed in the schematic. The inner centromere is the region of DNA (and associated proteins) between the two
kinetochores. The inner kinetochore (orange) contacts the centromeric DNA, and the outer kinetochore (red)
forms adjacent to it and provides binding sites for microtubules (MTs). The unattached kinetochore has a
clearly visible fibrous corona, where checkpoint proteins and kinetochore-associated motor proteins localise.
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The trilaminar ultrastructure of the proteinaceous kinetochore region appears to 
reflect functionally distinct regions. The inner kinetochore region contains proteins that 
associate constitutively with the centromeric DNA, such as the histone variant Cenp-A 
(abbreviated from centromeric protein A), which forms the nucleosomes at centromeres 
and is critical for kinetochore specification in higher eukaryotes (Foltz et al., 2006).  In 
vertebrates, Cenp-A associates with 13 other proteins (Cenp-H, Cenp-I and Cenp-K to 
Cenp-U) collectively known as the constitutive centromere-associated network (CCAN) 
(Cheeseman and Desai, 2008).  The proteins of the inner kinetochore region form the 
platform for outer kinetochore assembly.  The outer kinetochore region contains a 
conserved multisubunit complex known as the KNL network (KNL1-Mis12 complex-
Ndc80/Hec1 complex) and Zwint.  This region (specifically the Ndc80/Hec1 complex) 
forms the primary binding site for spindle microtubules (Cheeseman et al., 2006; DeLuca 
et al., 2006; Guimaraes et al., 2008) and also provides binding sites for constituents of the 
outermost kinetochore region, the fibrous corona.  This is where core checkpoint signalling 
molecules are enriched, including the Mads, Bubs, and Mps1.  It also contains the RZZ 
complex, Cenp-F, and the kinetochore-based motor proteins Cenp-E and Dynein-dynactin 
(Musacchio and Salmon, 2007).   
The link between the kinetochore and mitotic checkpoint signalling was strengthened 
by elegant experiments in cultured marsupial Potoroo tridactylis kidney cells (Ptk1 cells).  
Rieder and colleagues filmed cells going through mitosis and noted that cells delayed 
anaphase until the last chromosome became bioriented and congressed to the metaphase 
plate (1994).  Furthermore, a subsequent report showed that laser ablation of the last 
remaining unattached kinetochore in a prometaphase cell allowed anaphase to commence 
in the presence of the laser-ablated unaligned chromosome, leading the authors to conclude 
that the unattached kinetochore must have been creating a diffusible signal to restrain 
anaphase (Rieder et al., 1995).   
The localisation of all vertebrate checkpoint proteins to the kinetochore in mitosis, 
and the depletion of these proteins from kinetochores after biorientation further supported 
a key role for this structure (Chen et al., 1998; Chen et al., 1996; Li and Benezra, 1996; 
Taylor et al., 1998; Taylor and McKeon, 1997).  Furthermore, the vertebrate proteins 
Bub1, BubR1 and Mps1 are all kinases (Abrieu et al., 2001; Mills et al., 1992; Taylor et 
al., 1998; Taylor and McKeon, 1997), making these enzymes candidates for production of 
the diffusible checkpoint signal via a phosphorylation signalling cascade.  Kinetochores 
were already known to contain phosphorylated species: a study using an antibody towards 
an unknown phosphoepitope (known as 3f3/2) reported kinetochore staining in PtK1 cells 
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 (Gorbsky and Ricketts, 1993).  Gorbsky and Ricketts (1993) showed that not only did this 
antibody stain kinetochores in a phosphorylation-dependent manner, but it preferentially 
stained the kinetochores of unaligned chromosomes, suggesting these chromosomes were 
more highly phosphorylated compared to those that had already achieved biorientation.  
While we now know more about the kinases contributing to kinetochore phosphorylation 
(e.g. those discussed in Section 1.7), the precise molecular details are far from being fully 
understood.   
1.4.5 | Inhibition of the APC/C by mitotic checkpoint complexes 
A great deal of effort has been focused on understanding how the checkpoint 
prevents anaphase onset by inhibiting APC/CCdc20.  Early observations showed that Mad2 
was associated with the APC/C in mitotic HeLa cells, and could inhibit cyclin B 
ubiquitination in Xenopus egg extracts (Li et al., 1997), suggesting Mad2 might mediate 
the checkpoint’s effect by directly inhibiting the activation of APC/CCdc20.  A recombinant 
tetrameric form of human Mad2 was subsequently shown to bind directly to Cdc20 and 
inhibit APC/C activity in vitro (Fang et al., 1998), giving rise to the idea that Mad2 is a 
downstream effector of the mitotic checkpoint signalling network.  Furthermore, if the 
interaction between Cdc20 and Mad2 was perturbed in budding or fission yeast, cells lost 
checkpoint function (Hwang et al., 1998; Kim et al., 1998).  A similar role was also 
described for BubR1: BubR1 and Bub3 co-purified with Cdc20 from mitotic HeLa cell 
extracts could inhibit APC/C in vitro at approximately physiological concentrations 
independent of its kinase activity, making it a more potent inhibitor than tetrameric Mad2 
(Fang, 2002; Tang et al., 2001).  The binding of Mad2 and BubR1 to Cdc20, the APC/C 
coactivator, suggested the checkpoint may function by simply sequestering the coactivator 
away from APC/C and thereby preventing it from ubiquitinating securin and cyclin B. 
An important study by Sudakin and co-workers (2001) identified and named the 
mitotic checkpoint complex (MCC), which comprised Mad2, Bub3, BubR1 and Cdc20.  
This complex, which was isolated from mitotic HeLa cells, potently inhibited the APC/C.  
Biochemical analysis has indicated that the MCC can exist alone or bound to the APC/C 
itself (Morrow et al., 2005; Sudakin et al., 2001).  The structure of the human APC/C in 
complex with the entire MCC has been reported (Herzog et al., 2009), providing 
confirmation that the MCC can directly inhibit APC/C, rather than simply sequestering 
Cdc20.  This is in agreement with data from S. cerevisiae showing that Mad3 (related to 
BubR1) is a pseudo-substrate inhibitor of the APC/C (Burton and Solomon, 2007), 
meaning it is recognised by APC/CCdc20 and binds tightly, precluding the ubiquitination of 
true substrates. 
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 A recent study by Kulukian and colleagues (Kulukian et al., 2009) also provided 
evidence against simple sequestration.  The authors reconstituted a system of checkpoint-
mediated APC/C inhibition by using purified chromosomes as a source of unattached 
kinetochores, plus purified checkpoint components.  This provided a highly manipulable 
system for analysis of the level of APC/C inhibition produced under different conditions.  
Kulukian et al found that unattached kinetochores had a catalytic effect on the production 
of an APC/C inhibitor from purified checkpoint proteins.  This inhibitor could be formed 
by preincubation of Bub3, BubR1, Mad2, and Cdc20 with chromosomes, followed by 
incubation of this mixture with APC/C.  Importantly, it could also equally effectively 
inhibit APC/C with Cdc20 pre-bound compared to APC/C without Cdc20, demonstrating 
non-sequestration mediated inhibition, in keeping with previous reports (Morrow et al., 
2005; Sudakin et al., 2001).  Notably, Kulukian et al (2008) did not find evidence to 
support the existence of an true MCC consisting of Bub3-BubR1, Mad2 and Cdc20 as 
others have reported: rather, the authors showed by size-exclusion chromatography of 
inhibitor-containing complexes that the majority of Cdc20 was bound to BubR1-Bub3, 
with very little Mad2 present (Kulukian et al., 2009), in keeping with a previous report 
(Nilsson et al., 2008).  The quaternary MCC may exist as a transient intermediate.  
Importantly however, Mad2 is a critical regulator of first steps of kinetochore mediated 
checkpoint signalling – see description of the Mad2 template model in Section 1.4.6. 
Since a single unattached kinetochore can sustain anaphase arrest, the checkpoint-
derived inhibitor has always been thought to be diffusible, at least within the spindle 
vicinity (Rieder et al., 1997).  Kulukian et al (2009) presented evidence that unattached 
kinetochores can indeed create a soluble, diffusible inhibitor of the APC/C: removal of 
chromosomes after inhibition with Bub3, BubR1, Mad2 and Cdc20 resulted in the 
production of an equally effective APC/C inhibitor as when the chromosomes were left in.  
Taken together with the above data, this implies that the checkpoint is capable of inhibition 
of APC/CCdc20 directly, and also by production of a soluble inhibitor complex.  This 
soluble inhibitor may function partly by sequestering Cdc20, since APC/C without any 
bound coactivator has been shown to exist in cells with an active checkpoint (Herzog et al., 
2009).  However, evidence suggests that an APC/C-bound pseudosubstrate-like inhibitor is 
an important product of mitotic checkpoint signalling.  Interestingly, Cdc20’s 
ubiquitination (via APC/C) and degradation has been shown to be required for checkpoint 
activity, adding another facet to the function of the Cdc20-containing inhibitory complex 
(Nilsson et al., 2008).   
This section has summarised current ideas regarding the identity of the APC/C 
inhibitor, the end-point of mitotic checkpoint signalling.  As detailed earlier, the 
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 kinetochore, where all checkpoint components localise, is considered important for 
checkpoint signalling to create this APC/C inhibitor, which is likely to comprise BubR1, 
Bub3 and Cdc20, with or without Mad2.  The following section will address the role of 
kinetochores as catalytic platforms for checkpoint signal generation. 
1.4.6 | The Mad2 template model 
A kinetochore-based model for checkpoint signalling has developed, built on several 
years’ worth of biochemical, structural and cell-based data.  In this model, the kinetochore 
provides a catalytic scaffold for production of an APC/C inhibitor.  Fixed-cell analysis had 
shown that Mad2 localised to unattached kinetochores produced by treatment with the 
microtubule-depolymerising agent nocodazole (Chen et al., 1996; Waters et al., 1998).  
Subsequently, Howell and colleagues (2000) made a key observation in the development 
of the kinetochore-based signalling theory: they found that Mad2 is not stable at 
unattached kinetochores, but dynamic.  This important observation helped firmly establish 
the idea that kinetochores somehow signalled their lack of proper attachment to the cytosol 
via Mad2.  In subsequent studies, Cdc20, BubR1, Bub3 and Mps1 were also found to flux 
on and off unattached kinetochores, whereas Mad1 and Bub1 were relatively stable 
components (Howell et al., 2004; Shah et al., 2004).  Thus, all components of the MCC 
(plus Mps1) cycle on and off kinetochores, strengthening the idea that the kinetochore 
functions as a catalytic platform. 
An intriguing observation was made during the analysis of Mad2 dynamics.  Mad2 
apparently existed in two separate, equally-sized pools: one pool was stably associated 
with unattached kinetochores, and one rapidly exchanging with the cytosol (Shah et al., 
2004).  In addition to binding Cdc20 (Fang et al., 1998; Hwang et al., 1998; Kim et al., 
1998; Luo et al., 2000), Mad2 binds tightly to Mad1, and this interaction is required for 
Mad2’s kinetochore localisation (Chen et al., 1999; Chen et al., 1998; Chung and Chen, 
2002; Sironi et al., 2002).  The existence of both free, non-Mad1-associated and also 
stable, Mad1-bound forms of Mad2 was found to be necessary for checkpoint signalling in 
Xenopus egg extracts (Chung and Chen, 2002).  These data led to the idea that Mad1 
recruits Mad2 to kinetochores in order to hand it over to Cdc20, a key step in formation of 
the MCC or MCC-like APC/C inhibitor complexes. 
Structural and biochemical data shed more light on the nature of the Mad1-Mad2 
interaction, and how this might mediate checkpoint signalling.  Mad2 binds Cdc20 and 
Mad1 mutually exclusively (Luo et al., 2002; Sironi et al., 2002), and the two ligands share 
10-residue Mad2 binding sites despite being otherwise structurally quite dissimilar (Luo et 
al., 2002).  On binding either Mad1 or Cdc20, Mad2 undergoes substantial structural 
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 rearrangement, changing from an inactive, open conformation (O-Mad2), to an active, 
closed conformation (C-Mad2) through movement of the ‘safety belt’ domain (Luo et al., 
2000; Luo et al., 2002; Luo et al., 2004; Sironi et al., 2002).  Thus, Mad1-bound Mad2 
exists in the closed conformation at the kinetochore, where it forms a tight tetrameric 
complex with a second pair of Mad1-C-Mad2 heterodimers (Sironi et al., 2002): this 
represents the stable, non-dynamic kinetochore pool of Mad2 (Shah et al., 2004).  The 
cytosolic dynamic pool of Mad2 is recruited to kinetochores as unbound O-Mad2 and 
handed over to Cdc20 (De Antoni et al., 2005b).  Since Mad2’s conversion from O-Mad2 
to active C-Mad2 is not trivial and occurs spontaneously only very slowly (Luo et al., 
2004; Simonetta et al., 2009), a pressing question presented itself: how can the kinetochore 
Mad1-C-Mad2 core complex catalyse the binding of soluble O-Mad2 to Cdc20, so that C-
Mad2-Cdc20 could be produced? 
This question was elegantly addressed by De Antoni et al (2005a), who proposed the 
Mad2 template model for initiation of checkpoint signalling (see Figure 1.5).  The authors 
analysed Mad1, Mad2 and Cdc20 binding in vitro and were able to show that C-Mad2 
bound to Mad1 forms a receptor for soluble O-Mad2.  The Mad1-C-Mad2 tetrameric 
‘template’ catalyses the conversion of soluble O-Mad2 to C-Mad2 bound to Cdc20, via 
dimerisation of C-Mad2 and O-Mad2.  This newly formed C-Mad2-Cdc20 is released from 
kinetochores, allowing the re-recruitment of more soluble O-Mad2, and explaining the 
dynamics of fluorescently tagged Mad2 at the kinetochore (Shah et al., 2004).  After 
release from the kinetochore, the C-Mad2-Cdc20 dimer could theoretically create an 
amplification loop in the cytosol, binding more O-Mad2 and catalysing the hand-over to 
Cdc20, though this remains unproven (De Antoni et al., 2005a; Musacchio and Salmon, 
2007).   
Aspects of the Mad2 template model have been reinforced by subsequent work.  
Structural studies and mapping of the C-Mad2-O-Mad2 interface are consistent with a 
model in which O-Mad2 selectively binds C-Mad2 and undergoes structural rearrangement 
to enable it to bind Cdc20, probably via an intermediate partially unfolded form (I-Mad2). 
(Mapelli et al., 2006; Mapelli et al., 2007; Yang et al., 2008).  Furthermore, reconstitution 
of checkpoint signalling with purified chromosomes and checkpoint components 
reinforced the necessity for direct interaction between kinetochores (with bound Mad1) 
and Mad2 for subsequent production of an APC/C inhibitor comprising BubR1, Bub3 and 
Cdc20 (Kulukian et al., 2009).  Mad2 homo-dimerisation was also essential for 
kinetochore-mediated amplification of APC/C inhibition in the reconstituted system 
(Kulukian et al., 2009), as demonstrated by the double point mutant Mad2RQ, which cannot 
dimerise (De Antoni et al., 2005a; De Antoni et al., 2005b).  
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Figure 1.5 The Mad2 template model
(A) Stable Mad1-C-Mad2 heterodimers localise to unattached kinetochores, and recruit cytosolic O-Mad2.
Conformational dimerisation between O-Mad2 and C-Mad2 facilitates its conversion to C-Mad2 bound to
Cdc20. Together with BubR1 and Bub3, C-Mad2-Cdc20 forms the mitotic checkpoint complex (MCC). The
MCC may both sequester Cdc20 away from APC/C and also bind directly to the APC/C, preventing it from
ubiquitinating cyclin B and securin. Note that the MCC (Cdc20, Mad2, BubR1 and Bub3) may only be tran-
siently formed: Mad2 may be released from the complex (not shown on schematic).
(B) Theoretically, cytosolic C-Mad2-Cdc20 can create an positive feedback loop, catalysing the conversion
of more O-Mad2 into C-Mad2-Cdc20, and thus amplifying the checkpoint signal.
(C) As microtubule occupancy increases, the minus end motor Dynein/dynactin strips Mad1 and Mad2 off
kinetochore, contributing to checkpoint silencing. Evidence suggests p31comet, a Mad2 antagonist and struc-
tural mimic, may be reactivated at metaphase and bind to C-Mad2, preventing Mad2 conformational
dimerisation and inactivating checkpoint signalling.
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A putative negative regulator of the Mad2 template model, p31comet, has been 
described.  Originally designated CMT2 (Habu et al., 2002), p31comet is a Mad2-binding 
protein and negative regulator of the checkpoint: RNAi-mediated knockdown of p31comet 
leads to a checkpoint-mediated arrest (Habu et al., 2002; Xia et al., 2004).  P31comet appears 
to act as antagonist of Mad2 activation by selectively binding C-Mad2 and competing with 
O-Mad2 for C-Mad2 binding (Mapelli et al., 2006; Vink et al., 2006; Xia et al., 2004).  
The crystal structure of the p31comet-Mad2 complex showed that p31comet is structurally 
very similar to Mad2, and binds C-Mad2 at its dimerisation interface, preventing Mad2 
conformational dimerisation by molecular mimicry (Yang et al., 2007a). In this way, 
p31comet prevents the formation of Mad2-Cdc20 and inactivates the checkpoint (see Figure 
1.5).   
Whilst the Mad2 template model is now relatively well supported, several questions 
remain.  For example, we do not know how exactly the dramatic Mad2 conformation 
change is brought about.  The O-Mad2 to C-Mad2-Cdc20 transition involves a massive 
structural alteration, plus the threading of a β-strand of Cdc20’s binding site through the β-
sheet of Mad2’s binding site, making a chain link-like structure (Mapelli et al., 2007; 
Sironi et al., 2002). Mad2 has been described as ‘prion-like’ (De Antoni et al., 2005a; 
Mapelli et al., 2006), and the quite remarkable structural rearrangement it undergoes has 
led to the suggestion that it may partially unfold and refold during conformational 
dimerisation and Cdc20 binding (Skinner et al., 2008).  The precise mechanisms governing 
this rate-limiting step in checkpoint signalling are yet to be elucidated. 
1.4.7 | Checkpoint satisfaction – tension and attachment 
What exactly the mitotic checkpoint senses remains one the most challenging 
questions in the field.  Evidence suggests an important role for kinetochore-microtubule 
attachment in checkpoint satisfaction: the checkpoint effectors Mad1 and Mad2 enrich at 
unattached kinetochores, and are depleted from vertebrate kinetochores as microtubule 
occupancy increases by a mechanism involving Dynein-dynactin-mediated poleward 
transport (Chen et al., 1996; Howell et al., 2001; Waters et al., 1998).  The stripping of 
Mad1/Mad2 from attached kinetochores is therefore thought to correlate with decreased 
formation of the APC/CCdc20 inhibitor, and therefore anaphase onset (see Figure 1.5).  
However, as well as being attached to microtubules emanating from each pole, bioriented 
kinetochores and the centromeric chromatin between them are also under tension, therefore 
it seems appropriate for cells to monitor tension as an indicator of correct alignment 
(McIntosh, 1991).  The idea that tension is important for checkpoint silencing was 
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 supported by seminal micromanipulation experiments: Li and Nicklas (1995) showed that 
preying mantid spermatocytes with a single unaligned chromosome would divide if tension 
was applied to the chromosome.  Furthermore, staining of the 3f3/2 phosphoepitope was 
reduced at tensionless kinetochores (Nicklas et al., 1995; Waters et al., 1998), and since 
prevention of dephosphorylation at this site(s) prevented anaphase (Campbell and 
Gorbsky, 1995), a link between tension and checkpoint silencing was made.  Further 
evidence came from experiments in budding yeast mutants with unreplicated, single 
chromatids: these cells could not satisfy the checkpoint, leading to the conclusion that 
tension across the centromere was important for checkpoint satisfaction (Stern and Murray, 
2001).  In agreement, arresting human cells with a monopolar spindle and normal 
microtubule dynamics does not prevent attachment, but does prevent tension across the 
centromere, and causes a checkpoint-mediated arrest (Kapoor et al., 2000).   
On the other hand, studies on human cells undergoing mitosis in the presence of an 
unreplicated genome (MUGs, which have a single centromere and therefore no inter-
centromere stretch) indicated that checkpoint satisfaction does not require inter-
kinetochore stretch, and supported arguments against a role for tension in checkpoint 
signalling (O'Connell et al., 2008).  However, there is much debate regarding the ability of 
the checkpoint to sense tension (reviewed in Maresca and Salmon, 2010; Nezi and 
Musacchio, 2009; Pinsky and Biggins, 2005).  At the heart of the debate is the question of 
whether or not tensionless kinetochores directly influence checkpoint signalling, or have 
an indirect effect via the destabilisation of low-tension attachments, which produces 
unattached kinetochores. The role of Aurora B is central to the debate.  Aurora B is a 
serine/threonine kinase that forms a complex with its regulatory subunits INCENP, 
Survivin and Borealin creating the chromosome passenger complex (CPC), and localises to 
the centromeric region from prophase to metaphase (Carmena et al., 2009).   
1.4.8 | Aurora B – checkpoint signaller or just coincidental? 
Aurora B has a well accepted role in error correction (see Section 1.6), but it’s role in 
the checkpoint is subject to some controversy.  The budding yeast Aurora B homologue 
Ipl1 was shown to be required for the checkpoint response to lack of tension (Biggins and 
Murray, 2001).  However, it has been suggested that rather than directly promoting 
tension-sensitive checkpoint signalling, Aurora B activity may simply destabilise 
tensionless attachments, leading to reduced microtubule occupancy and attachment-
sensitive checkpoint signalling (Hauf et al., 2003; Pinsky et al., 2006; Yang et al., 2009).  
This would explain why Aurora B inhibition leads to rapid mitotic exit in the presence of 
Taxol, which stabilises microtubules; but is less effective at inducing checkpoint override 
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 in the presence of nocodazole, which depolymerises microtubules and causes unattached 
kinetochores (Ditchfield et al., 2003; Hauf et al., 2003).  
 However, the situation is far from clear cut.  There is evidence that Aurora B does 
contribute directly to checkpoint signalling (Kallio et al., 2002; Morrow et al., 2005; 
Petersen and Hagan, 2003; Santaguida et al., 2010; Vader et al., 2007).  Recent advances 
have lead to the suggestion that intrakinetochore tension may regulate Aurora B activity, 
whilst also possibly providing a source of checkpoint signalling independent of 
microtubule attachment (Maresca and Salmon, 2009; Maresca and Salmon, 2010; Uchida 
et al., 2009; Wan et al., 2009).  These ideas build upon previous work in which inter-
kinetochore, centromeric stretching was found to regulate Aurora B’s access to substrates 
and provide an explanation for its ability to sense biorientation (Liu et al., 2009).  It is 
currently unclear whether intrakinetochore stretch contributes to checkpoint activity 
through Aurora B or some other means, but the evidence is building for a direct role for 
tension in checkpoint signalling as well as the process of chromosome alignment 
(reviewed in Maresca and Salmon, 2010; Nezi and Musacchio, 2009).   
1.5 | Checkpoint signalling, aneuploidy and cancer 
1.5.1 | Aneuploidy and CIN 
Aneuploidy, the condition in which cells possess a chromosome number deviating 
from the normal diploid quota, has been viewed as a likely causal factor in tumourigenesis 
for almost a century.  In his 1914 monograph on the subject, Theodore Boveri proposed 
that chromosome loss or gain as a result of aberrant cell division could alter the behaviour 
of a cell and lead to malignancy (reviewed in Manchester, 1995).  Cytogenetic analysis 
indicates that aneuploidy is certainly a common feature of human cancers, in both solid 
and haematopoietic tumours (Weaver and Cleveland, 2006).  In some cases, tumours can 
be considered stably aneuploid; that is, in possession of an abnormal of chromosome 
number, but without an elevated frequency of missegregation.  In such cases, 
missegregation will have been induced by a transient event at some point in tumour 
development, producing a stably inherited aneuploid karyotype (Lingle et al., 2002).  A 
non-tumour related form of stable aneuploidy is found in the cells of humans with trisomy-
related syndromes, such as Down’s syndrome (Antonarakis et al., 2004).  While 
aneuploidy is not exclusively associated with cancer, chromosomal instability (CIN; an 
elevated rate of chromosome loss or gain, leading to the state of aneuploidy) is.  CIN was 
first identified as a characteristic of colon cancer cells (Lengauer et al., 1997).  Since then, 
the relationship between aneuploidy, CIN and cancer has been subject to much scrutiny 
(for recent review, see Holland and Cleveland, 2009; Thompson et al., 2010). 
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 1.5.2 | How is aneuploidy produced? 
Aneuploidy (and CIN) has been linked to subnormal mitotic checkpoint function 
(Cahill et al., 1998).  Mitotic checkpoint dysfunction can lead to aneuploidy and CIN, as 
demonstrated by the cellular phenotype of patients with mosaic variegated aneuploidy 
(MVA), a rare inherited disorder which is caused by mutations in BUB1B, the gene 
encoding BubR1 (Hanks et al., 2004; Matsuura et al., 2006).  Patients exhibit mosaicism 
for multiple different chromosome gains and losses throughout different tissues, indicative 
of CIN.  The propensity of MVA individuals to develop childhood cancers provides 
evidence that aneuploidy can drive the progression of malignancies (Hanks et al., 2004; 
Matsuura et al., 2006). 
Studies using mouse models provide further support for the idea that mitotic 
checkpoint perturbation can lead to aneuploidy and consequently tumourigenesis.  
Homozygous deletion of Mad2, Mad1, Bub1, BubR1 or Bub3 is embryonic lethal in mice 
(Dobles et al., 2000; Iwanaga et al., 2007; Jeganathan et al., 2007; Kalitsis et al., 2000; 
Perera et al., 2007; Wang et al., 2004), but mice heterozygous for mutations in checkpoint 
component genes are viable.  Such studies have indicated that mice with heterozygous for 
Mad2 (Michel et al., 2001), Mad1 (Iwanaga et al., 2007), or Bub1 (Jeganathan et al., 2007) 
had increased rates of spontaneous tumourigenesis.  Furthermore, mice heterozygous for a 
mutant, checkpoint-deficient form of Cdc20 that cannot bind Mad2 (AAA-Cdc20) had a 
significantly increased tumour formation rate, consistent with the idea that mitotic 
checkpoint defects (as opposed to unknown, non-checkpoint functions) can promote 
aneuploidy and tumourigenesis (Li et al., 2009).  However, though mutations in mitotic 
checkpoint genes are occasionally identified in cancer cell lines (e.g. Cahill et al., 1998; 
Percy et al., 2000) and in tumour samples (e.g. Kan et al., 2010), it has become apparent 
that mutations in checkpoint genes are too infrequent to account for the amount of 
aneuploidy and CIN seen in human cancers.   
In fact, it is now acknowledged that the original causative link between checkpoint 
inactivation/weakening and the CIN reported in colon cancer cells (Cahill et al., 1998) 
might have been misleading.  Subsequent studies showed that CIN cells do in fact have 
robust mitotic checkpoint responses to spindle depolymerisation (Gascoigne and Taylor, 
2008; Tighe et al., 2001), and are capable of restraining anaphase until all chromosomes 
are aligned in an unperturbed mitosis (Thompson and Compton, 2008).  It follows that 
tumour cells often become aneuploid via other mechanisms.  Persistent merotelic 
attachment (see Figure 1.6), leading to lagging chromosomes at anaphase, is a possible 
alternative cause of aneuploidy in CIN cells (Gascoigne and Taylor, 2008; Thompson and 
Compton, 2008).  Merotelic attachments are not sensed by the mitotic checkpoint since 
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 kinetochores are both attached and under tension, but are usually corrected prior to 
anaphase (Cimini, 2008).  Evidence suggests that aneuploidy can be caused by alterations 
in microtubule dynamics that prevent effective correction of merotelics: overexpression of 
two kinetochore/centromeric microtubule-depolymerising kinesins, Kif2b and MCAK, 
reduced the frequency of missegregation events in a CIN cell line (Bakhoum et al., 2009).  
Another possible cause of aneuploidy is defective chromatid cohesion: mutations in genes 
encoding proteins involved in cohesion have been detected in aneuploid colon cancer cells 
(Barber et al., 2008).  Possession of abnormally high numbers of centrosomes has also 
been linked to the production of aneuploid progeny: while multipolar division can lead to 
highly aneuploid, inviable daughter cells which are eliminated from the population, cells 
with more than 2 spindle poles tend to undergo centrosome clustering to simulate a bipolar 
spindle, allowing relatively normal rates of proliferation (Brinkley, 2001; Ganem et al., 
2009).  The formation of pseudo-bipolar spindles from a transient multipolar intermediate 
increases the frequency of erroneous attachments such as merotelics, placing additional 
stress on the correction machinery and increasing the likelihood that errors will remain 
uncorrected and lead to missegregation and aneuploidy (Ganem et al., 2009). 
However it happens, increased incidence of aneuploidy is clearly able to promote 
cancer progression (Holland and Cleveland, 2009).  This seems logical: CIN allows 
constant reshuffling of genes in a cell population, meaning cells are more likely to acquire 
the genetic alterations required to promote tumourigenesis and malignancy.  However, it 
also seems logical that aneuploidy cannot always be beneficial in terms of cell growth and 
survival: some genetic changes can be detrimental.  Indeed, aneuploid yeast strains with 
extra chromosomes grew slowly compared to those with normal chromosome number 
(Torres et al., 2007).  Moreover, mouse cells engineered to contain extra copies of one of 4 
mouse chromosomes grew more slowly than diploid cells (Williams et al., 2008).  In vivo, 
tumour-promoting missegregation events are likely to be quite rare compared to 
detrimental ones, which are presumably eliminated from the cell population.   
Additionally, further genetic changes are probably required to enable a cell to survive with 
aneuploidy, since it is frequently detrimental to cell fitness (Torres et al., 2008).  In 
keeping with the idea that aneuploidy does not always promote tumourigenesis, Weaver 
and co-workers (2007) showed that mice haploinsufficient for Cenp-E exhibited 
aneuploidy in vivo, but developed fewer carcinogen-induced tumours than control mice, 
and also fewer liver tumours (Weaver et al., 2007).  In addition, Cenp-E+/- mice that were 
genetically predisposed to cancer by deletion of both copies of the tumour suppressor 
p19ARF developed tumours more slowly then Cenp-E+/+, p19ARF-/- mice that were not 
prone to aneuploidy (Weaver et al., 2007).  This indicates that aneuploidy can act as a 
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 tumour suppressor.  Remarkably however, in the same Cenp-E+/- animals, the incidence of 
spontaneous lymphoma and lung cancer was increased, indicating that aneuploidy caused 
by Cenp-E haploinsufficiency can also act oncogenically (Weaver et al., 2007).  Thus, the 
cellular context has a role in determining the effects of aneuploidy.   
1.5.3 | Targeting the mitotic checkpoint as a cancer therapy 
It is thought that while relatively minor missegregation events can promote 
tumourigenesis in some contexts, very severe aneuploidy is incompatible with cell survival 
(Holland and Cleveland, 2009).  In keeping with the embryonic lethality reported in mice 
with homozygous deletions of checkpoint proteins (Dobles et al., 2000; Iwanaga et al., 
2007; Jeganathan et al., 2007; Kalitsis et al., 2000; Perera et al., 2007; Wang et al., 2004), 
fully ablating the mitotic checkpoint by RNAi leads to apoptosis in cultured cancer cells 
(Kops et al., 2004; Michel et al., 2004).  These observations led to the suggestion that the 
mitotic checkpoint may be a plausible target for cancer therapeutics (Kops et al., 2004; 
Michel et al., 2004).  However, it remains to be seen whether the mitotic checkpoint can be 
targeted without affecting normal cells in vivo, although there have been encouraging hints 
that perturbing Mps1 or BubR1 function in combination with low dosage Taxol treatment 
may be a strategy for selectively targeting cancer cells by raising aneuploidy to intolerable 
levels (Janssen et al., 2009). 
1.6 | The mechanism of chromosome alignment 
To prevent errors in segregation, the mitotic checkpoint restrains anaphase until all 
chromosomes are properly attached to the microtubules mitotic spindle and aligned at the 
metaphase plate.  To get the chromosomes to this point requires the cooperative 
functioning of kinetochores, spindle microtubules and associated motor proteins (for 
review, see Walczak and Heald, 2008).  As prometaphase progresses, chromosomes are 
captured by microtubules from each pole, and move towards the spindle equator.  In 
metazoans, chromosomes and microtubules begin to interact after NEBD.  The 
centrosomes nucleate microtubules at the minus ends, allowing the dynamically unstable 
plus ends to contact chromosomes; following end-on attachment to kinetochores, 
microtubules become stabilised (Kirschner and Mitchison, 1986).  Once stable, end-on 
attachments have been formed between the kinetochore of each of the paired sister 
chromatids, biorientation has been achieved.  However, since kinetochore-microtubule 
attachment is stochastic and random, many improper attachments are likely to form before 
the goal of biorientation is reached.  Thus, the correction of errors is crucial to facilitate 
biorientation.  Examples of erroneous attachments between the spindle and kinetochores 
are depicted in Figure 1.6. 
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 Syntely, the condition in which both sister kinetochores become attached to the same 
pole of the spindle, is predicted to occur transiently during a normal prometaphase.  
Syntelic attachments must be corrected, and to do this the microtubule attachments must be 
destabilised in order to provide a new opportunity for biorientation to occur.  Merotelic 
attachments, where one sister kinetochore forms attachments to both of the spindle poles, 
must also be corrected before anaphase, or the chromatid will be pulled in both directions 
creating a lagging chromosome, reminiscent of an anaphase bridge, which may be lost 
from the daughter cell (Cimini, 2008).  Aurora B, as part of the CPC (Carmena et al., 
2009) is involved in ensuring syntelic and merotelic attachments are destabilised.   
1.6.1 | Aurora B and error correction 
In mammalian cells, the Aurora kinase family consists of three members: Aurora A, 
B and C (for review see Carmena et al., 2009; Vader and Lens, 2008).  Yeast only have 
one Aurora family kinase: Ipl1 in budding yeast and Ark1 in fission yeast.  Work in 
budding yeast showed that Ipl1 activity destabilises kinetochore-microtubule attachments 
lacking in tension (Tanaka et al., 2002).  In keeping with this, inhibiting Aurora B activity 
in human cells using the small molecule Hesperadin led to an increase in the frequency of 
syntelic attachments (Hauf et al., 2003).  In elegant experiments using successive inhibitor 
treatments in human cells, Lampson and co-workers were able to demonstrate the 
importance of Aurora B in correction of syntelic attachments (Lampson et al., 2004).  Cells 
were treated transiently with monastrol, an inhibitor of spindle pole separation (Kapoor et 
al., 2000; Mayer et al., 1999).  Since cells were kept in a monopolar state, they had a high 
probability of forming syntelic attachments (Kapoor et al., 2000).  After monastrol was 
removed and the spindle allowed to bipolarise, cells with active Aurora B could correct the 
syntelic attachments, achieving full alignment.  Cells lacking Aurora B activity were 
unable to destabilise the monopolar, syntelic attachments, and persisted with chromosomes 
attached to only one pole of the bipolar spindle (Lampson et al., 2004).  Taken together, 
these data suggest a role for Aurora B/Ipl1 in correction of erroneous attachments arising 
during prometaphase. 
The molecular mechanisms by which this occurs are becoming clearer.  One way 
Aurora B appears to influence microtubule stability at kinetochores is via the microtubule 
depolymerase MCAK.  Aurora B activity is required to recruit MCAK to the 
centromere\kinetochore, and phosphorylation leads to a decrease in MCAK activity, and in 
turn an increase in local microtubule stability (Andrews et al., 2004; Lan et al., 2004).   
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Figure 1.6 Kinetochore-microtubule attachment and alignment
(A) Types of correct and incorrect chromosome attachment to the mitotic spindle. Amphitelic attachment:
sister kinetochores are correctly attached, via stable end-on microtubule interactions, to opposite spindle
poles (bioriented). The kinetochore/centromere region is under tension. When all chromosomes have
achieved amphitelic attachment, the checkpoint is satisfied and anaphase commences. Syntelic attachment:
a form of incorrect attachment in which both sister kinetochores are attached to one spindle pole. An Aurora
B dependent mechanism corrects these attachments. Monotelic attachment: one kinetochore is attached to
one spindle pole while its sister remains unattached. Merotelic attachment: One sister kinetochore is
attached to both spindle poles. While anaphase is delayed in the presence of monotelic and syntelic attach-
ments, merotelics are not detected by the checkpoint, but are usually corrected prior to anaphase by a mech-
anism involving Aurora B.
(B) Error correction after monastrol wash-out. Monastrol arrests cells with the centrosomes close together,
forming a monopolar spindle with a high incidence of syntelic attachments (left-hand diagram). If
monastrol is removed from the cells, the spindle poles separate (middle diagram), allowing the syntelic
attachments to be effectively corrected and converted to biorientation. In unperturbed cells, Aurora B and
Cenp-E cooperate to correct these syntelic attachments: Aurora B activity destabilises syntelic attachments
and promotes shortening of microtubules, moving the chromosome toward the pole. At the pole, the mono-
oriented chromosome congresses toward the cell equator via lateral association between the unattached sis-
ter and a pre-existing K-fibre. Aurora B inhibition or Cenp-E RNAi therefore prevents chromosomes from
aligning at the metaphase plate by inhibiting syntelic destabilsation/MT shortening or poleward congression,
respectively. (B) is adapted from Kapoor, et al (2006).
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 Aurora B also phosphorylates Ndc80/Hec1, a component of the Ndc80 complex in the 
KMN network at the inner kinetochore, and in doing so, destabilises microtubule 
attachments; this function is conserved from yeast to human (Cheeseman et al., 2002; 
Cheeseman et al., 2006; Ciferri et al., 2008; DeLuca et al., 2006; Guimaraes et al., 2008). 
But how might Aurora B distinguish between microtubules that require destabilisation and 
those that do not?  As previously mentioned, spatial separation, governed by tension across 
the kinetochore and centromere, affects the access of Aurora B to its various substrates and 
allows error correction to occur only at tensionless kinetochores (Liu et al., 2009).  
Intrakinetochore stretching may also contribute to this mechanism (Maresca and Salmon, 
2010).  
1.6.2 | Microtubule motors and chromosome congression 
As well as the correction of improper attachments, microtubule motor-mediated 
movement of chromosomes during mitosis contributes to proper alignment (reviewed in 
Cheeseman and Desai, 2008; Kops et al., 2010).  As well as forming end-on attachment 
with microtubules, kinetochores can associate laterally with microtubules of the spindle.  
Evidence suggests these lateral connections facilitate chromosome movement prior to 
biorientation, thereby helping to position chromosomes in places where end-on 
attachments are likely to occur.  The two motor proteins that are known to localise to 
kinetochores in mitosis are Cenp-E, a plus-directed kinesin (Kapoor et al., 2006; Schaar et 
al., 1997; Wood et al., 1997; Yen et al., 1992) and minus-end directed Dynein-dynactin 
(Pfarr et al., 1990; Yang et al., 2007b). 
Early in prometaphase, the Dynein-dynactin complex is thought to promote poleward 
movement, taking chromosomes to a position where many microtubules are found and thus 
increasing the chance of end-on kinetochore capture (Yang et al., 2007b).  Cenp-E powers 
congression from the polar region toward the metaphase plate at the cell equator, which, in 
a normal prometaphase, is necessary for congression of a few chromosomes that become 
trapped at the poles, though many chromosomes align normally (Kapoor et al., 2006; 
Weaver et al., 2003; Wood et al., 1997).  The role of Cenp-E was elegantly demonstrated 
by Kapoor and colleagues (2006) who, in an extension of a previous study (Lampson et al., 
2004), used monastrol to arrest cells transiently with a monopolar spindle, then washed the 
drug out, allowing bipolarisation in the presence of numerous syntelic attachments.  Using 
a combination of drug treatments and RNAi, followed by live-cell imaging, 
immunofluorescence and electron microscopy, the authors showed that Aurora B activity 
was required for destabilisation of syntelic attachments and shortening of microtubules, 
bringing the chromosomes towards the pole, but congression of monotelic polar 
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 chromosomes towards the metaphase plate via lateral association with other kinetochore 
fibres (K-fibres) was not possible without Cenp-E (Kapoor et al., 2006).  In other words, 
Cenp-E takes mono-oriented polar chromosomes towards the equator by ‘piggy-backing’ 
on pre-formed K-fibres, promoting contact with microtubules emanating from the opposite 
pole and, therefore, biorientation.  This study demonstrated nicely how cooperation 
between error correction (via Aurora B) and microtubule motors is required to promote 
alignment and accurate segregation (see Figure 1.6).   
As well as powering chromosome movements to promote biorientation, both 
Dynein-dynactin and Cenp-E are reported to have other roles at the kinetochore.  Dynein-
dynactin promotes stable kinetochore-microtubule attachments (Chan et al., 2009; Yang et 
al., 2008); similarly Cenp-E depleted kinetochores reportedly bind fewer microtubules than 
those in control cells (McEwen et al., 2001; Putkey et al., 2002).  Cenp-E may also 
contribute to the amplification of checkpoint signalling, via activation of BubR1 kinase 
activity (Mao et al., 2003; Mao et al., 2005; Weaver et al., 2003), whereas Dynein-dynactin 
is required for poleward trafficking of checkpoint components away from kinetochores, 
contributing to checkpoint silencing on bioriented chromosomes (Howell et al., 2001). 
1.7 | Mitotic kinases in the checkpoint and chromosome alignment 
It is notable that the template model of kinetochore-based checkpoint signalling does 
not include any kinases.  However, the requirement for kinases for full checkpoint function 
in cells is undisputed, and in addition to their putative role in MCC/MCC-like complex 
generation, kinetochores may function as a platform to facilitate a phosphorylation cascade 
(Burke and Stukenberg, 2008).  A recent study showed unattached kinetochores were not 
critical for formation of an APC/C inhibitor from purified MCC components per se, but 
their presence did amplify production of the inhibitor (Kulukian et al., 2009): importantly, 
a proportion of several kinetochore-bound kinases (Mps1, Aurora B and Bub1) was 
retained on the purified mitotic chromosomes that provided the unattached kinetochores.  
This suggests an important function of kinetochore phosphorylation may be signal 
amplification to enable the checkpoint to sense one unaligned kinetochore.  Aurora B is 
one mitotic kinase with a role in alignment and, arguably, a role in checkpoint signalling 
too, as has already been outlined in Section 1.4 and 1.6.  The role of Mps1 in mitosis will 
be discussed in Section 1.8.  Several other mitotic kinases, some of which have been 
mentioned above, have been implicated in checkpoint signalling and/or chromosome 
alignment, including Bub1, BubR1 and Plk1.  I will briefly outline the proposed roles of 
these molecules below. 
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 1.7.1 | Bub1 
Bub1 interacts with Bub3 and BubR1 and is recruited to unaligned kinetochores in 
prophase (Johnson et al., 2004; Taylor et al., 1998).  In contrast to Bub3 and BubR1, Bub1 
is a relatively stable kinetochore resident (Howell et al., 2004; Shah et al., 2004), and may 
act as scaffold to facilitate recruitment of other checkpoint proteins (Rischitor et al., 2007; 
Sharp-Baker and Chen, 2001).  Full depletion of Bub1 protein by RNAi (Meraldi and 
Sorger, 2005) or BUB1 knock-out (Perera et al., 2007) leads to checkpoint malfunction in 
human cells and mouse embryonic fibroblasts (MEFs) respectively.  Bub1 has been shown 
to phosphorylate Cdc20, thereby contributing to APC/C inhibition (Kang et al., 2008; Tang 
et al., 2004).  However, the requirement for Bub1 kinase activity in checkpoint signalling 
is controversial: a recent study found that kinase-dead mutants could rescue checkpoint 
signalling in BUB1 null MEFs (Perera and Taylor, 2010).  Interestingly, Bub1 is reported 
to play a role in chromosome alignment (Johnson et al., 2004; Meraldi and Sorger, 2005; 
Perera et al., 2007); this also appears to be independent of its kinase activity (Perera and 
Taylor, 2010).  So, while Bub1’s presence at kinetochores seems to be important for both 
checkpoint signalling and alignment, the role of its activity is subject to debate.  
1.7.2 | BubR1 
As discussed above, BubR1 is part of the MCC or MCC-like complex that inhibits 
the APC/CCdc20.  The analogous protein in budding yeast, Mad3, has no kinase activity (Li 
and Murray, 1991).  In human cells, BubR1 depletion causes spindle checkpoint 
inactivation and accelerates progression through an unperturbed mitosis (Chan et al., 1999; 
Meraldi et al., 2004; Morrow et al., 2005); however, there are contrasting reports as to the 
requirement of its kinase activity for checkpoint signalling in vertebrate cells (Chen, 2002; 
Malureanu et al., 2009; Mao et al., 2003).  BubR1 is also involved in chromosome 
alignment (Ditchfield et al., 2003; Lampson and Kapoor, 2005), and this function may 
require its kinase activity (Rahmani et al., 2009).  BubR1 is hyperphosphorylated in 
mitotic cells (Chan et al., 1999; Taylor et al., 2001), and has been shown to be substrate for 
Aurora B, Plk1 and Mps1 (Ditchfield et al., 2003; Elowe et al., 2007; Hauf et al., 2003; 
Huang et al., 2008; Matsumura et al., 2007).  BubR1’s phosphorylation status may be 
regulated differently by microtubule attachment and tension (Huang et al., 2008), 
suggesting it may receive and transduce signals from upstream kinases monitoring various 
aspects of kinetochore-spindle interaction.  
1.7.3 | Plk1 
Plk1 has multiple roles in mitosis and cytokinesis (reviewed in Archambault and 
Glover, 2009; Petronczki et al., 2008).  Its enrichment at the centromere/kinetochore 
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 region peaks in prometaphase and depends upon its own activity (Arnaud et al., 1998; 
Lenart et al., 2007).  Evidence suggests Plk1 (or the X. laevis homologue Plx1) is the 
kinase responsible for producing the tension-sensitive 3f3/2 phosphoepitope (Ahonen et 
al., 2005; Wong and Fang, 2005).  In X. laevis egg extracts, the 3f3/2 epitope is a Plx1-
mediated phosphorylation site on BubR1 (Wong and Fang, 2007).  Plk1 also 
phosphorylates Bub1 (Qi et al., 2006), and both Bub1 and BubR1 require prior Cdk1-
mediated phosphorylation prime to facilitate Plk1 binding (Qi et al., 2006; Wong and 
Fang, 2007).  There are clearly links between Plk1 and mitotic checkpoint components; 
however, in human cells devoid of Plk1 activity, cells enter a robust checkpoint-mediated 
arrest with monopolar spindles and normal levels of kinetochore-bound Mad2 (Lenart et 
al., 2007), indicating Plk1 kinase activity is dispensable for the mitotic checkpoint.  
Instead, Plk1 activity appears to promote formation of stable end-on kinetochore-
microtubule attachments, perhaps through the aforementioned interaction with BubR1 
(Elowe et al., 2007; Lenart et al., 2007; Matsumura et al., 2007). 
1.8 | Mps1, a kinase with a dual role in mitosis 
1.8.1 | Mps1 family history 
The Monopolar spindle 1 (MPS1) gene was discovered in budding yeast in a screen 
for regulators of spindle pole body (SPB; the yeast equivalent of the centrosome) 
duplication (Winey et al., 1991).  It was later found to encode a dual-specificity protein 
kinase (Lauze et al., 1995), and to be essential for spindle checkpoint function in budding 
yeast (Weiss and Winey, 1996).  Mps1 is conserved from yeast to humans (Fisk et al., 
2004), though Caernorhabditis elegans does not possess an obvious homologue; a unique 
kinase Zyg1 is postulated to play an analogous role (O'Connell et al., 2001).  Mps1’s 
human homologue was originally identified as TTK or PYT (Hogg et al., 1994; Lindberg 
et al., 1993; Mills et al., 1992) a cell cycle-regulated kinase associated with cell 
proliferation, and is still referred to as TTK in some databases.  The human Mps1/TTK 
gene (NCBI accession number NM_003318) encodes an 857 residue, 97 kDa protein with 
a 525 amino acid N-terminal domain, followed by the 266 residue catalytic domain and a 
short C-terminal extension of 66 amino acids (see Figure 1.7). 
1.8.2 | Centrosome duplication 
Mps1 is required for spindle pole body duplication in budding yeast (Winey et al., 
1991), however its role in centrosome duplication in mammals is subject to debate.  
Several report have suggested that either human or murine Mps1 localises to centrosomes 
(Fisk et al., 2003; Fisk and Winey, 2001; Tyler et al., 2009) and is required for centrosome  
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Figure 1.7 Schematic diagram of human Mps1
The domain structure of human Mps1 kinase is shown. The N-terminal region (1-301) is involved in kineto-
chore binding; the catalytic (kinase) domain is towards the C-terminal of the protein. Catalytic domain point
mutants used experimentally are marked with asterisks: the M602A gatekeeper residue mutation renders the
kinase sensitive to inhibition with bulky ATP analogues (Mps1AS); the D664A mutation renders the kinase
catalytically inactive or kinase-dead (Mps1KD) because it changes a critical aspartate residue in the highly
conserved DFG motif, which is necessary to orient ATP in the active site.
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 duplication during S phase (Fisk et al., 2003; Fisk and Winey, 2001; Mattison et al., 2007).  
However, there have also been reports suggesting human Mps1 has no role at the 
centrosome (Stucke et al., 2004; Stucke et al., 2002).  Another very recent report saw no 
effect on centrosome duplication in cells lacking Mps1 activity (Kwiatkowski et al., 2010).  
The reason(s) for the discrepancy between studies is unclear; differences in antibody and 
cell line behaviour have been cited (Winey and Huneycutt, 2002). It is possible that very 
low levels of Mps1 activity are needed to perform the centrosome duplication function 
during S phase, making a defect difficult to produce (Fisk et al., 2003). 
1.8.3 | Mps1 and the mitotic checkpoint 
The requirement for Mps1 in the mitotic checkpoint can reasonably be described as 
universal: studies in yeast (He et al., 1998; Weiss and Winey, 1996), D. melanogaster 
(Fischer et al., 2004), X. laevis (Abrieu et al., 2001), Danio rerio (Poss et al., 2004) and 
human cells (Jelluma et al., 2008b; Liu et al., 2003; Stucke et al., 2002; Tighe et al., 2008) 
have concluded that Mps1 is required for the checkpoint.  In human cells, Mps1 is required 
not only for the checkpoint response to spindle damage (e.g. nocodazole treatment), but 
also to restrain anaphase onset in an otherwise unperturbed mitosis (Jelluma et al., 2008b; 
Tighe et al., 2008).  In addition to accelerated passage through an unperturbed mitosis, 
cells lacking Mps1 also exit mitosis with unaligned chromosomes, yielding aneuploid 
daughter cells (Jelluma et al., 2008b; Tighe et al., 2008). 
The idea that Mps1 was at, or near, the top of the checkpoint signalling network 
initially came from studies in budding yeast, which showed that Mps1 overexpression 
activated the spindle assembly checkpoint, causing an arrest that was abolished by 
simultaneous mutation of other the checkpoint components Mad2, Mad2, Bub1, or Bub3 
(Hardwick et al., 1996).  In budding yeast, the downstream target of Mps1 appears to be 
Mad1, which becomes hyperphosphorylated after Mps1 overexpression (Hardwick and 
Murray, 1995; Hardwick et al., 1996).  There is currently no evidence to support Mps1 
phosphorylation of Mad1 in human cells, though localisation data does support a role for 
Mps1 upstream in the signalling network in vertebrates.  Mps1 is required to recruit the 
checkpoint effector molecules Mad1 and Mad2 to kinetochores in human cells (Jelluma et 
al., 2008b; Liu et al., 2003; Liu et al., 2006; Martin-Lluesma et al., 2002; Tighe et al., 
2008; Xu et al., 2009).  Inhibition of Mps1 has also been shown to lead to BubR1 loss at 
kinetochores in human cells (Schmidt et al., 2005), and immunodepletion of Mps1 from X. 
laevis egg extracts reportedly perturbs Bub1, Bub3, Mad1, Mad2 and Cenp-E localisation 
(Abrieu et al., 2001; Vigneron et al., 2004).  
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 Other than putative Mad1 phosphorylation in budding yeast (Hardwick et al., 1996), 
the targets of Mps1 that regulate checkpoint activity are yet to be fully elucidated.  Some 
progress has been made: a recent report found that Mps1 phosphorylated several sites in 
the N-terminal of Ndc80/Hec1 in budding yeast (Kemmler et al., 2009).  Mutation of 14 of 
the phosphorylation sites to alanine to prevent phosphorylation caused checkpoint failure; 
conversely, mutation of the same sites to phospho-mimetic aspartate residues caused 
metaphase arrest due to a constitutively active checkpoint.  Whether this function is 
conserved remains to be seen.  Mps1 has also been shown to phosphorylate Dam1, a 
protein implicated in microtubule binding at the budding yeast kinetochore (Shimogawa et 
al., 2006).  Mps1 phosphorylation of this protein impairs coupling between Dam1 and 
microtubules (Shimogawa et al., 2006).  As Dam1 is not conserved, it is currently unclear 
whether Mps1 performs an analogous function in higher organisms. 
In human cells, Mps1 was reported to contribute to BubR1 phosphorylation on 4 
serine residues: phospho-specific antibodies to the sites on BubR1 showed a decrease in 
signal after Mps1 depletion by RNAi (Huang et al., 2008).  While these Mps1 sites await 
more rigorous validation, and the functional relevance of this phosphorylation is not fully 
understood, Mps1 may be one of several mitotic kinases targeting BubR1 to control 
checkpoint signalling.  If the role of Mps1 in phosphorylation of Ndc80 is conserved in 
humans, this may be another example of human Aurora B and Mps1 converging upon the 
same substrates. 
1.8.4 | Mps1 and Aurora B in error correction 
The emerging relationship between Mps1 and Aurora B was the subject of a recent 
report from Jelluma and co-workers (2008b).  The authors used an RNAi complementation 
approach to replace endogenous Mps1 with active (wild type, WT) or inactive (kinase 
dead, KD) alleles, and found that cells lacking Mps1 activity had difficulty aligning 
chromosomes, even after cells were kept in mitosis for an extended period by treatment 
with the proteasome inhibitor MG132.  Jelluma et al found that these misalignments were 
attributable to a lack of error correction, which in turn was a consequence of decreased 
Aurora B activity, both globally (as shown by a decrease in immunoprecipitated Aurora B 
activity, and Aurora B substrate phosphorylation by western blot) and at centromeres (as 
shown by immunofluorescence using antibodies to Aurora B centromeric substrates).  
Furthermore, Mps1-catalysed phosphorylation of Borealin on 4 threonine residues was 
shown to be the cause of the decreased Aurora B activity (Jelluma et al., 2008b).  This 
report presented the first evidence that Mps1 was involved in alignment in human cells, 
though an earlier study had concluded that Mps1 was required for error correction in 
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 budding yeast (Maure et al., 2007).  However, Maure and colleagues did not see any 
decrease in Ipl1 activity.  Whether or not the mechanisms are fully conserved, the 
requirement of Mps1 activity for both checkpoint signalling and error correction adds a 
new facet to the relationship between chromosome alignment and checkpoint signalling. 
The two processes might be controlled by an interwoven web of signalling pathways, 
rather than operating though distinct linear molecular networks.  Mps1 joins Bub1, Aurora 
B and BubR1 as kinases reported to have dual roles in alignment mechanics and the 
checkpoint surveillance mechanism. 
1.8.5 | Mps1 regulation  
Mps1 is maximally active and phosphorylated in mitosis (Hogg et al., 1994; Liu et 
al., 2003; Stucke et al., 2002).  Levels of Mps1 phosphorylation increase following 
treatment with nocodazole or taxol, suggesting this phosphorylation is linked to checkpoint 
activity (Stucke et al., 2002).  The amount of Mps1 protein in the cell is also cell cycle 
regulated: when analysed by western blot, Mps1 is visible in lysates derived from cells in 
all stages of the cell cycle, however its levels increase concomitant with cyclin B as cells 
enter mitosis, and drop again after mitotic exit (Palframan et al., 2006; Stucke et al., 2002).  
In budding yeast, the APC/CCdc20 degrades Mps1 after anaphase (Palframan et al., 2006); it 
is not yet known whether this mechanism is conserved. 
Several studies have reported that Mps1 can autophosphorylate, and that this 
autophosphorylation is required for full activity (Chu et al., 2008; Jelluma et al., 2008a; 
Kang et al., 2007; Mattison et al., 2007; Mills et al., 1992; Stucke et al., 2004).  Moreover, 
autophosphorylation at threonine 676 in the activation loop of the catalytic domain is 
important for full activity (Jelluma et al., 2008a; Kang et al., 2007; Mattison et al., 2007).  
The crystal structure of the Mps1 catalytic domain has been solved, and suggests that 
phosphorylation in the activation loop may cause a conformational change that allows 
proper orientation of the adenosine triphosphate molecule (ATP) in the active site, thus 
increasing kinase activity (Chu et al., 2008).  Mps1 is capable of trans-autophosphorylation 
at T676; indeed, forced dimerisation of Mps1 in cells hyperactivates the kinase (Kang et 
al., 2007).  This led to speculation that Mps1 may dimerise and trans-activate at 
kinetochores, though the relationship between T676 phosphorylation, kinetochore 
localisation and Mps1 activity is unknown. 
Like other checkpoint proteins, Mps1 localises to the kinetochores in mitosis (Abrieu 
et al., 2001; Stucke et al., 2002).  In human cells, this is dependent on proper assembly of 
the outer kinetochore: depletion of components of this complex, Hec1 (Martin-Lluesma et 
al., 2002) or Nuf2 (Stucke et al., 2004) leads to perturbation of the outer plate (DeLuca et 
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 al., 2005) and loss of Mps1 kinetochore localisation.  The kinetochore-binding region of 
Mps1 has been narrowed down to amino acids 1-301 of the N-terminal domain (Liu et al., 
2003; Stucke et al., 2004).  This region localises to kinetochores and behaves in a 
dominant-negative way, preventing endogenous Mps1 from localising to kinetochores and 
perturbing the mitotic checkpoint (Liu et al., 2003).  Analysis of fluorophore-tagged Mps1 
in living cells revealed that its localisation at the kinetochores is dynamic (Howell et al., 
2004). 
Little is known about the regulation of Mps1 kinetochore targeting.  Though the 
localisation of an N-terminal fragment lacking the catalytic domain to kinetochores 
suggests kinase activity is not intrinsically required for binding to kinetochores, it is not 
clear whether or not the fragment localises by virtue of interaction with the endogenous 
kinase (e.g. intermolecular phosphorylation).  There is conflicting data regarding the 
importance of Mps1 kinase activity to localise to kinetochores: while some studies report 
that kinase-dead mutant Mps1 is reduced at kinetochores compared to wild type in human 
cells or X. laevis egg extracts depleted of Mps1 (Xu et al., 2009; Zhao and Chen, 2006), 
other groups have shown that kinase-dead Mps1 is readily visible at kinetochores under 
comparable conditions (Abrieu et al., 2001; Jelluma et al., 2008b).  In X. laevis egg 
extracts and human cells, phosphorylation by MAP kinase at a conserved serine residue 
(S821 in human Mps1) reportedly promotes Mps1’s localisation to kinetochores (Borysova 
et al., 2008; Zhao and Chen, 2006). 
1.8.6 | The role of Mps1 kinase activity in the checkpoint and alignment 
The identification of substrates is an important goal in the quest to understand the 
role of a kinase’s activity in cells.  To date, a number of Mps1 substrates have been 
identified.  Several of these are relevant to SPB or centrosome function (see Table 1.1). 
Additionally, the reported phosphorylation of Smad2 and Smad3 implicated Mps1 activity 
in regulation of gene expression via a non-canonical Smad signalling pathway (Zhu et al., 
2007).  Mps1 was also reported to phosphorylate BLM (Bloom) helicase, and perturbation 
of this phosphorylation was associated with an increase in chromosomal instability in 
Bloom Syndrome (BS) cells (Leng et al., 2006); however the function of BLM helicase in 
mitosis is not known.  Intriguingly, Mps1 was reported to phosphorylated the DNA 
damage checkpoint protein Chk2 in response to DNA damage, mediating G2/M arrest, and 
leading to speculation that the mitotic checkpoint and DNA damage sensing machinery 
may be linked (Wei et al., 2005).   
Several substrates have been identified with direct relevance to checkpoint and/or 
chromosome alignment function, namely Ndc80, Mad1, Borealin, BubR1 and Mps1 itself  
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 Mps1 substrates 
Protein Phosphorylation site Species Proposed function Reference(s) 
Mad1 Multiple residues Budding 
yeast 
Mitotic checkpoint 
signalling 
(Hardwick et al., 
1996) 
Ndc80 14 A and T residues in N-
terminus 
Budding 
yeast 
Mitotic checkpoint 
signalling 
(Kemmler et al., 
2009) 
Borealin T88, T94, T169, T230 Human Aurora B activation, 
error correction 
(Jelluma et al., 
2008b) 
BubR1 S435, S543, S670, S1043 Human S670: mediating end-
on attachments  
(Huang et al., 
2008) 
Mps1 T676 (activation loop) Human Auto-activation (Jelluma et al., 
2008a; Kang et 
al., 2007; 
Mattison et al., 
2007) 
Chk2 T68 Human G2 arrest in response 
to DNA damage 
(Wei et al., 
2005) 
BLM S144 Human Regulation of genome 
stability  
(Leng et al., 
2006) 
TACC2 Multiple residues Human Centrosome function (Dou et al., 
2004) 
Mortalin Multiple residues Human Centrosome cycle (Kanai et al., 
2007) 
Smad2/3 SSxS, C-terminal Human TGFβ-independent 
Smad signalling 
(Zhu et al., 
2007) 
Spc42 Multiple residues Budding 
yeast 
Centrosome assembly (Castillo et al., 
2002) 
Spc98 S60, S64, T68 Budding 
yeast 
Centrosome assembly (Pereira et al., 
1998) 
Spc110 Multiple residues Budding 
yeast 
Centrosome assembly (Friedman et 
al., 2001) 
 Table 1.1  Currently known Mps1 substrates. 
 
(see Table 1.1 and earlier sections for references and descriptions).  However, it is possible 
that more substrates remain to be discovered, and this is likely to be a key focus of future 
studies. 
Over the past few years, much effort has been focused upon understanding the role 
of Mps1 kinase activity.  Researchers have employed several strategies: in X. laevis, 
Abrieu and colleagues (2001) used immunodepletion followed by addition of wild type or 
kinase-dead mutant alleles to show that normal levels of Cenp-E recruitment depended on 
Mps1 kinase activity (Abrieu et al., 2001).  In human cells, RNAi complementation 
approaches (as opposed to simple RNAi-mediated protein repression) have been used to 
examine the role of Mps1 kinase activity (Jelluma et al., 2008b; Tighe et al., 2008).  The 
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 work of Tighe and co-workers (2008) illustrates how this kind of technique can reveal 
differences between loss of protein and loss of kinase activity only: the authors found that 
while Mps1 depletion led to the loss of both Mad1 and Mad2 at the kinetochores in human 
cells, Mad1 levels could be partially rescued with kinase dead Mps1, whereas Mad2 levels 
could not (Tighe et al., 2008).  In other words, Mad2 localisation appeared exquisitely 
sensitive to loss of Mps1 activity, whereas Mad1 appeared less affected.  This suggested 
that either Mps1 was only structurally required for Mad1 recruitment [an explanation 
which seems at odds with the dynamic behaviour of Mps1 at kinetochores, and the stability 
of Mad1 (Howell et al., 2004; Shah et al., 2004)]; or Mad1 required much lower levels of 
Mps1 activity to promote its kinetochore binding.   
Cell-permeable small molecule inhibitors make excellent tools with which to discern 
the roles of kinase activity in cells, and have been used to great effect in the study of 
mitotic kinases like Plk1 and Aurora B (for review see Taylor and Peters, 2008).  Unlike 
RNAi, they rapidly exert their effects in cells, and therefore allow precise temporal control 
of kinase activity in a dose-dependent manner.  One way of achieving selective kinase 
inhibition is by mutagenesis of the active site of cloned kinases to render sensitivity to 
bulky analogues of ATP, providing specificity and potency in cells expressing the mutant 
form of the target kinase (reviewed in Bishop et al., 2001).  Expression of this analogue 
sensitive mutant combined with RNAi has proved an effective approach for study of Mps1 
activity in both human cells (Sliedrecht et al., 2010; Tighe et al., 2008) and budding yeast 
(Jones et al., 2005).  Jones and colleagues were able to specifically examine Mps1’s role in 
spindle assembly and chromosome segregation in mitosis (as distinct from its role in SPB 
duplication in S phase) by creating analogue-sensitive mutant strains.  One potential pitfall 
of this approach is that mutant analogue sensitive kinases tend to lose activity, as was 
observed for yeast and human Mps1 (Jones et al., 2005; Sliedrecht et al., 2010), meaning 
cells expressing the uninhibited mutant do not provide the ideal control for normal activity 
levels, even if (as is the case for Mps1) lower levels of activity apparently support normal 
functions (Jones et al., 2005; Sliedrecht et al., 2010).  Additionally, in human cells, RNAi 
knockdown is still required, adding a potential source of variability to experiments, though 
this issue has been alleviated somewhat by the creation of stable cell lines expressing 
Mps1 shRNA in a doxycycline-dependent manner (Sliedrecht et al., 2010).  A very recent 
report described an extension of the analogue-sensitive approach to Mps1 study: 
Maciejowski and co-workers described a novel human cell line in which the endogenous 
Mps1 gene had been replaced with an analogue-sensitive mutant allele (Maciejowski et al., 
2010). 
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 Selective, potent small molecule inhibitors targeting endogenous kinases are 
desirable tools, since they can be used on unengineered cell lines, and avoid the need for 
RNAi.  Additionally, compounds targeting endogenous enzymes can be tested against 
cancer cell lines to assess any potential therapeutic value.  Therefore, effective small 
molecule inhibitors are sought for those mitotic kinases for which one is not yet available.  
The mitotic checkpoint kinase Mps1 is one such candidate for a small molecule tool.  An 
inhibitor of budding yeast Mps1 has been described, however use of this compound is 
limited since it is ineffective in mammalian cells (Dorer et al., 2005).  At the time this 
study commenced, only one inhibitor of human Mps1 had been reported: SP600125 
(Schmidt et al., 2005), a compound originally identified as a JNK inhibitor (Bennett et al., 
2001).  However, the specificity of SP600125 has been called into question (Bain et al., 
2007), making it a less than ideal tool.  As a result, more selective Mps1 inhibitors have 
been sought in recent years.  New compounds targeting Mps1 have been characterised and 
published concurrent with the one I describe here (published in Hewitt et al., 2010, 
appended): namely Mps1-IN-1 (Kwiatkowski et al., 2010) and Reversine (Santaguida et 
al., 2010).  
1.9 | Aims of this study 
Mps1 is a kinase with a dual role in mitosis: it controls anaphase onset, and also 
contributes to the mechanism of chromosome alignment.  The latter function is reportedly 
mediated through Aurora B activation (Jelluma et al., 2008b).  Despite these advances, the 
precise role of Mps1’s catalytic activity in the maintenance of genomic stability is far from 
being fully understood. 
The ultimate aim of this study was to examine the role of Mps1 kinase activity in 
cells, and by doing so shed more light upon the mechanisms by which cells ensure accurate 
transmission of genetic material to the next generation.  AZ3146, a novel small molecule 
Mps1 inhibitor originally developed by AstraZeneca, was a prospective tool for these 
studies, but characterisation was necessary before I could confidently use the inhibitor to 
probe the role of Mps1 in cells.  Thus, I set out to test AZ3146’s ability to inhibit Mps1 in 
vitro and in cells.  
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 2 | Materials and Methods 
2.1 | Chemicals 
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich or Melford 
Laboratories. 
2.2 | Cell Culture 
All cell lines used in this study, and their origins, are listed in Table 2.1.  Cells were 
cultured as adherent monolayers at 37°C in a humidified chamber with 5% CO2.  Cell 
culture media consisted of Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 
10% (v/v) heat-inactivated foetal calf serum (FCS; Invitrogen). Cells were passaged and 
harvested by washing with warm phosphate-buffered saline (PBS) and incubating for 5 
minutes with warmed trypsin solution in PBS (10%).  Detached cells were resuspended in 
media, diluted and replated as required.  To determine cell density, an aliquot of cell 
suspension was transferred to an Improved Neubauer haemaocytometer (VWR) for 
counting.  For storage, cells were harvested and collected in a 15 ml tube, centrifuged at 
212 × g (1000 rpm) for 5 minutes and resuspended in FCS with 10% (v/v) dimethyl 
sulfoxide (DMSO).  The cell suspension was aliquotted into cryovials (Nunc) and frozen 
slowly by placing in a polystyrene box at -80°C for 24 hours before long-term storage in 
liquid nitrogen. 
 
Cell line Description Source/reference 
TA-HeLa Human cervical adenocarcinoma (Taylor and McKeon, 1997) 
DLD1 Human colorectal 
adenocarcinoma 
ATCC  
HCT116 Human colorectal carcinoma ATCC 
hTERT-RPE Human retinal pigmented 
epithelium 
Dr S. Doxsey, Univ. of 
Massachusetts 
HeLa FRT GFP-Histone H2B Human cervical 
adenocarcinoma; stable cell line 
(Morrow et al., 2005) 
DLD1 FRT/TO Myc-LAP CENP-
E tail, Histone-H2B-DsRed 
Human colorectal 
adenocarcinoma; stable cell line  
Dr A. Holland, UCSD 
(Gurden et al., 2010) 
HeLa FRT/TO GFP-Mps1 
WT/KD, RNAiR 
Human cervical 
adenocarcinoma; stable cell line 
Dr A. Tighe (Taylor lab) 
(Tighe et al., 2008) 
Table 2.1 – Cell lines used in this study.  ATCC = American type culture collection 
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Drug and source Stock concentration Final concentration 
Nocodazole  5 mg/ml 200 ng/ml 
Taxol  10 mM 10 µM 
Monastrol  100 mM 100 µM 
MG132 (Z-leu-leu-leu-al) 20 mM 20 µM 
Thymidine  200 mM 2 mM 
Tetracycline 1 mg/ml Dependent on cell line 
ZM447439 (Tocris Bioscience) 10 mM 2 µM 
AZ12783146 (AZ3146; AstraZeneca) 10 mM Various  (2 µM unless stated) 
Table 2.2 – Drugs used in this study  
2.2.1 | Drug treatments 
All compounds used to treat cells in this study were made up using sterile DMSO 
and stored at -20 or -80°C in glass vials, except for thymidine and tetracycline which was 
dissolved in autoclaved water, passed through a 0.2 µm filter and stored at 4°C (short term 
storage of thymidine) or -20 °C (tetracycline).  Unless otherwise stated, cells were treated 
with drugs diluted in warmed cell culture media to the final concentrations listed in Table 
2.2.  Drugs were purchased from Sigma-Aldrich unless indicated otherwise.  
2.2.2 | Use of tetracycline-inducible stable cell lines 
In this study I used two stable isogenic cell lines expressing tagged transgenes under 
the control of the Tet repressor.  Both were made using the Flp-In T-REx system 
(Invitrogen) and have been described previously (see Table 2.1, bottom two rows).   To 
induce expression of Myc-LAP-tagged CENP-E tail (amino acids 1547-2580 of Swiss-Prot 
entry Q02224-3) in the DLD1 cell line, media was supplemented with 50 ng/ml 
tetracycline and cells were cultured for 24 hours before analysis.  To induce expression of 
wild type (WT) or kinase-dead (KD) GFP-tagged Mps1 in the HeLa cell line, 1 µg/ml 
tetracycline was used and cells were left for 24-48 hours until analysis.  HeLa tetracycline-
inducible cell lines were cultured in hygromycin (40 µg/ml, Roche) and blasticidin (4 
µg/ml, Melford) 
2.2.3 | Cell synchronisation 
A double thymidine block was used to synchronise a cell population in early S phase.  
Cells were incubated with media containing thymidine for 16 hours, and then released 
from arrest by removing thymidine media, washing twice with PBS and replacing the 
media with plain media.  After 8 hours, thymidine was added again, for a further 16 hours. 
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 When released from the second block, cells proceeded through the cell cycle as a 
synchronised population and were harvested and processed for flow cytometry (Section 
2.11) as required.  
2.2.4 | Monastrol wash-out experiments 
To study chromosome alignment I used a monastrol wash-out protocol.  Cells grown 
on glass coverslips were treated with monastrol for 4 hours, then washed twice with warm 
complete media and once with media containing MG132 with or without the kinase 
inhibitors AZ3146 or ZM447439.  After the third and final wash, cells were incubated in 
the same media (MG132 ± kinase inhibitors) for 60-90 minutes, and then cells were fixed 
and stained for immunofluorescence. 
2.3 | Molecular Biology 
2.3.1 | PCR to amplify a DNA coding sequence  
To amplify an open reading frame (ORF) for cloning into a vector, polymerase chain 
reaction (PCR) was used.   Primers were designed complementary to sequences at each end 
of the region of interest, with the addition of restriction enzyme cut sites to allow ligation 
into a vector.  Primers used are listed in Table 2.3 and were purchase from Invitrogen.  The 
template DNA for amplification of the human Mps1 catalytic domain was 
pcDNA5/FRT/GFP-Mps1 (originally made by P. Eyers).  PCR reaction mixtures included 
10 µl 10X Cloned Pfu DNA Polymerase Buffer (Stratagene), 10 µl dNTP mix (2.5 mM, 
Roche), 10 µl of 10 µM forward and reverse primers, ~600 ng of plasmid template DNA, 
0.5 µl cloned Pfu DNA polymerase (2.5 U/µl; Stratagene) and sterile water to a total  
 
Primer name Sequence (5ʼ to 3ʼ) Restriction site Purpose 
Mps1 catalytic 
domain (510-857) 
forward 
GCCGCCGGATCCGCATCTT
CTTCAGCAAATGAATGC 
BamH1 
Mps1 cat reverse GCCGCCGCGGCCGCTCATT
TTTTTCCCCTTTTTTTTTCAA
AAGTCTTGG 
Not1 
Cloning Mps1 catalytic 
domain (510-857) 
ORF into pET28a  
T7 Promoter 
(forward) 
TAATACGACTCACTATAGGG - Sequencing – pET28a 
inserts from 5ʼ vector 
region 
T7 Terminator 
(reverse)  
GCTAGTTATTGCTCAGCGG - Sequencing – pET28a 
inserts from 3ʼ vector 
region 
Table 2.3 – Primers used in this study, with restriction enzyme recognition sites in bold. 
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Temperature (°C) Time (min) Number of cycles 
Thermocycling conditions for ORF amplification 
94 3:00 1 
94 
45 
72 
0:30 
0:30 
2:00 (2 min per kb) 
2 
94 
55 
72 
0:30 
0:30 
2:00 
25 
72 5:00 1 
4 ∞ 1 
Thermocycling conditions for DNA sequencing 
96 1:00 1 
96 
50 
60 
0:10 
0:15 
4:00 
32 
4.0 ∞ 1 
Table 2.4 – Thermocycling conditions 
volume of 100 µl. Reactions were carried out in thin walled 0.2 ml PCR tubes in a 
GeneAmp® PCR System 2700 (Applied Biosystems).  Thermocycling conditions are 
described in Table 2.4.  5 µl of the completed PCR reaction was run on a 1% agarose gel to 
check the success of the reaction (see Section 2.3.3).  The PCR reaction was purified using 
a QIAQuick PCR Purification Kit (Qiagen) in accordance with the manufacturer’s 
instructions. 
2.3.2 | Restriction enzyme digest 
To prepare DNA for ligation, a standard double digest was set up containing plasmid 
or insert DNA (0.5-1 µg), 10 units of each restriction enzyme, the appropriate buffer and 
BSA if required (enzymes, buffers and BSA were from New England Biolabs).  Samples 
were incubated at 37 °C for 4 hours, then mixed with 5× DNA loading buffer (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol).  Digested fragments 
were subjected to gel electrophoresis. 
2.3.3 | Gel electrophoresis and DNA purification from agarose gels 
DNA molecules were separated according to size by electrophoresis.  Gels were 
made with 1% agarose dissolved in TBE (88 mM Tris, 88 mM boric acid, 2 mM EDTA, 
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 pH8.2). When DNA was to be excised and used directly in ligations (Section 2.3.4), low 
melting agarose (Flowgen) was used. Samples were mixed with DNA loading buffer 
before electrophoresis.  A lambda phage DNA ladder (New England Biolabs) was loaded 
alongside samples.  Gels were run at 100V for approximately 1 hour and stained with 
ethidium bromide, then DNA was visualised using a UV lamp.  The required insert or 
plasmid backbone bands were excised and used in ligations. 
2.3.4 | In-gel ligation 
‘Sticky-ended’ plasmid and insert DNA was ligated by an in-gel method.  First, gel 
slices were placed at 70 °C for 10 minutes to melt the agarose.  Then 7 µl of insert, 1 µl of 
plasmid, and 1 µl of T4 ligase buffer (New England Biolabs) were mixed, placed on ice 
and allowed to set and cool.  1 µl of T4 ligase (New England Biolabs) was pipetted on top 
of the solidified agarose and the mixture was placed at room temperature for at least 3 
hours.  After the addition of 40 µl of water, the mixture was heated to 70 °C for 10 minutes 
and 10 µl was used to transform competent bacteria.  Control ligations were performed in 
parallel using blank agarose in the place of either insert or plasmid. 
2.3.5 | Bacterial transformation and preparation of DNA 
Bacterial transformations were carried out according a standard protocol.  For 
plasmid propagation, XL-1 Blue chemically competent Escherichia coli were used.  A 50 
µl aliquot of thawed cells was incubated on ice for 20 minutes with 1 µl of plasmid DNA 
or 10 µl of ligation mixture.  Cells were heat-shocked at 42 °C for 90 seconds, 400 µl of 
LB medium was added, and the tubes were placed at 37 °C in a shaking incubator for 1 
hour to allow the cells to recover.  Cells were plated on agar containing 100 µg/ml 
carbenacillin or 50 µg/ml kanamycin, depending on the resistance conferred by the vector.  
Plates were incubated at 37 °C overnight.  Then, single colonies were picked and grown up 
overnight at 37 °C in a shaking incubator in 3 ml of Luria-Bertani medium (LB) with 25 
µg/ml ampicillin or 50 µg/ml kanamycin.  To isolate DNA from these cultures, a QIAprep 
Spin Miniprep kit (Qiagen) was used as per the manufacturer’s instructions. 
2.3.6 | Glycerol stock preparation 
To store transformed E. coli, a 15% glycerol stock was prepared from an overnight 
culture.  A mixture of 200 µl sterile 50% glycerol and 466 µl bacterial cell suspension was 
stored at -80 °C.  This stock was used to inoculate cultures or streaked on agar plates as 
required. 
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 2.3.7 | Sequencing 
The BigDye v3.1 Terminator Sequencing Kit (Applied Biosystems) was used to 
sequence plasmid DNA.  A reaction mix was assembled containing 300-800 ng plasmid 
DNA, 10 pmol sequencing primer (see Table 2.3), 3.5 µl AB Buffer, 1 µl BigDye mix 
and sterile distilled water to a final volume of 20 µl.   Thermocycling conditions are shown 
in Table 2.4.  After completion of the reaction, the DNA was precipitated with ethanol as 
follows: the volume was made up to 100 µl with distilled water, then 10 µl of sodium 
acetate pH5.2, 250 µl 100% ethanol and 1 µl GlycoBlue (15 mg/ml, Ambion) was 
added.  The tubes were incubated on ice for 15 minutes, and then centrifuged at 17968 × g 
(14000 rpm) for 15 minutes in a Sigma 1-15K refrigerated microfuge with rotor 12124.  
The pellet was washed with 500 µl 70% ethanol and centrifuged again.  After careful 
removal of the supernatant, the pellet was air-dried at room temperature and sent to the in-
house DNA Sequencing Facility. 
2.4 | Production of recombinant Mps1CAT in E. coli. 
2.4.1 | Protein expression 
The C-terminal catalytic domain of Mps1, corresponding to amino acids 510-857, 
was cloned into the bacterial expression vector pET28a (Novagen), as detailed in Section 
2.3.  This vector allowed expression of a fusion protein with an N-terminal 6His-tag 
(Mps1CAT).   BL21 (DE3) pLysS E. coli (Novagen) were transformed with the plasmid and 
a glycerol stock was made (see Section 2.3.5 and 2.3.6).  The glycerol stock was used to 
inoculate 3 ml LB with 50 µg/ml kanamycin and incubated overnight at 37 °C with 
shaking.  This culture was diluted 1:1000 into 1 litre LB media and incubated at 37 °C with 
shaking until the optical density measured at 600 nm (OD600) was ~ 0.7.  Expression was 
induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and cultures were 
incubated for 16 hours at 18 °C with shaking.  After induction, cells were pelleted by 
centrifugation at 4302 × g (4500 rpm) in a Sigma 6K-15 centrifuge fitted with rotor 11150.  
The pellet was stored at -80 °C prior to purification. 
2.4.2 | Bacterial cell lysis and purification of 6His-tagged Mps1CAT by metal ion 
affinity chromatography 
Pelleted bacteria were resuspended in ice-cold lysis buffer containing 50 mM Tris-
HCl pH7.4, 300 mM NaCl, 0.1% (v/v) Triton X-100, 10 mM imidazole, 0.1 mM EDTA, 
0.1 mM EGTA, 0.03% β-mercaptoethanol, 0.4 mM phenylmethylsulfonyl fluoride (PMSF) 
1 mM benzamidine and complete EDTA-free protease inhibitor cocktail tablet (Roche) and 
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 sonicated using a Vibracell ultrasonic processor (Sonics) on ice for 1 minute in 10 second 
pulses at 40% amplitude.  Insoluble debris was pelleted by centrifugation at 21036 × g 
(14000 rpm) in a Sigma 6K-15 centrifuge with rotor 12166 for 45 minutes, and the 
resulting supernatant was incubated with 1 ml of equilibrated TALON® metal affinity resin 
(Clontech) for 1.5 hours at 4 °C with end-over-end rotation.  The resin was washed with 50 
ml wash buffer (50 mM Tris-HCl pH7.4, 500 mM NaCl, 10 mM imidazole, 0.1 mM 
EDTA, 0.1 mM EGTA, 0.03% β-mercaptoethanol).  6His-tagged Mps1CAT was eluted 
from the resin in 0.5-1 ml fractions with elution buffer containing 50 mM Tris-HCl pH7.4, 
300 mM NaCl, 300 mM imidazole, 0.1 mM EDTA, 0.1mM EGTA and 0.01 % β-
mercaptoethanol.  A visual assay was performed using Coomassie Plus Bradford reagent 
(Pierce) to determine the fractions with the highest protein concentration. These were 
pooled, before changing the buffer by dialysis in a Slide-a-Lyzer dialysis cassette (3.5 kDa 
molecular weight cut-off, Pierce) against dialysis buffer containing 50 mM Tris-HCl 
pH7.4, 150 mM NaCl, 0.1 mM EGTA and 0.1 % β-mercaptoethanol.  Dialysis was 
performed overnight at 4 °C in a volume of 500 ml with gentle stirring, with one change of 
buffer after 2 hours.  Following dialysis, the purified 6His-Mps1CAT solution was 
concentrated by centrifugation at 4000 × g in a Vivaspin (Sartorius) 2 ml capacity 
concentrator column with a 5 kDa cut-off.  Total protein concentration was determined by 
Bradford assay using Coomassie Plus Bradford assay reagent, using bovine serum albumin 
(BSA) as standards.  SDS-PAGE and Coomassie staining (see Section 2.5) were used to 
estimate the concentration of full-length recombinant Mps1CAT.   The rest of the 
concentrate was split into single-use aliquots, snap-frozen on liquid nitrogen and stored at -
80°C until use in initial kinase assays (see Section 2.7) with a small range of inhibitor 
concentrations.    
For determination of AZ3146’s IC50 by assaying a wide range of inhibitor 
concentrations (Figure 3.2C), purified 6His-Mps1CAT was obtained from Matthew Chu 
(Tabernero lab, University of Manchester).  This was expressed and purified as described 
in (Chu et al., 2008).  
2.5 | SDS-PAGE and western blotting 
2.5.1 | SDS-PAGE 
Sodium-dodedcyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins by size.  After running gels, proteins were visualised by 
Coomassie staining (see Section 2.5.2) or western blotting (see Section 2.5.3).  To prepare 
samples for SDS-PAGE, they were mixed with 6X SDS-PAGE sample buffer (350 mM 
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 Tris-HCl pH6.8, 10% SDS (w/v), 600 mM dithiothreitol (DTT), 0.06% (w/v) bromophenol 
blue, 30% (v/v) glycerol) and boiled for 5 minutes. For SDS-PAGE of total cell lysates, 
cells were harvested by trypsinisation (see Section 2.2), washed once with PBS, followed 
by lysis of the pelleted cells directly into SDS-PAGE sample buffer by resuspending cells 
in the buffer and boiling for 5 minutes.  SDS-PAGE gel casting equipment and gel tanks 
were from Hoefer.  Gels were cast in plates separated by 1.5 mm or 0.75 mm spacers with 
10- or 15-well combs.  The acrylamide percentage in the resolving gel was selected 
according to the molecular weight of the proteins to be resolved. The resolving gel was 
poured first and allowed to polymerise before the stacking gel was layered on top. 
The polymerised gel was clamped into a Mighty Small SE250/SE260 running tank, 
which was filled with running buffer (25 mM Tris, 200 mM glycine and 0.1% (w/v) SDS).  
Protein samples and a molecular weight marker (Precision Plus Dual Colour, Bio-Rad) 
were loaded into wells and the gel was run at a constant voltage of 150V.   
2.5.2 | Coomassie staining 
To directly visualise relatively large amounts of protein after SDS-PAGE, gels were 
fixed and stained in Coomassie solution (0.2% (w/v) Coomassie Brilliant Blue, 40% 
methanol, 7% acetic acid) for up to 1 hour at room temperature whilst rocking gently.  
Gels were washed in destain solution (40% methanol, 7% acetic acid) at room temperature 
for several hours until bands were visible and background was reduced.   
2.5.3 | Western blotting 
For detection of a specific protein in a sample using an antibody, proteins were separated 
by SDS-PAGE then transferred to either an Immobilon P polyvinylidene fluoride (PVDF; 
Millipore) or nitrocellulose (Whatman) membrane.  A standard transfer sandwich was 
assembled with Whatman filter paper wetted with transfer buffer (25 mM Tris, 190 mM 
glycine, 0.1% (w/v) SDS and 20% methanol.  The membrane was placed on the anode side 
of the SDS-PAGE gel in a Trans-blot semi-dry transfer system (Bio-Rad), which was run 
at 15V for 1 h.  When the protein of interest was larger than 100 kDa, a wet transfer system 
(Bio-Rad) was used. In this case the tank was filled with wet transfer buffer (50 mM Tris, 
380 mM glycine, 0.2% (w/v) SDS, 5% methanol) and 50V was applied for 1 hour.   
After transfer of the proteins to the membrane, non-specific antibody binding was 
prevented by incubation with a blocking solution of TBST with 5% milk solution (100 mM 
Tris, 150 mM NaCl, 0.1% (v/v) Tween-20, 5% (w/v) non-fat powdered milk) for 30-60  
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 minutes.  The primary antibody (see Table 2.5) was appropriately diluted in the blocking 
solution and incubated with the membrane overnight at 4 °C with gentle rocking. 
Membranes were then washed for 5 minutes 5 times with TBST (100 mM Tris, 150 
mM NaCl, 0.1% (v/v) Tween-20) before incubation for 1 h at room temperature with HRP-
conjugated secondary antibody.  After washing again 5 times with TBST, the membrane 
was incubated with SuperSignal West Pico Chemiluminescent Substrate (Pierce) was 
added to the membrane.  Luminescence was detected by exposure of the membrane to 
Biomax MR photographic film (Kodak). 
2.5.4 | Phos-tag SDS-PAGE gels 
To separate proteins in a total cell lysate according to their relative phosphorylation 
levels in addition to their size, Phos-tag (Phos-tag Consortium, Japan) was used according 
to the manufacturer’s instructions.  Briefly, Phos-tag (25 µM) and MnCl2 (50 µM) were 
added to standard SDS-PAGE resolving gels containing 6% (for anti-Mps1) or 8% (for 
anti-Aurora B) acrylamide.  To resolve the samples, a constant current of 30 mA was 
applied until the dye front reached the bottom of the gel.  Following washing of the gel in 
wet transfer buffer with EDTA (50 mM Tris, 380 mM glycine, 0.2% (w/v) SDS, 5% 
methanol and 100 mM EDTA), proteins were transferred to PVDF by wet transfer and 
processed for western blotting as described (see Section 2.5.3). 
Western blotting - primary antibodies 
Antibody Antigen Species Working dilution Source/Reference 
SMP1.1 hMps1 Sheep 1:2000 (Tighe et al., 2008) 
Phospho-
Aurora 
Phospho-hAurora A 
(T288)/hAurora B 
(T232)/hAurora C 
(T198) 
Rabbit 1:2000 Cell Signaling 
Technology 
Phospho-
Histone H3 
Phospho-S10 
hHistone H3 
Rabbit 1:10000 Millipore 
SAA1.1 hAurora A Sheep 1:5000 (Girdler et al., 2006) 
SAB1.2 hAurora B Sheep 1:1000 (Girdler et al., 2006) 
Mps1 CT Mps1 C-terminal Mouse 1:1000 Millipore 
His 6xHis tag Mouse 1:1000 Sigma 
Secondary antibodies 
HRP-
conjugated 
secondary 
Anti-sheep IgG Rabbit 1:500 Invitrogen 
HRP-
conjugated 
secondary 
Anti-rabbit/goat IgG Goat 1:500 Invitrogen 
Table 2.5 Antibodies used for Western blotting 
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 2.6 | Immunoprecipitation from cell lysates 
2.6.1 | Preparation of cell lysates 
To prepare cell lysates for immunoprecipitation of endogenous Mps1 from mitotic 
TA-HeLas, cells plated on 15 cm dishes (1 dish per 5 IPs) were treated with nocodazole for 
14 hours.  Loosely-adherent mitotic cells were collected by shake-off, pelleted by 
centrifugation at 306 × g (1200 rpm) in a Sigma 6K15 centrifuge with rotor 11150, then 
washed once with chilled PBS.   The washed pellet was resuspended in 1.25 ml ice-cold 
mammalian cell lysis buffer (250 µl per IP) consisting of 50 mM Tris-HCl pH7.4, 100 mM 
NaCl, 0.5% NP-40, 5 mM EDTA, 5mM EGTA, 40 mM β-glycerophosphate, 0.2 mM 
PMSF, 1 mM DTT, 1 mM sodium orthovanadate, 20 mM sodium fluoride, 1 µM okadaic 
acid (Calbiochem) and complete EDTA-free protease inhibitor cocktail tablet (Roche).  
Cells were lysed on ice for 30 minutes with occasional mixing, and centrifuged at 17968 × 
g (14000 rpm) for 20 minutes in a Sigma 1-15K refrigerated microfuge with rotor 12124 to 
pellet insoluble cell debris.  The supernatant was split into 250 µl aliquots and used 
immediately, or snap frozen on liquid nitrogen, and stored at -80 °C until use.  
2.6.2 | Covalent cross-linking of antibody to beads 
Mps1 was immunoprecipitated from cell lysates using a sheep anti-Mps1 polyclonal 
antibody (SMP1.1, Tighe et al., 2008) coupled to a Protein G Sepharose 4 Fast Flow 
matrix (GE Healthcare).  100 µl of settled Protein G Sepharose beads was washed three 
times with 1 ml PBST (phosphate-buffered saline with 0.1% (v/v) Tween-20), centrifuging 
at 4000 × g at 4 °C for 2 minutes to pellet beads between washes.   After resuspending the 
washed beads in 0.5 ml of PBST, 6 µl of SMP1.1 or sheep non-specific IgG was added.  
Beads and antibody were allowed to bind by incubating for 1 hour at 4 °C with end-over-
end rotation.  After two washes with 1 ml PBST and two washes with 1 ml 0.2 M sodium 
borate pH9, beads were resuspended in 1 ml of sodium borate and the cross-linker 
dimethylpimelimidate (DMP) was added to final concentration of 20 mM.  This was 
incubated at room temperature for 45 minutes with end-over-end rotation.   The beads were 
pelleted, washed twice with 1 ml of 0.2 M ethanolamine pH 8 to quench the reaction, then 
resuspended in 1 ml ethanolamine and rotated for 1 hour at room temperature.   The 
coupled antibody-bead complexes were stored at 4 °C and washed three times with cell 
lysis buffer before use in IPs. 
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 2.6.3 | Immunoprecipitation 
All immunoprecipitation steps were performed on ice using chilled buffers and 
centrifugation steps were carried out at 4°C.  To pre-clear the lysates of proteins binding 
non-specifically to the matrix, lysates were incubated with washed Protein G Sepharose 
beads (20 µl of 50% slurry per 250 µl lysate) and rotated at 4 °C for 30 minutes.  Beads 
were pelleted, and the pre-cleared supernatant was removed.  An aliquot of this lysate was 
removed for analysis and labelled as the IP input.  Antibody-coupled beads were added  
(20 µl of 50% slurry per 250 µl lysate), and samples were incubated at 4 °C for 2 hours 
with end-over-end rotation.  Non-specific sheep IgG-coupled beads were used alongside 
SMP1.1 as control IPs.  After binding of antibody-bead complexes to the target protein, the 
complexes were pelleted and washed once with 1 ml high salt wash buffer (50 mM Tris-
HCl pH7.4, 400 mM NaCl, 0.5% NP-40, 5 mM EDTA, 5mM EGTA, 40 mM β-
glycerophosphate, 0.2 mM PMSF, 1 mM DTT, 1 mM sodium orthovanadate, 20 mM 
sodium fluoride) and twice with 1 ml wash buffer (as high salt wash buffer, but with 100 
mM NaCl).   Pelleted immune complexes were used in kinase assays (see Section 2.7) or 
boiled in sample buffer for SDS-PAGE analysis (see Section 2.5) 
2.7 | γ32P incorporation assays (kinase assays) 
Radioactive in vitro assays were used to measure the effect of various concentrations 
of AZ3146 on the kinase activity of Mps1.  To measure the activity of recombinant 
Mps1CAT, the purified enzyme was added to an assay buffer containing 25 mM Tris-HCl 
pH7.4, 100 mM NaCl, 50 mg/ml BSA, 0.1 mM EGTA, 0.1% β-mercaptoethanol, 10 mM 
MgCl2 and 0.5 mg/ml of the exogenous substrate myelin basic protein (MBP; Upstate).  
The final assay volume was 40 µl.  In initial assays testing AZ3146 over a small 
concentration range (see Figure 3.2B), ~1 µg of Mps1CAT was used per assay.  For 
determination of the IC50 for AZ3146 in this assay (see Figure 3.2C) 500 ng of 
recombinant Mps1CAT was used.  Pelleted bead complexes were used in assays to measure 
the activity of immunoprecipitated Mps1 from cells (see Section 2.6). 1 µl of AZ3146 
diluted in DMSO was added to the assay mix to achieve the required final inhibitor 
concentration, and DMSO was included in control assays to account for the solvent.  
Assays were started by addition of [γ32P] ATP (Perkin Elmer) to a final concentration of 
100 µM (2 µCi per assay), followed by incubation at 30 °C for 20 minutes.  When assays 
contained bead-bound Mps1 from cells, samples were incubated with shaking at 250 rpm.  
Assays were then processed depending on the required read-out, as described below.  
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 2.7.1 | Quantitation of Mps1 kinase activity by Cerenkov counting 
For determination AZ3146’s IC50, proteins phosphorylated during the assay were 
captured on phosphocellulose paper to measure their radioactivity.  After completion of the 
incubation time, assays were spotted onto labelled squares of P81 paper (Whatman), then 
dropped into a beaker of 0.5% phosphoric acid containing a magnetic stir bar.  The papers 
were left to wash for 10 minutes before replacing the phosphoric acid and washing for 5 
minutes a further three times.  Papers were submerged in acetone for 2 minutes, air-dried, 
placed inside vials without scintillation fluid and the incorporated γ32P was measured by 
Cerenkov counting in a Packard 2100 scintillation counter for 1 minute per sample.  The 
background level of radioactivity, as determined by a no-kinase control, was subtracted 
from the sample readings.  All AZ3146-treated samples were normalised to the level of 
radioactivity in the solvent-only assay.  IC50s were determined by fitting a sigmoidal dose-
response curve using Prism v4.0 software (GraphPad Software). 
2.7.2 | Quantification of Mps1 kinase activity by 2D densitometry 
The activity of immunoprecipitated Mps1 from cells was measured by 2D 
densitometry of the MBP or Mps1 after separating proteins in the kinase assay by SDS-
PAGE.   After incubation at 30 °C, assays were stopped by addition of 10 µl 6X sample 
buffer, heated at 75 °C for 10 minutes and spun down.  Samples were loaded onto a 15% 
acrylamide gel and run as described in Section 2.5.  After resolving the proteins, the gel 
was Coomassie stained (Section 2.5.2) and dried down.  The dried gel was exposed to a 
Fugi phosphorimaging plate and imaged using a Fugi FLA 3000 phosphorimager.  
Quantification of 32P signal intensity was carried out using AIDA software (Raytest 
Isotopenmessgerate GmbH).  The background level of phosphorylation, as determined by a 
non-specific sheep IgG control IP, was subtracted from the values for each sample.  
AZ3146-treated samples were normalised to the signal in the Mps1 IP treated with DMSO 
alone, and graphs were drawn as above. 
2.8 | Selectivity screen 
To assess the selectivity of AZ3146, a single point screen was carried out by 
Invitrogen’s SelectScreen Kinase Profiling service.  A panel of 50 kinases were selected 
from those available and assayed with 1 µM AZ3146. 
2.9 | Colony formation assays 
To test the effect of various concentrations of AZ3146 on viability of cultured human 
cell lines, colony formation assays were carried out.  TA-HeLa, RPE-hTERT and HCT116 
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 cells were seeded on 6-well plates at a density of 21 cells/cm2 (200 cells/well) and left 24 
hours to adhere.  Fresh media was then added, either without drug, or containing AZ3146 
at concentrations of 10, 5, 2, 1, and 0.5 µM.  After 8-9 days, cells were washed with PBS, 
fixed in 4% formaldehyde for 20 minutes, washed with distilled water and stained with 
0.1% (w/v) crystal violet solution for 5 minutes.  After further washes, plates were dried in 
an oven before counting the visible colonies and solubilising the stain with 10% (v/v) 
acetic acid (1 ml per well).  Aliquots of solubilised stain from each well were transferred to 
a microtitre plate, and the absorbance at 595 nm was read on a Biotek Synergy HT plate 
reader with KC4 software.  The background absorbance of 10% acetic acid-filled blank 
wells was subtracted from each sample measurement, and absorbance readings were 
normalised to control (no AZ3146) levels. 
2.10 | Flow cytometry 
Propidium iodide and anti-MPM2 (anti-phospho-Ser/Thr-Pro, Upstate) staining was 
used to analyse DNA content and mitotic index of a population of fixed cells.  Cells were 
grown on 10 cm dishes, treated with drugs when appropriate and harvested by 
trypsinisation, collecting all media and washes.  Harvested cells were washed with 5 ml 
cold PBS and pelleted by centrifugation at 212 × g (1000 rpm) for 5 minutes.  The pellet 
was resuspended in 100 µl cold PBS and 350 µl ice-cold ethanol was added drop-wise 
whilst gently vortexing.  Fixed cells were stored at -20 °C for at least 16 hours prior to 
staining.  Immediately before staining, cells were washed twice with PBS, centrifuging at 
478 × g (1500 rpm) to pellet cells.  Pellets were resuspended in 500 µl anti-MPM2 diluted 
1:2000 in PBS, then incubated with the antibody for 1-2 hours at 4 °C.  After further 
washing with PBS, the cells were incubated with FITC-conjugated donkey anti-mouse 
secondary antibody (Jackson Labs) for 1 hour at 4 °C in darkness.  Cells were then washed 
again with PBS.  To stain the DNA, cells were resuspended in 500 µl of propidium iodide 
(40 µg/ml) and ribonuclease A (RNase A, 50 µg/ml) in PBS and incubated for 30 minutes 
at room temperature in darkness.  Stained cells were analysed on a CyAn flow cytometer 
(Dako) with Summit software. 
2.11 | Immunofluorescence 
To allow visualisation of specific cellular proteins using antibody labelling, cells 
were seeded onto 19 mm glass coverslips at 5.4 × 104 per coverslip for analysis 24 hours 
later, or 3.6 × 104 per coverslip for analysis 48 hours later.  Cells were treated with 
compounds as required, washing coverslips once with drug-containing media before 
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 addition of the final media.  Cells were fixed and stained by one of three protocols as 
detailed below.   
For most applications, the following fixation conditions were used:  Coverslips were 
washed once with PBS, fixed in 1% formaldehyde in PBS for 10 minutes, and then washed 
a further three times with PBS.  After incubation for 5 minutes in ~10 mM glycine block 
solution (1 drop of 1M glycine-Tris HCl pH8.5 in 4 ml PBS), cells were permeabilised by 
washing with 0.1% (v/v) Triton X-100 in PBS (PBS-T).  Primary antibodies were diluted 
in glycine block solution (see Table 2.6) and coverslips were incubated with antibodies for 
1 hour at room temperature.  Next, coverslips were washed twice with PBST and then 
incubated with the appropriate fluorophore-conjugated secondary antibodies for 1 hour at 
room temperature in darkness.  Following further washes with PBST, 1 µg/ml Hoechst 
33258 diluted in PBST was placed on coverslips for 2 minutes to stain DNA.  After two 
more washes, coverslips were mounted on slides on a drop of mounting media (90% 
glycerol, 20 mM Tris-HCl pH8.0).  The edges were sealed with clear nail varnish. 
To visualise tubulin, a microtubule-kinetochore stabilising buffer (MT-KC buffer: 
100 mM PIPES, 1 mM MgCl2, 0.1 mM CaCl2, 0.1% Triton X-100) was used to pre-extract 
the cells.  First, coverslips were washed once with PBS, then MT-KC buffer was added to 
the coverslips for 90 seconds at room temperature, followed by fixation in 4% 
formaldehyde in the same buffer for 10 minutes.  Blocking and staining proceeded as 
described in the previous paragraph.   
For staining of Cenp-E and components of the RZZ/Zwint complex, kinetochore 
buffer (KB: 20 mM Tris-HCl pH7.4, 150 mM NaCl, 0.1% BSA and 0.2% Triton X-100, 
Chan et al., 2000) was used to pre-extract cells.  After washing with PBS, coverslips were 
incubated with KB for 2 minutes at room temperature.  Cells were fixed in 4% 
formaldehyde in PBS for 7-10 minutes, then blocked and stained as detailed above.   
Slides were stored at -20 °C prior to viewing cells by fluorescence microscopy as 
described in Section 2.13. 
2.12 | Microscopy 
After fixation and staining, cells were analysed on a microscope. Two microscope 
systems were used in this study.  For routine analysis (referred to as ‘standard fluorescence 
microscopy’ in subsequent chapters), cells were viewed using a Zeiss Axioskop 2 upright 
microscope and images captured used a CoolSNAP HQ CCD camera (Photometrics).  
MetaMorph (Universal Imaging) software was used for image acquisition.  For high- 
quality, deconvolved images and where quantification was required, a Delta Vision 
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 Immunofluorescence 
Antibody name Antigen Species Dilution Source/Reference 
Primary antibodies 
ACA Centromeres Human 1:500 Bill Earnshaw, University 
of Edinburgh, UK 
TAT1 α-Tubulin Mouse 1:100 Keith Gull, University of 
Oxford, UK 
Cenp-E hCenp-E Rabbit 1:2000 Don Cleveland, UCSD, 
USA 
SCF.2 hCenp-F Sheep 1:800 (Holt et al., 2005) 
SB1.3 hBub1 Sheep 1:1000 (Taylor et al., 2001) 
SBR1.1 hBubR1 Sheep 1:1000 (Taylor et al., 2001) 
SAA.1 hAurora A Sheep 1:5000 (Girdler et al., 2006) 
SAB.1 hAurora B Sheep 1:1000 (Girdler et al., 2006) 
Phospho-Aurora Phospho-
hAurora A 
(T288)/hAurora B 
(T232)/hAurora 
C (T198) 
Rabbit 1:500 Cell Signaling Technology 
9B10 hMad1 Mouse 1:1000 Abcam 
SM2.2 hMad2 Sheep 1:500 (Johnson et al., 2004) 
Cenp-A hCenp-A Rabbit 1:200 Millipore 
Phospho-Cenp-A Phospho-S7 
hCenp-A 
Rabbit 1:1000 Millipore 
Phospho-Histone H3 Phospho-S10 
hHistone H3 
Rabbit 1:500 Millipore 
MCAK MCAK Rabbit 1:1000 Cytoskeleton 
Rod hRod Rabbit 1:1000 Gordon Chan, University 
of Alberta, Canada 
ZW10 hZW10 Rat 1:1000 Gordon Chan, University 
of Alberta, Canada 
Zwich hZwilch Rat 1:500 Gordon Chan, University 
of Alberta, Canada 
Zwint hZwint Rabbit 1:5000 Gordon Chan, University 
of Alberta, Canada 
GFP GFP Rabbit 1:3000 Abcam 
Secondary Antibodies 
Cy2-, Cy3- and Cy5-
conjugated 
secondaries 
 
Anti-
sheep/mouse/ 
rabbit/human/rat 
IgG 
Donkey 1:500 
(1:250 for 
Cy5) 
Jackson Immunoresearch 
Table 2.6 Antibodies used for immunofluorescence. 
 
61
 RT (Applied Precision) restoration microscope was used, equipped with a 100×/1.40 
UPlan S Apo objective, a Sedat Quad 86000v2 filter set (Chroma Technology Corp.) and 
an API XYZ stage.  Images were captured using a CoolSNAP HQ CCD camera, with a Z-
optical spacing of 0.2 µm.  Raw image stacks were deconvolved using SoftWoRx software 
(Applied Precision).  Maximum intensity projections were created from deconvolved 
stacks; these images were used for quantification where required, and are shown in the 
Results. 
2.12.1 | Quantitation of kinetochore protein localisation  
Protein levels at kinetochores were quantified by normalising to the ACA signal of 
each kinetochore pair.  SoftWoRx software was used to capture the total pixel intensity of 
wavelengths in the kinetochore region, and background readings were taken in non-
kinetochore areas.  The background pixel intensity per pixel was calculated for each 
wavelength and appropriate values subtracted from the reading for each kinetochore pair.  
A ratio was calculated (protein of interest/ACA) for each kinetochore, and these were used 
to compare levels between control and drug-treated cells.  Datasets were normalised to the 
mean control ratio and graphs drawn using Prism software. 
2.13 | Live cell imaging 
HeLa cells stably expressing a GFP-tagged Histone H2B (see Table 2.1) were filmed 
to analyse mitotic timing and monitor chromosome segregation.  Twenty-four hours before 
filming, cells were plated onto either a 4-well glass bottomed chamber slide (LabTek) at 7 
× 104 cells per well, or onto a clear 24-well plate (Corning) at 9.6 × 104 cell per well.  On 
the day of filming, cells were treated with drugs or solvent alone as required, and filming 
commenced ~2 hours later.   Cells were viewed using a Zeiss Axiovert 200 microscope 
system with a 32×/0.4 LD A-Plan objective.  The microscope was equipped with an 
environmental control chamber (Solent Scientific) and a PZ-2000 motorised stage 
(Applied Scientific Instrumentation) to enable multiple XY point visiting.  Cells were 
maintained at 37 °C with a humidified stream of 5% CO2.  Images were captured every 2 
minutes with a CoolSNAP HQ camera (Photometrics), and acquisition was controlled by 
MetaMorph software.  Mitoses were analysed manually using MetaMorph.  Movies and 
sequential TIFFs were made in MetaMorph and exported to QuickTime (Apple) or 
Photoshop (Adobe). 
2.14 | Mps1 RNAi add-back experiments 
Endogenous Mps1 expression was perturbed in cells using a shRNA-based approach, 
followed by induction of an RNAi-resistant GFP-Mps1 transgene using tetracycline (Tighe 
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 et al 2008, and see Section 2.2.2).  The procedure was essentially the same as that 
described previously (Tighe et al 2008).  Twenty-four hours prior to transfection, 4 × 104 
HeLa FRT/TO GFP-Mps1 WTR/KDR cells were seeded onto a 24-well plate in antibiotic-
free media.  Cells were transfected with pRS HuSH shRNA vectors (Origene) containing a 
21 nt Mps1 targeting sequence (target locus: nucleotides 1686-1706 of Mps1 coding 
sequence, NCBI ID CCDS4993.1) or a control pRS vector, mixed in a ratio of 9:1 with 
pcDNA5 DsRed-Histone H2B (Tighe et al., 2008).  Lipofectamine PLUS (Invitrogen) 
was used for transfections according the manufacturer’s instructions.  Briefly, 1 µl 
Lipofectamine and 4 µl PLUS reagent were used to form DNA-lipid complexes with 
400 ng total DNA per well (360 ng : 40 ng).  Media was replaced with 200 µl of serum and 
antibiotic-free media, and complexes were added to wells in a volume of 50 µl.  
Complexes were left on cells for ~6 hours before addition of 250 µl 20% serum media, 
with or without 2 µg/ml tetracycline, in order that final well concentrations were 10% 
serum and 1 µg/ml tetracycline.   Twenty-four hours later, cells were replated to coverslips 
for immunofluorescence, or 6 well plates for western blotting.  Cells were maintained in 
tetracycline where appropriate.  A further 24 hours later, coverslips were treated with 
nocodazole and MG132 for 2 hours before fixing and staining for immunofluorescence 
(Section 2.12).  Six-well plates were harvested by trypsinisation and lysed directly in SDS-
PAGE sample buffer before SDS-PAGE and western blotting (Section 2.5). 
 
63
 3 | Results Chapter I: AZ3146, a novel inhibitor of Mps1 
3.1 | Introduction 
A great deal of insight has been gained into the roles of human Mps1 in the mitotic 
checkpoint and chromosome alignment using RNAi-based techniques (Fisk et al., 2003; 
Jelluma et al., 2008b; Liu et al., 2003; Sliedrecht et al., 2010; Stucke et al., 2002; Tighe et 
al., 2008).  Despite these advances, the role of Mps1 kinase activity is far from fully 
understood.  When this study began, only one inhibitor of endogenous human Mps1 had 
been described: SP600125 (Schmidt et al., 2005).  However, this inhibitor is of limited use 
since it inhibits a broad range of kinases in cells (Bain et al., 2007).  Thus, new inhibitors 
of endogenous human Mps1 would be of great value.   
AZ3146 was developed at AstraZeneca, Macclesfield, after a high-throughput screen 
for inhibitors of Mps1 activity.  The original hit compound has been modified to increase 
potency and specificity, resulting in AZ3146, which is depicted in Figure 3.1A. The initial 
aims of this study were to assess the ability of this compound to inhibit Mps1.  In this 
chapter, I describe kinase assays designed to test the inhibitors potency and selectivity, 
followed by analysis of its effect on Mps1 in cells. 
3.2 | AZ3146 inhibits recombinant Mps1CAT in vitro 
To determine whether AZ3146 can indeed inhibit Mps1’s enzymatic activity, I set up 
an in vitro kinase assay using recombinant Mps1 purified from bacteria, MBP as an 
artificial substrate and γ32P-labelled ATP.  Instead of expressing and purifying the full-
length kinase, I used a C-terminal fragment encompassing the catalytic domain (amino 
acids 310-857) with an N-terminal 6xHis-tag (Mps1CAT) that has previously been shown to 
be active in vitro (Chu et al., 2008).  This fusion protein was expressed in E. coli and 
isolated from the bacterial cell lysate by metal ion affinity chromatography using Talon™ 
resin.  To assess the purity of the eluted protein, it was resolved by SDS-PAGE and the gel 
was stained with Coomassie Brilliant Blue.  The protein appeared largely free from 
contaminants and migrated at a position consistent with its expected molecular mass 
(Figure 3.1B, marked by an arrowhead).  The band appeared as a smear, consistent with 
reports that Mps1 purified from bacteria is highly phosphorylated (Mattison et al., 2007).  
To confirm that the affinity-purified protein was 6xHis-tagged Mps1CAT, I processed 
protein samples for western blot and probed them with antibodies against the Mps1 C-
terminal and the 6xHis-tag.  A band was detectable at the expected molecular weight with 
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Figure 3.1 The structure of AZ3146 and the purification of recombinant Mps1CAT from E. coli
(A) The chemical structure of AZ3146.
(B) Purified 6xHis-tagged Mps1CAT was expressed in E. coli and purified by metal ion affinity chromatog-
raphy using Talon® resin. The eluted protein was resolved by SDS-PAGE, and gel was Coomassie stained
to visualise total protein. The major band, which appears at the predicted molecular weight for 6xHis-tagged
Mps1CAT, is marked by an arrowhead.
(C) The purified protein was processed for western blotting and probed with antibodies raised against the C-
terminal domain of Mps1 (αMps1-CT, left panel) and the 6xHis-tag (right panel, αHis). The arrowhead
marks the band corresponding to the full-length 6xHis-tagged protein. The lower molecular weight bands
visible in the Mps1-CT blot are likely to represent degradation products.
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  both antibodies (Figure 3.1C), indicating that the protein I had purified was indeed 6xHis-
tagged Mps1CAT, and could be used in kinase assays. 
Several physiologically relevant substrates have been reported for human Mps1 (Dou 
et al., 2004; Jelluma et al., 2008b; Kanai et al., 2007; Leng et al., 2006; Wei et al., 2005; 
Zhu et al., 2007), and both full-length Mps1 and its catalytic domain have been shown to 
autophosphorylate (Chu et al., 2008; Jelluma et al., 2008a; Kang et al., 2007; Mattison et 
al., 2007; Mills et al., 1992; Stucke et al., 2004).  However, for convenience, I chose to use 
the non-specific substrate MBP in assays, since this acts as a good substrate for Mps1 in 
vitro (Lauze et al., 1995; Stucke et al., 2002).  Kinase assays were started by addition of 
[γ32P]ATP, incubated at 30°C for 20 minutes,  then the reactions were stopped by addition 
of SDS-PAGE sample buffer and proteins were separated by SDS-PAGE.  32P 
incorporation was visualised by exposing the dried gel to photographic film.  When 
Mps1CAT was included in the assays, bands corresponding to radiolabelled MBP and 
Mps1CAT were readily detectable by autoradiography (Figure 3.2A, lane 1), consistent with 
phosphorylation of the exogenous substrate and the kinase itself.  To rule out the presence 
of contaminants in the assay components, a no-kinase control was included (lane 8).  No 
radiolabelled MBP could be detected in the absence of the kinase, showing that the MBP 
phosphorylation relied upon the addition of affinity-purified Mps1CAT.  While I cannot 
completely exclude the presence of co-purifying kinases in the Mps1CAT prep, the lack of 
visible contaminants in the eluted protein (see Figure 3.1B), plus prior reports (Lauze et 
al., 1995; Stucke et al., 2002), allows a reasonable level of confidence that Mps1CAT kinase 
activity is responsible for MBP phosphorylation.  Therefore, these assays provide a useful 
read-out of Mps1 activity in vitro. 
Having set up a suitable in vitro assay of Mps1 activity, I tested the ability of 
AZ3146 to inhibit this activity.  Increasing concentrations of the compound were added to 
the assay mix before the reactions were started with [γ32P]ATP, producing a dose-
dependent decrease in 32P incorporation into both MBP and Mps1CAT itself when the 
proteins were visualised by autoradiography (Figure 3.2A).  The reduction in 32P-MBP and 
32P-Mps1CAT in response to AZ3146 treatment is consistent with the notion that the 
compound inhibits the catalytic activity of Mps1.  Taken together with data provided by 
AstraZeneca (Stephen Green, personal communication), these data verify that AZ3146 is a 
reasonably potent Mps1 inhibitor, justifying further investigation. 
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Figure 3.2 AZ3146 inhibits Mps1CAT kinase activity in vitro.
(A) Kinase assays were performed with bacterially-expressed Mps1CAT and concentrations of the inhibitor
ranging from 50 nM to 2 µM. Solvent only (lane 1) and no kinase (lane 8) controls were included. After
incubation with [γ32P]ATP, proteins were separated by SDS-PAGE and radiolabelled Mps1CAT (upper
panel) and MBP (middle panel) were visualised by autoradiography. The Coomassie-stained gel (lower
panel) shows roughly equal loading of MBP.
(B) In vitro kinase assays were carried out with Mps1CAT and a range of AZ3146 concentrations (0.1, 0.3, 1,
3, 10, 30 nM, 0.1, 0.3, 1, 3, 10, 30 µM) MpsCAT activity was measured by spotting assays onto P81 paper
followed by scintillation counting. Background readings were subtracted and values were normalised to the
solvent only control, and a sigmoidal dose response curve was fitted using Prism software. The dashed line
approximates the position of the IC50 calculated from the curve. Data points represent the mean values from
3 independent experiments, ± s.e.m.(error bars).
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Having shown that AZ3146 is indeed capable of inhibiting Mps1 in vitro, I sought to 
quantify its potency by establishing an IC50 for the compound.  To facilitate a more 
quantitative approach, I turned to Cerenkov counting, which measures the blue light given 
off by high-energy beta emitters such as 32P.  Kinase assays were carried out essentially as 
described above, except I used Mps1CAT provided by Matthew Chu (University of 
Manchester, purified as in Chu et al., 2008), and spotted the reactions onto negatively 
charged phosphocellulose paper before immersing the papers in phosphoric acid solution.  
This simultaneously stopped the reaction and conferred a positive charge to the proteins in 
the assays, causing them to stick to the phosphocellulose paper.  Unbound [γ32P]ATP was 
washed away, and the dry papers were placed in vials and counted in a scintillation counter 
(Hastie et al., 2006).  The background level of radioactivity in the no-kinase control was 
subtracted from each reading and the solvent-only control readings were set to 100% 
before plotting the data points on a graph, and fitting a sigmoidal dose-response curve 
using Prism v4.0 software (Figure 3.2B).   
The IC50 value calculated for the AZ3146 dose-response curve was 35 nM (Figure 
3.2B, marked on the graph by a dashed line).  It is noteworthy that at concentrations below 
3 nM, the radioactivity of the samples increased reproducibly to 115-120% of the control, 
solvent-only levels.  It is possible that the presence of the inhibitor, or some contaminant 
contained within the solution, may have had a stimulatory effect on kinase activity leading 
to an increase in radiolabelling in those samples.  Nevertheless, it is reasonable to conclude 
that their effect on the calculated IC50 would be relatively slight, so I proceeded to use the 
data to generate the IC50 value. 
The IC50 of 35 nM suggested a reasonable level of potency.  While it is difficult to 
compare the IC50s obtained for distinct kinase-inhibitor combinations under different assay 
conditions, it is nevertheless worth noting that this value is similar to the reported IC50 of 
an ATP-competitive Aurora B inhibitor, ZM447439 [50 nM, assayed at the same ATP 
concentration as this study (Girdler et al., 2006)].  ZM447439 potently inhibits Aurora B in 
cells at 2 µM (Ditchfield et al., 2003) and indeed has been widely used to investigate 
Aurora B function (Taylor and Peters, 2008).  It therefore seemed reasonable to speculate 
that AZ3146 might be able to yield similarly potent Mps1 inhibition.  Also noteworthy is 
the observation that AZ3146’s IC50 is value is ~10-fold lower than that of the other 
published human Mps1 inhibitor SP600125 (Schmidt et al., 2005) when used to inhibit 
Mps1CAT under identical assay conditions (356 nM – Matthew Chu, personal 
communication), indicating that AZ3146 is more potent than SP600125, and therefore 
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 potentially more effective in cells at lower concentrations, which would make AZ3146 a 
preferential tool for study of Mps1 function.   
In summary, under the assay conditions used in this study, AZ3146 inhibits Mps1CAT 
with an IC50 of ~35 nM.  While it can be difficult to extrapolate in vitro data to predict 
efficacy in cells, this in vitro IC50 suggests that the potency of AZ3146 may indeed be 
sufficient to produce potent Mps1 inhibition in cells at low micromolar concentrations. 
3.3 | AZ3146 inhibits full-length Mps1 from cells 
The capacity of AZ3146 to inhibit recombinant Mps1CAT in vitro was encouraging.  
However, before moving on to cell-based assays, I wanted to check that AZ3146 could 
inhibit full-length Mps1 isolated from human cells.  For this purpose, I used endogenous 
Mps1 immunoprecipitated from cells in kinase assays.  HeLa cells were challenged with 
the microtubule-depolymerising drug nocodazole to arrest the population in mitosis, then 
harvested and a soluble lysate produced.  Mps1 was immunoprecipitated from these 
mitotic lysates and pelleted bead complexes were used in kinase assays.  A fraction of the 
reaction mix was analysed by western blot (Figure 3.3A, upper panel), indicating that the 
kinase was present in roughly equal amounts in each assay (lanes 1-8), unless a non-
specific IgG was used for immunoprecipitations, in which case Mps1 was absent (lane 9).  
To visualise and quantify the incorporation of 32P into both the MBP and the Mps1, the 
proteins were resolved by SDS-PAGE and exposed to a phosphorimaging plate.  
Representative images are shown in Figure 3.3A (middle and lower panels). 
Endogenous human Mps1 is maximally active and phosphorylated in mitosis (Liu et 
al., 2003; Stucke et al., 2002).  When immunoprecipitated Mps1 was used in kinase assays, 
32P was incorporated into both the MBP (Figure 3.3A, bottom panel) and the 
immunoprecipitated Mps1 (middle panel), consistent with the notion that the kinase is 
active against both the exogenous substrate and itself.  Note however that I am unable to 
rule out the contribution of co-immunoprecipitated kinases to this phosphorylation.  When 
a control immunoprecipitation was performed, no 32P-Mps1 was discernable (middle 
panel, lane 9).  I was, however, able to detect radiolabelled MBP (bottom panel, lane 9), 
indicating that contaminant MBP kinase(s) that bind non-specifically to the Protein G 
Sepharose™ beads or control sheep IgG were present in the assays.  However, when 
Mps1-bead complexes were assayed, 32P-MBP levels increased more than 5-fold compared 
to levels in the control assay (compare lanes 1 and 9, bottom panel), consistent with the 
notion that the immunoprecipitated Mps1 phosphorylates the substrate.  Therefore, I was 
able to use radiolabelling of both immunoprecipitated Mps1 itself and MBP as a read-out  
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Figure 3.3 AZ3146 inhibits endogenous Mps1 immunoprecipitated from mitotic cells.
Mps1 was immunoprecipitated from nocodazole-treated HeLa lysates. The bead-bound proteins were used
in kinase assays with the indicated concentrations of AZ3146. (A) A fraction of the assay was resolved by
SDS-PAGE and blotted for Mps1 (upper panel). Note the absence of Mps1 in the control IgG IP (lane 9).
Assays were also processed by SDS-PAGE followed by phosphorimaging to visualise both radiolabelled
Mps1 (middle panel) and MBP (lower panel). (B) Mps1 phosphorylation and (C) MBP phosphorylation was
quantified by 2D densitometry. Background readings from the IgG control were subtracted, and values were
normalised to the solvent only control. The dashed line approximates the position of the IC50 calculated
from the curve.
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  of Mps1 activity in this assay.  
To verify the ability of AZ3146 to inhibit the immunoprecipitated Mps1, I included 
increasing doses of the compound in the assay mixes. Radiolabelling of Mps1 and MBP 
was quantified by 2D densitometry, the background levels from the IgG IP were 
subtracted, the control solvent-only readings were set to 100% and the data was graphed 
(Figure 3.3 B and C).  As predicted, the amount of 32P incorporated into both the Mps1 and 
the MBP fell in response to higher concentrations of AZ3146 (Figure 3.3 A and B). 32P-
Mps1 levels dropped markedly with 100 nM AZ3146, and decreased further at higher 
concentrations, becoming very low at 10 µM (Figure 3.3A, middle panel and 3.3B).  
Concurrent with the decrease in radiolabelling, a distinct band-shift from a slower mobility 
form of Mps1 (middle panel, marked by the open arrowhead) towards a faster mobility 
species (closed arrowhead) was evident as AZ3146 concentration in the assay increased, 
suggesting that this band-shift may be due to phosphorylation.  The decrease in 32P-MBP 
signal was more sudden, with a sharp fall in radiolabelling of the substrate between 10 nM 
and 100 nM AZ3146, after which levels plateaued (Figure 3.3A, bottom panel and 3.3C).  
The IC50s for AZ3146 in this assay were calculated to be ~80 nM and ~12 nM for Mps1 
phosphorylation and MBP phosphorylation respectively, which is in the same broad range 
as that determined using Mps1CAT (Figure 3.2B).   There are clearly slight differences 
between the IC50s and dose response curves obtained for MBP and Mps1 (Figure 3.3B and 
C), however more work would be required to establish whether or not these differences are 
reproducible and if so, what this might mean.  Taken together, these data provide evidence 
for AZ3146-mediated inhibition of full-length Mps1 immunoprecipitated from mitotic 
cells leading to a decrease in both Mps1 autophosphorylation and phosphorylation of the 
exogenous substrate MBP. 
3.4 | AZ3146 is a reasonably selective Mps1 inhibitor 
Having established that AZ3146 could inhibit the kinase activity of both recombinant 
Mps1CAT and also Mps1 immunoprecipitated from mitotic HeLa cells, I set out to gain an 
insight into its selectivity.  The selectivity of an inhibitor refers to its ability to inhibit its 
target kinase (or kinases) with a higher level of potency compared to other kinases.  
Selectivity is a desirable quality in most kinase inhibitors, since it means that the 
compound’s effect in cells are more likely to be specifically attributable to inhibition of the 
target, rather than to off-target effects.   Although the original hit compound had been 
optimised for enhanced selectivity and potency (Stephen Green, personal communication), 
I wanted to obtain an independent assessment of AZ3146’s selectivity.  To achieve this, I 
made use of Invitrogen’s SelectScreen™ Kinase Profiling Service, and screened panel of 
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 50 diverse kinases with 1 µM AZ3146 (Figure 3.4). A broad range of both serine/threonine 
and tyrosine kinases were selected, including representatives from 7 of the 9 conventional 
kinase groups as classified by sequence homology (Manning et al., 2002).  Kinases with 
reported roles in control of mitotic events were selected for inclusion the screen, such as 
the Aurora kinases (Carmena and Earnshaw, 2003), cyclin dependent kinases (Malumbres 
and Barbacid, 2005), Tao1 (Draviam et al., 2007), Gsk3β (Tighe et al., 2007), Plk1 
(Archambault and Glover, 2009), Erk2 (Borysova et al., 2008; Chen, 2004; Chung and 
Chen, 2003; Zhao and Chen, 2006).  Unfortunately the mitotic checkpoint kinases Bub1 
and BubR1 were not available, and so could not be tested in this screen.  Mps1 was also 
unavailable for selection, and so could not be included in the panel as a control.  However, 
as shown in Figure 3.2B, the concentration used for the screen almost completely inhibited 
Mps1CAT in vitro (96%). The majority of kinases in the screen, 46 out of the 50, were not 
greatly affected by 1 µM AZ3146, with inhibition levels <40% (Figure 3.4).   
Four kinases were inhibited by more than 40%, namely FAK (43%), KIT (58%), 
JNK1 (68%) and JNK2 (64%).  FAK is cytosolic tyrosine kinase with roles in the 
regulation of proliferation, survival, adhesion and migration (Hauck et al., 2002).  KIT is a 
receptor tyrosine kinase of the platelet-derived growth factor receptor family particularly 
associated with haematopoietic stem cells, with reported roles in regulation of proliferation 
and survival (Masson and Ronnstrand, 2009).  JNK1 and JNK2 are MAP kinases 
associated with the JNK/p38 pathway, which are implicated in regulation of transcription 
in response to environmental stress, and have also been shown to regulate apoptosis 
(Weston and Davis, 2007).  To the best of my knowledge, none of these kinases have been 
implicated in the regulation of mitosis, so there is no precedent to suggest inhibition of 
these kinases could have cellular effects attributable to Mps1 inhibition.  However, it is 
interesting to note that both AZ3146 and SP600125 are capable of inhibiting both Mps1 
and JNK (this study and Schmidt et al., 2005), pointing to a level of similarity between the 
catalytic domain of JNK1/2 and Mps1 (Chu et al., 2008; Schmidt et al., 2005), and perhaps 
the mechanism of inhibitor binding.   
 In summary, the selectivity screen described above allows AZ3146 to be considered 
a reasonably selective inhibitor, since at a concentration that potently inhibits the kinase 
activity of Mps1, only a small fraction of the kinases screened were inhibited to moderate 
levels.  This confirmed data from AstraZeneca (Stephen Green, personal communication) 
and provided further support for the notion that AZ3146 will be a useful tool for studying 
Mps1 in cells. 
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Figure 3.4 AZ3146 has limited activity against a panel of 50 kinases.
A single point screen with 1 µM AZ3146 was carried out by Invitrogen’s SelectScreen™ Kinase Profiling
Service. 50 diverse kinases were selected from the available list. Kinases were assayed at the approximate
Km for ATP, except B-RAF, MEK1, MEK2, MAPK14, JNK1 and JNK2, which were assayed with 100 µM
ATP. The Mps1 data included in the table is from the assays described in this study, where ATP was at 100
µM.
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3.5 | AZ3146 affects Mps1 phosphorylation in cells 
Having determined AZ3146’s potency and selectivity in vitro, I determined to assess 
its effect on Mps1 in cells.  Currently, there are no reliable phosphospecific antibodies with 
which to estimate Mps1 activity in cells, so instead I looked for changes in the 
electrophoretic mobility of the kinase itself when AZ3146 was added to the culture 
medium.   To prepare extracts for analysis by western blot, HeLa cells were treated with 
nocodazole overnight, then collected by mitotic shake-off and replated into nocodazole or 
Taxol, with or without 2 µM AZ3146.  The proteasome inhibitor MG132 was also 
included to prevent mitotic exit, since the predicted effect of an Mps1 inhibitor would be to 
override the checkpoint-mediated mitotic arrest in the presence of spindle toxins, resulting 
in changes in the phosphorylation as a result of mitotic exit and obscuring the effect of 
Mps1 inhibition.  After incubation with the indicated drug combinations, harvested cells 
were lysed in SDS-PAGE sample buffer, and then resolved on a polyacrylamide gel 
supplemented with the phosphate-binding ligand Phos-tag (Phos-tag Consortium), which 
enhances phosphorylation-induced mobility shifts in SDS-PAGE by facilitating separation 
of differentially phosphorylated forms (Kinoshita et al., 2006).  Consequently, a ladder of 
bands was visible when the blot was probed with an anti-Mps1 antibody (Figure 3.5).  
When the lysate blotted was from interphase cells (adherent cells left behind after mitotic 
shake-off), Mps1 appeared as 3 relatively fast migrating bands (lane 1, marked with 
asterisks).  When nocodazole or Taxol-treated lysates were probed (lanes 2 and 4), the 
majority of Mps1 now largely appeared as 2 shifted, slower-mobility bands (marked by 
arrowheads).  Importantly, when mitotic cells were treated with 2 µM AZ3146, the 
uppermost band decreased markedly (lanes 3 and 5, white arrowhead).  This was true for 
both nocodazole and Taxol-treated samples.  The banding pattern produced from the Phos-
tag gel can be interpreted to mean that in nocodazole- or Taxol treated mitotic cells, the 
majority of Mps1 is more highly phosphorylated than in interphase cells (compare lane 1 
with lanes 2 and 4).  When mitotic cells are treated with AZ3146, the disappearance of this 
slow-mobility band likely reflects a decrease in phosphorylation of Mps1.  In support of 
this, work carried out by my colleague, Anthony Tighe, has confirmed using phosphatase 
treatment that the ladder of Mps1 bands observed after running mitotic samples on Phos-
tag gels are indeed due to phosphorylation (Hewitt et al., 2010).  While the identity of the 
site(s) in Mps1 which might be dephosphorylated with AZ3146 treatment are unknown, 
and I cannot rule out indirect effects, this provides evidence of an effect on Mps1 
74
Inter
Noc
- AZ
Tax
- AZ
Figure 3.5 AZ3146 affects Mps1 autophosphorylation in cells.
HeLa cells were treated with nocodazole for 12 hours. Mitotic cells were collected and replated into the indi-
cated drug combinations (plus MG132 to prevent mitotic exit) for 2 hours. Adherent cells left behind after
mitotic shake-off were harvested and constituted the interphase sample (lane 1). AZ3146 was used at 2 µM
and DMSO was used in controls to account for the solvent. Harvested cells were lysed directly in SDS-
PAGE sample buffer and run on gels containing Phos-tag. Proteins were transferred to a PVDF membrane
and probed with an anti-Mps1 antibody. Asterisks mark the 3 bands evident in interphase samples; the
closed arrowhead indicates the major Mps1 band in mitotic lysates; the open arrowhead indicates the slow-
est-mobility band which virtually disappears from mitotic samples on treatment with AZ3146.
Contributions to this figure:
Cells were treated with drugs and harvested by Anthony Tighe. Samples were run on Phos-tag gels and
immunoblotted by Laura Hewitt.
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 phosphorylation in response to AZ3146, in both nocodazole and Taxol.  As such, this is 
entirely consistent with AZ3146-mediated inhibition of Mps1 in cells. 
3.6 | Summary 
This chapter describes the initial stages in the characterisation of the novel Mps1 
inhibitor AZ3146.  The compound inhibited recombinant Mps1CAT in kinase assays, with 
an IC50 of ~35 nM.  At a concentration that inhibited Mps1 activity by 96%, the compound 
exhibited relatively low inhibition of a panel of 46 out of 50 diverse kinases, indicating 
some selectivity for Mps1.  Inhibition of full-length Mps1 immunoprecipitated from HeLa 
cells was also observed.  Importantly, when mitotic cells were cultured with media 
containing AZ3146, the banding pattern on a Phos-tag gel suggested that endogenous 
Mps1 phosphorylation was reduced.  Since Mps1 autophosphorylation has been shown to 
correlate with kinase activity (Jelluma et al., 2008a; Kang et al., 2007; Mattison et al., 
2007), this decrease in phosphorylation might correlate with a reduction in activity.  
Encouragingly, the effect was achieved with 2 µM AZ3146, a relatively low molarity, 
meaning the risk of off-target effects in cells is reduced.  Taken together, the above data 
show that AZ3146 is a potentially useful tool for studying the function of Mps1 kinase 
activity in cells.  I next sought to extend my characterisation of the inhibitor by 
establishing its effect on the viability and mitotic checkpoint response of cultured tumour 
cell lines. 
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 4 | Results Chapter II: AZ3146 affects cell viability and leads to 
mitotic checkpoint override 
4.1 | Introduction 
Mps1 is a conserved component of the mitotic checkpoint, which delays anaphase in 
the presence of unattached or maloriented kinetochores, and thereby helps to safeguard 
against missegregation and the subsequent production of aneuploid daughter cells.  Several 
reports focusing on cultured human cancer cell lines have shown that complete abrogation 
of the spindle checkpoint by siRNA-mediated depletion of Mad2 or BubR1 results in 
widespread death in a cell population after 6 or 7 days due to catastrophic segregation 
errors (Kops et al., 2004; Michel et al., 2004).  Consistent with this, complete depletion of 
Mps1 by RNAi (Janssen et al., 2009), its replacement with a kinase-dead mutant (Jelluma 
et al., 2008a; Jelluma et al., 2008b), or replacement of endogenous Mps1 with a bulky ATP 
analogue-sensitive form (Sliedrecht et al., 2010) causes loss of viability in tumour cells.  
There has been some confusion in the literature regarding the effect of loss of Mps1 
activity on untransformed ‘normal’ cells: BJ-TERT fibroblasts were shown to be resistant 
to checkpoint override induced by the non-specific Mps1 inhibitor SP600125 (Schmidt et 
al., 2005), and, unlike tumour cell lines, VH-10 fibroblasts were resistant to death when 
treated with taxol concurrent with partial Mps1 depletion (Janssen et al., 2009).  However, 
recent work showed that ablation of Mps1 catalytic activity negatively affects proliferation 
and viability in both tumour cells lines and ‘normal’ untransformed cells lines 
(Kwiatkowski et al., 2010; Maciejowski et al., 2010).  
In this chapter, I sought to establish whether AZ3146-treated cells behaved as 
predicted for treatment with an Mps1 inhibitor.  The existing body of work on Mps1’s role 
in the mitotic checkpoint provided a clear framework with which to test the compound, and 
enabled me to make several predictions.  An inhibitor of Mps1 should: (1) kill tumour 
cells, and probably untransformed cells (Janssen et al., 2009; Jelluma et al., 2008b; 
Kwiatkowski et al., 2010; Maciejowski et al., 2010); (2) prevent cells arresting in the 
presence of drugs known to perturb the mitotic spindle (Jelluma et al., 2008b; Liu et al., 
2003; Schmidt et al., 2005; Stucke et al., 2002; Tighe et al., 2008); (3) hasten mitotic 
progression in an otherwise unperturbed mitosis, and lead to errors in chromosome 
segregation (Jelluma et al., 2008b; Maure et al., 2007; Tighe et al., 2008).   
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 4.2 | AZ3146 affects the viability of cultured human cancer cell lines and 
immortalised untransformed cells 
To compare the effect of AZ3146 with published reports (Janssen et al., 2009; 
Jelluma et al., 2008a; Kwiatkowski et al., 2010; Maciejowski et al., 2010; Sliedrecht et al., 
2010), I sought to find out if AZ3146 treatment was detrimental to the survival of different 
cell lines.  I wanted to observe the compound’s effect on more than one class of tumour-
derived cell line, so I chose to test one aneuploid cervical adenocarcinoma cell line (HeLa) 
and one near-diploid colon carcinoma cell line (HCT116).  I also included the 
immortalised retinal pigmented epithelium cell line (hTERT-RPE) as an example of a non-
transformed human cell line (Jiang et al., 1999).   
To obtain a read-out of the viability of these cell lines in response to AZ3146-
treatment, I used colony-formation assays.  These assays measure the ability of single cells 
to give rise to colonies when cells are plated at low density and cultured for several days, 
i.e. the cloning efficiency.  Two hundred cells were plated into each well of a 6-well 
culture plate, allowed to adhere, then cultured in media containing a range of AZ3146 
concentrations for 8-9 days.  The colonies were visualised by fixing and staining the cells 
with crystal violet and photographed.  Representative images of stained plates are shown in 
Figure 4.1.  Stained colonies were readily visible in the control wells for all 3 cell lines 
(top left well of each plate).  The mean colony number ± s.e.m. for the HeLa, HCT116 and 
hTERT-RPE untreated controls were 157.3 ± 6.0, 142.7 ± 11.8, and 91.3 ± 6.8 
respectively, suggesting that, while the cloning efficiency was reasonably high for both 
HeLa and HCT116s, a more significant amount of cell death may have occurred in the 
hTERT-RPE controls.  However, it is also plausible that the hTERT-RPE colony number 
was slightly underestimated due to merging of the relatively widespread, less dense 
colonies seen in this cell type (Figure 4.1C).   
In order to quantify the cell number in each well without introducing inaccuracies 
due to counting difficulties, the crystal violet stain was solubilised and the absorbance at 
595 nm was read.  A further advantage of this method over simply counting the colonies is 
that differences in colony size, as well as number, are reflected in the absorbance readings.  
The A595 values for control, untreated wells were set to 100% and data for each cell line 
was graphed (Figure 4.1).  For all 3 cell lines tested, addition of AZ3146 concentrations of 
1 µM or higher to the wells produced a marked decrease in staining, reflecting decreased 
cell viability.  At 2 µM, 5 µM and 10 µM, very little colony staining was evident for any 
cell line; reflecting this, A595 readings plateaued at a low level.  It should be noted that 
small increases in A595 were observed for both HeLa (Figure 4.1A) and 
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Figure 4.1 AZ3146 affects the viability of human cancer cells and immortalised untransformed cells.
HeLa (A), HCT116 (B), and hTERT-RPE (C) cells were cultured in 6-well plates for 8-9 days in the presence
of AZ3146 at the indicated molarities, before fixation and staining with crystal violet to visualise colonies.
Representative images of stained plates are shown (left panel). To quantify cell survival, the crystal violet
was solubilised and the absorbance at 595 nm was read (see graphs, right panel). The black line represents
the mean level of absorbance from 3 independent experiments. The value for each independent replicate
(grey diamond) is itself a mean derived from 2 duplicate wells. Values are normalised to the absorbance
reading from untreated wells.
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 hTERT-RPE (Figure 4.1C) when cells were cultured with 0.5 µM AZ3146.  Whilst I 
cannot rule out a stimulatory effect of AZ3146 on cell proliferation at low molarity, 
perhaps due to some unknown off target-effect, it is also possible that this increase is 
caused by slight inaccuracies in cell distribution between wells.   
To summarise, at concentrations of 1 µM or higher, AZ3146 had a severely 
detrimental affect on HeLa, HCT116 and hTERT-RPE cell viability in these colony 
formation assays.  The hTERT-RPEs appeared to be slightly more resistant to AZ3146-
induced cell death than HeLa and HCT116 cells, based on the comparatively large number 
of surviving hTERT-RPE cells after culture in 1 µM AZ3146 (44.5 ± 8.5% of control 
levels, compared to 24.6 ± 6.7 % for HeLa cells and 11.7 ± 2% for HCT116 cells; compare 
Figure 4.1C to A and B), but the differences between the cell lines was not large.  These 
data suggest that Mps1 inhibition by AZ3146 treatment can affect the viability of both 
cancer cell lines and immortalised untransformed cells. 
4.3 | AZ3146 causes degeneration of DNA content profiles in a dose-
dependent manner 
A plausible explanation for the reduction in of HeLa, HCT116 and hTERT-RPE cells 
after long term AZ3146 treatment is that perturbation of Mps1 activity at ≥1 µM AZ3146 
caused missegregation events which, over the 9-10 day duration of the assay, were not 
compatible with survival or growth of colonies.  To see if there were indeed segregation 
errors after AZ3146 treatment, I treated asynchronous populations of each cell line with a 
range of AZ3146 concentrations for 24 hours, which would allow for 1-2 divisions in the 
presence of the drug, then analysed the DNA content of the population by flow cytometry 
(Figure 4.2).  This kind of DNA content analysis is a relatively low-resolution method of 
detecting segregation errors, but it does provide a view of a relatively large cell population 
(in this case ~10,000 cells).  The DNA content profiles for the control populations showed 
slight variability between cell lines, presumably reflecting differences in the lengths of cell 
cycle phases, but all control profiles appeared to reflect a normal, cycling asynchronous 
population: 2N and 4N peaks were well defined, and an S-phase population was evident in 
between these (Figure 4.2, top row).  After 24 hours treatment with 1 µM AZ3146, profiles 
still appeared largely normal (second row).  When 2 µM of AZ3146 was used, the profiles 
for all 3 cell lines showed signs of deviation from the norm (third row):  the 2N and 4N 
peaks were wider than those in the control profiles.  Of the 3 cell lines tested, hTERT-
RPEs (right panel) appeared least severely affected by the compound in this assay; 2 µM 
AZ3146 caused only a slight effect on the DNA profile of this cell line.  At 5 µM and 10 
µM AZ3146, further deterioration of the profiles was evident for all 3 cell lines.  The 
80
2n 4n 4n2n
2 µM
DMSO
1 µM
10 µM
2n 4n
5 µM
HeLa HCT116 hTERT-RPE
Figure 4.2 AZ3146 causes degeneration of DNA content profiles in a dose-dependent manner
Asynchronous HeLa (left panel), HCT116 (middle panel) and hTERT-RPE cells (right panel) were cultured
with DMSO as a solvent-only control, or AZ3146 at the indicated molarities for 24 hours then harvested and
processed for DNA content analysis by flow cytometry.
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 widening of the 2N and 4N peaks reflects an increase in the number of cells with 
chromosome complements deviating from the normal copy number, and is therefore 
consistent with the notion that AZ3146-mediated Mps1 inhibition causes chromosome 
missegregation, giving rise to aneuploid cells.   
When treated with 5 µM or 10 µM AZ3146, the HCT116 population (middle panel) 
contained some cells abnormally high DNA contents of up to ~8N.  A fraction of HeLa 
cells treated with 5 µM or 10 µM of the compound (left panel) also had DNA contents of 
more than 4N.  These fractions presumably contain cells that have failed to segregate their 
chromosomes, but exited mitosis in a tetraploid state and proceeded into the next cell 
cycle, re-entering S phase.  There are at least two possible explanations for the existence of 
tetraploid cells.  Firstly, at the highest AZ3146 concentrations, Mps1 inhibition (and 
checkpoint override) may be more complete, meaning a larger proportion of cells might 
exit mitosis before bipolar spindle formation and cytokinesis can occur, as has been 
reported for DLD1 cells depleted of BubR1 (Morrow et al., 2005).  This might leave more 
tetraploid cells after exit from mitosis. Alternatively, perhaps higher concentrations of 
AZ3146 prevent cytokinesis itself from occurring in small subset of cells, through direct or 
indirect inhibition of pathways required for its completion.  Either way, since no prolonged 
mitotic arrest has occurred, some or all of these tetraploid cells may be capable of 
progression into the next S phase (Uetake and Sluder, 2007), as a similar effect was 
observed in cells where cytokinesis is prevented by depolymerising microtubules and 
inactivating the mitotic checkpoint (Kops et al., 2004; Taylor and McKeon, 1997), or 
inhibition of Aurora B (Ditchfield et al., 2003).  It is not possible to determine the 
mechanism governing formation of these >4N cells from the data shown here, however it 
seems reasonable to say that cytokinesis failure and/or the production of octaploid cells is a 
minor effect of AZ3146 treatment in asynchronous cells, but can occur in a subset of cells, 
most noticeably when AZ3146 is used at concentrations over 2 µM.   
The profiles shown in Figure 4.2 indicate that when cells were treated with 1 µM 
AZ3146 for 24 hours, the population appeared to be relatively unaffected.  However, the 
colony formation assays in Figure 4.1 showed that in the long term (9-10 days) cell 
viability was adversely affected by 1 µM of the compound in all 3 of the cell lines tested.  
How might this apparent contradiction be reconciled?  On possible answer is that with 1 
µM AZ3146, each mitosis produces only mild segregation errors leading to only very 
small deviations from the 2N and 4N populations, perhaps only in a proportion of cells.  
Such mild errors might be imperceptible in the DNA content profile of the cell population 
after only 24 hours, but might accumulate in the population over several rounds of division 
and be detrimental to survival over a longer period.  
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 In summary, after incubation with AZ3146 at 2 µM or higher for 24 hours, HeLa, 
HCT116 and hTERT-RPE cells exhibit DNA content profiles consistent with chromosome 
loss or gain.  This is entirely consistent with premature inactivation of the mitotic 
checkpoint and an increased rate of missegregation as a consequence of Mps1 kinase 
activity reduction. 
4.4 | 2 µM AZ3146 causes degeneration of DNA content profiles over time. 
Having established the effect of a range of doses of AZ3146 on the DNA content of 
cells at a single time point, I wanted to see what effect AZ3146 treatment had on the cell 
population over a longer time period.  For this, I used 2 µM of the drug, since this molarity 
causes phenotypes consistent with Mps1 inhibition in cells: it affects the phosphorylation 
of Mps1 in cells (Figure 3.5), leads to loss of viability in colony formation assays (Figure 
4.1), and causes a phenotype consistent with checkpoint override when DNA content was 
analysed by flow cytometry (Figure 4.2).  HeLa, HCT116 and hTERT-RPE cells were 
cultured in the presence of 2 µM AZ3146 and harvested at 24 h, 48 h and 72 h time points 
before analysis by flow cytometry.  The control populations appeared as expected for the 
duration of the experiment (Figure 4.3, DMSO profiles).  When cells were treated with 2 
µM AZ3146 for 24 hours, aneuploid cells were evident in the DNA content profiles for all 
3 cell lines, in keeping with the results shown in Figure 4.2.  For HeLa and HCT116 cells, 
the widening of the 2N and 4N peaks became more pronounced after 48 and 72 hour 
treatment, signifying more severe aneuploidy; this was accompanied by an increase in sub-
2N DNA, suggestive of cell death by apoptosis.  This was particularly marked in HCT116 
cells, where the DNA content profile had degenerated considerably after 72 hours with 2 
µM AZ3146.  The hTERT-RPE cell population also exhibited DNA contents suggestive of 
aneuploidy over the course of the experiment, but the deterioration of the profiles over 
time was less marked.  The hTERT-RPE cells did not exhibit a noticeable increase in sub-
2N DNA, which can be interpreted to mean there was less cell death in the population.   
These data strongly suggest that 2 µM AZ3146 treatment causes chromosome loss or 
gain, which, certainly in HeLa and HCT116 cells, leads to production of increasingly 
aneuploid cells over 3 days in culture.  The increase in sub-2N DNA is indictative of 
apoptosis, suggesting that in some cases this aneuploidy is lethal.  hTERT-RPE cells also 
showed signs of aneuploidy, but less evidence of lethality, suggesting that changes 
chromosome number were largely tolerated by the cell population over the 3 day duration 
of the experiment.  The loss of viability observed in the colony formation assays with 
hTERT-RPE cells (Figure 4.1) could indicate that the chromosome gains and losses  
 
83
Figure 4.3 AZ3146 treatment causes degeneration of DNA content profiles over time.
Asynchronous HeLa (top panel), HCT116 (middle panel), or hTERT-RPE (bottom panel) cells were cultured
in the presence of either DMSO (solvent-only control) or 2 µM AZ3146 for 24, 48 or 72 hours. Cells were
harvested and processed for DNA content analysis by flow cytometry.
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 induced by 2 µM AZ3146 are not compatible with viability over a longer period.  Overall, 
the data from all 3 cell lines supports the idea AZ3146 treatment leads to accumulation of 
aneuploidy as a result of impaired Mps1 function.  It also seems likely that the reduced 
colony formation of these cells (Figure 4.1) is caused, at least in part, by missegregation 
events as a consequence of Mps1 inhibition.   
4.5 | AZ3146 treatment results in bypass of a nocodazole-induced mitotic 
checkpoint  
Next, I sought to investigate a likely contributing factor to chromosome 
missegregation: mitotic checkpoint malfunction.  The catalytic activity of Mps1 is required 
for the mitotic checkpoint-mediated arrest in the presence of microtubule toxins that 
prevent spindle assembly (Jelluma et al., 2008b; Kwiatkowski et al., 2010; Schmidt et al., 
2005; Tighe et al., 2008).  Therefore, AZ3146 treatment is predicted to override the 
checkpoint-mediated arrest induced by nocodazole treatment.  To test this, I treated an 
asynchronous population of HeLa cells with nocodazole and 2 µM AZ3146 for 24 hours, 
then analysed the DNA content of the population by flow cytometry, and determined the 
fraction of the cell population with DNA content over 4N.  The DNA content profiles 
obtained for the various combinations of drug treatments are shown in Figure 4.4A, with 
the percentage of DNA >4N indicated in the upper right corner of each profile.  The 
control population appeared as expected, with a clear 2N and 4N peak and very few cells 
with a DNA quota exceeding 4N (1.0%; Figure 4.4A).  With AZ3146 alone, DNA contents 
diverging from 2N and 4N were observed, as seen in Figure 4.2 and 4.3, and the proportion 
of cells with >4N DNA very slightly increased (4.4%).  Twenty-four hours of nocodazole 
treatment caused accumulation of tetraploid cells, consistent with a checkpoint-induced 
mitotic arrest, and very few cells (1.3%) contained more than 4N DNA.  Importantly, when 
AZ3146 was combined with nocodazole, 52% of cells had a DNA complement of more 
that 4N, implying that the mitotic checkpoint response to nocodazole had failed.  
Checkpoint-deficient cells had exited mitosis without segregating DNA, avoided arrest or 
activation of pro-death pathways and proceeded into the next cell cycle, reduplicating their 
DNA in the subsequent S phase (Kops et al., 2004; Taylor and McKeon, 1997).  This is 
consistent with an AZ1346-mediated mitotic checkpoint override, and inhibition of Mps1 
catalytic activity (Jelluma et al., 2008b; Kwiatkowski et al., 2010; Schmidt et al., 2005; 
Tighe et al., 2008).   
To confirm the apparent mitotic checkpoint override induced by AZ3146, I wanted 
to observe its effect on a synchronised cell population.  To achieve this, I arrested HeLa 
cells in early S phase using a double thymidine block-and-release method, and then  
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Figure 4.4 AZ3146 treatment compromises a nocodazole-induced mitotic checkpoint.
(A) Asynchronous HeLa cells were cultured with DMSO (control) or the indicated combinations of AZ3146
(2 µM) and nocodazole for 24 hours before harvesting and processing for DNA content analysis by flow
cytometry. The percentage of cells with DNA content over 4N is shown in the top corner of each profile. (B,
C, and D) HeLa cells were synchronised in early S phase using a double thymidine block protocol, then
released into DMSO (control) or the indicated drug combinations. Cells were harvested at time points post-
release, and analysed by flow cytometry. (B) DNA content profiles from the indicated timepoints (t=0 to 50
h post-release). (C) Mitotic indices in the first 18 h post-release. Mitotic cells were defined as those with
4N DNA content and MPM2 positivity. (D) The percentage of cells with DNA contents of more than 4N
were determined from DNA content profiles.
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 released them into media containing the indicated combinations of nocodazole and 2 µM 
AZ3146.  Cells were harvested at subsequent time points and analysed to determine DNA 
content (Figure 4.4B).  Control DNA content profiles revealed cells progressing through S 
phase after release from thymidine block, then returning to 2N around 11 hours post-
release as cells went through mitosis.  Staining with the mitosis-specific phospho-antibody 
MPM2 confirmed that the mitotic index of the control population peaked around 10-11 
hours after release (Figure 4.4C).  Control cells then continued to cycle for the remainder 
of the experiment, and had lost synchrony by the final 50 hour time point (Figure 4.4B).  
Treatment with 2 µM AZ3146 alone caused the appearance of cells with abnormal DNA 
quotas after 1 or more rounds of division (11 hours post-release onwards), confirming 
previous observations (Figure 4.2, 4.3, 4.4A).  As predicted, cells released from thymidine 
into nocodazole arrested with 4N DNA content, with a mitotic index of ~50-60% up to 18 
hours after release (Figure 4.4B, C), indicative of a mitotic arrest due to spindle 
perturbation.  After 27 hours post-release, the appearance of sub-2N DNA suggested that 
many nocodazole-treated cells died (Figure 4.4B), while only a small fraction appeared to 
progress into the next cell cycle, reduplicating DNA (Figure 4.4D).  When cells were 
released into nocodazole and AZ3146, tetraploid cells began to accumulate in mitosis at a 
similar rate to cells treated with nocodazole alone, but, importantly, the mitotic index of 
AZ3146 and nocodazole treated cells fell dramatically after the 13 hour time point (Figure 
4.4B, C).  Furthermore, a large proportion of AZ3146 and nocodazole-treated cells went on 
to exhibit >4N DNA content (Figure 4.4B, C).  Strikingly, 27 hours after release from 
thymidine, 53% of AZ3146 and nocodazole-treated cells had >4N DNA, compared to only 
3% of cells that were released into nocodazole alone (Figure 4.4D).  These data indicate 
that AZ3146-treated cells fail to mount a robust mitotic checkpoint response to 
nocodazole, and continue to cycle in its presence.  This is in keeping with the previous data 
from asynchronous cells (Figure 4.4A).  Taken together, the data in Figure 4.4 strongly 
support the idea that AZ3146 treatment causes a mitotic checkpoint override, as one would 
expect from an Mps1 inhibitor. 
4.6 | AZ3146 accelerates mitotic exit in the presence of antimitotic drugs 
with varying mechanisms of action 
To extend the population-based analysis of AZ3146’s ability to induce mitotic 
checkpoint override in response to nocodazole (Figure 4.4), I next employed a direct, 
single cell approach to observe the compound’s effect in the presence of antimitotic drugs 
that target the spindle.  All three of these drugs prevent satisfaction of the mitotic 
checkpoint, leading to a mitotic arrest dependent on inhibition of the APC/CCdc20.  
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 However, the mechanism of action for each drug differs.  Nocodazole causes 
depolymerisation of microtubules, and thus a multitude of unattached kinetochores.  Taxol, 
on the other hand, prevents microtubule disassembly, leading to stabilised, non-dynamic 
microtubules that can form attachments at kinetochores, but their ability to form stable, 
amphitelic, checkpoint-satisfying attachments is severely compromised (Yang et al., 2009).  
Thirdly, the Eg5 kinesin inhibitor monastrol does not affect microtubule dynamics, but 
prevents centrosome separation, leading to monopolar spindles, syntelic attachments 
consequently and mitotic checkpoint activation (Kapoor et al., 2000; Mayer et al., 1999).   
To observe the effect of AZ3146 treatment on the duration of the mitotic arrest 
caused by these compounds, asynchronous HeLa cells stably expressing GFP-tagged 
Histone H2B were treated with the antimitotic drugs with or without 2 µM AZ3146, and 
filmed by timelapse microscopy.  Mitotic entry was defined as the point of NEBD, and 
mitotic exit was judged to have occurred when chromatin visibly began to decondense.  
Survival curves were plotted to visualise the data (Figure 4.5).  In nocodazole, the vast 
majority of cells (69 out of 71) remained in mitosis, with condensed chromatin, for at least 
500 minutes, consistent with mitotic checkpoint-mediated arrest.  In contrast, almost all 
AZ3146-treated cells analysed (76 out of 81) had decondensed their chromatin by 500 
minutes post-NEBD.  The variation in length of mitotic delay was wide, but concurs with 
the mitotic index values exhibited in Figure 4.4C: most cells remained in mitosis for at 
least ~180 minutes, after which the number of cells in mitosis dropped steadily.  Taxol 
treatment also led to a prolonged mitosis as measured by chromatin condensation: most 
cells (83 out of 91) kept their chromatin condensed for 500 minutes or more.  When 
AZ3146 was present, all cells (139 out of 139) had exited mitosis by ~220 minutes after 
NEBD.  Monastrol caused a comparatively transient arrest, with 65 out of 92 cells exiting 
mitosis after fewer than 500 minutes arrest.  Many of these cells divided, albeit often 
aberrantly (data not shown).  This might be a reflection of monastrol’s somewhat low 
potency: despite the continued presence of the drug, spindles can frequently bipolarise, and 
in cells that cannot resolve the merotelic attachments that arise during monopolar arrest, 
satisfy the spindle checkpoint (Gascoigne and Taylor, 2008).  Nevertheless, it is clear that 
AZ3146 markedly accelerated mitotic exit in the presence of monastrol: all cells had 
decondensed their chromatin by ~350 minutes post-NEBD.   
The data described above suggest that the mitotic checkpoint response to different 
types of drug that target microtubule dynamics, namely nocodazole and taxol, is attenuated 
by AZ3146 treatment. AZ3146-treated cells exited mitosis fastest in taxol; all cells 
analysed left mitosis after a delay of less than ~220 minutes.  Nocodazole- and AZ3146-  
88
Figure 4.5 AZ3146 accelerates mitotic exit in the presence of anti-mitotic drugs
Asynchronous HeLa cells stably expressing GFP-tagged Histone H2B were treated with nocodazole (top
left), taxol (top right) or monastrol (bottom centre), along with either DMSO (solvent-only control, blue
lines), or 2 µM AZ3146 (red lines) before tracking mitotic progression with fluorescence timelapse micros-
copy. The time each cell spent in mitosis was determined by recording the point of mitotic entry (NEB) and
exit (chromatin decondensation). Survival curves were plotted for each dataset.
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 treated cells took longer to exit mitosis (up to 350 minutes), and showed much wider 
variation in the duration of arrest, as shown by the gently sloping survival curve (Figure 
4.5).  One possible explanation for this is that the checkpoint in taxol is somehow easier to 
silence than the checkpoint in nocodazole, resulting in more rapid mitotic exit when cells 
are treated with taxol and AZ3146. Perhaps the presence of microtubules allows more 
efficient trafficking of checkpoint components off the kinetochore, meaning the signal can 
be extinguished more efficiently (Howell et al., 2001; Musacchio and Salmon, 2007).  Or, 
because kinetochores occupied by taxol-stabilised microtubules stimulate much less Mad2 
recruitment than unoccupied kinetochores (Waters et al., 1998), and have even been shown 
to be able to eventually cause checkpoint satisfaction (Yang et al., 2009), AZ3146 
treatment might more easily counteract the checkpoint in taxol.  Additional inputs into the 
downstream signalling cascade may exist in nocodazole-treated cells: Bub1 is reported to 
monitor kinetochore-microtubule attachment, and is therefore activated by nocodazole but 
not taxol (Morrow et al., 2005).  This extra positive influence on checkpoint signalling 
might mean cells treated with AZ3146 are able to sustain an arrest for longer in nocodazole 
than in taxol.  However, even if such additional input/s are able to delay mitotic exit in 
nocodazole, they are not sufficient to prevent checkpoint override in nocodazole when 
cells are treated with AZ3146.  In both nocodazole and taxol, almost all cells analysed 
were unable to sustain a checkpoint-mediated arrest when AZ3146 was present.  
Taken together, the timelapse microscopy data shown in Figure 4.5 strongly suggests 
that 2 µM AZ3146 treatment leads to inactivation of the mitotic checkpoint and 
consequently mitotic exit, despite the presence of antimitotic compounds that usually cause 
a more prolonged delay in mitosis.  This is entirely consistent with Mps1 inhibition.  
4.7 | AZ3146 accelerates passage through an unperturbed mitosis and 
causes missegregations 
As well as mediating mitotic arrest in response to spindle perturbations which inhibit 
the formation of checkpoint-satisfying microtubule-kinetochore attachments, the mitotic 
checkpoint is active in a ‘normal’, unperturbed mitosis to delay the onset of anaphase until 
all sister kinetochore pairs have achieved biorientation (Rieder et al., 1995). RNAi 
complementation assays have been used to show that Mps1 catalytic activity is required to 
stop premature anaphase initiation in human tumour cell lines (Jelluma et al., 2008b; 
Kwiatkowski et al., 2010; Sliedrecht et al., 2010; Tighe et al., 2008).  Therefore, I asked 
whether 2 µM AZ3146 treatment accelerated passage through mitosis.  I used timelapse 
microscopy to film asynchronous cells and recorded the duration of mitosis (NEB to 
chromatin decondensation), and extended my analysis to include both hTERT-RPE and  
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Figure 4.6 AZ3146 accelerates passage through an unperturbed mitosis
Asynchronous HeLa (A) and hTERT-RPE (B) cells stably expressing GFP-Histone H2B were cultured in the
presence of DMSO (control) or 2 µM AZ3146 and filmed using fluorescence microscopy. Time in mitosis
was defined as the time from NEB to chromatin decondensation. Data is displayed as box and whisker plots,
where the box shows the interquartile range and the median, and the whiskers show the full range. In (A),
the data shown is combined from 2 independent experiments; with a total of at least 75 HeLa cells analysed
per condition. In (B), the data shown is combined from 3 independent experiments, with a total of 150
hTERT-RPE cells analysed per conditon. (***P < 0.0001, Mann-Whitney U-test.)
*** ***
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 HeLa cells stably expressing GFP-tagged Histone H2B (Figure 4.6).  Control HeLa cells 
took a mean time of 90 min to complete mitosis; strikingly, the mean duration of mitosis 
was reduced to 32 minutes when AZ3146 was present (Figure 4.6A).  Control hTERT-
RPEs completed mitosis in a mean time of 37 min, in keeping with reports that 
untransformed cells take less time in mitosis than transformed cells (Rieder and Maiato, 
2004).  Again, AZ3146 addition reduced the mean duration of mitosis: hTERT-RPE cells 
now took an average of only 27 min from NEB to chromatin decondensation (Figure 
4.6B).  These data indicate that, in both a tumour cell line (HeLa) and immortalised 
“normal” cell line (hTERT-RPE), AZ3146 accelerated mitotic exit.  This effect is 
attributable to Mps1 inhibition via AZ3146, and suggests that Mps1 activity is required to 
restrain mitotic exit in both transformed and untransformed cells. 
As well as causing accelerated passage through mitosis, loss of Mps1 kinase activity 
(and consequently mitotic checkpoint function) is also associated with missegregation 
events in human tumour cells lines (Jelluma et al., 2008b; Kwiatkowski et al., 2010; 
Sliedrecht et al., 2010; Tighe et al., 2008).  To assess the mitotic phenotype of AZ3146-
treated cells, I classified the same HeLa and hTERT-RPE cells analysed in Figure 4.6 
according to the presence or absence of certain mitotic abnormalities.  The vast majority of 
untreated HeLa cells appeared to complete a normal mitosis, restraining the onset of 
anaphase until all chromosomes were properly aligned at the metaphase plate and cleanly 
segregating chromatin into two new daughter cells (Figure 4.7 A, montage i).  A fraction 
of untreated HeLa cells had mitotic abnormalities (21%), predominantly anaphase bridges; 
however, when cells were filmed in the presence of AZ3146 the proportion of cells with 
visible mitotic abnormalities increased dramatically, reaching 91%.  Two major 
phenotypes were evident.  Of these, segregation of DNA in the presence of misaligned 
chromosomes was the most common: 53% of AZ3146-treated HeLa cells exhibited this 
defect.  The severity of the defect varied from anaphase in the presence of one or more 
unaligned chromosomes at the poles (montage ii), to the absence of visible metaphase plate 
formation, with chromatin apparently cleaved by ingression of the furrow at cytokinesis 
(montage iii).  This resembles a ‘cut’-like phenotype that has been described in Mps1-
depleted cells (Jelluma et al., 2008b).  Missegregations like these could clearly produce 
aneuploid cells, in concurrence with the flow cytometry data (Figures 4.2-4.4).  The second 
most common phenotype in AZ3146-treated HeLa cells is illustrated in montage iv: 32% 
of cells failed to segregate their DNA, exiting mitosis with a single mass of chromatin.  
These cells frequently appeared to initiate anaphase prior to bipolar spindle formation, in a 
similar manner to cells depleted of BubR1 (Morrow et al., 2005).  Although cells with >4N  
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Figure 4.7 AZ3146 causes mitotic abnormalities consistent with mitotic checkpoint override
Asynchronous HeLa (A) and hTERT-RPE (B) cells stably expressing GFP-Histone H2B were cultured in the
presence of DMSO (control) or 2 µM AZ3146 and imaged using fluorescence timelapse microscopy. Mitotic
defects were classified and represented as bar graphs (A and B left panel; the legend in A also applies to B).
Representative examples are shown as image sequences (A and B i-iv). The time from NEB in minutes is
shown for each image. Arrowheads point to mis-aligned chromosomes and anaphase bridge-like structures.
Scale bars, 5 µm.
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 DNA contents were uncommon in asynchronous AZ3146-treated HeLa cells analysed by 
flow cytometry (Figures 4.2-4.4), some of the tetraploid cells produced by treatment with 2 
µM AZ3146 might be capable of progression into the next S phase: a modest increase in 
cells with >4N DNA content was apparent by flow cytometry in asynchronous AZ3146-
treated HeLa cells (Figure 4.4A), and when synchronised HeLa cells were released into 2 
µM AZ3146 (Figure 4.4B, D).  This timelapse data is consistent with AZ3146-mediated 
mitotic checkpoint override in HeLa cells, in agreement with the flow cytometry data. 
Analysis of the control population of hTERT-RPE cells revealed that almost every 
mitoses was normal in appearance (97%; Figure 4.7B, montage i).  Strikingly, treatment 
with 2 µM AZ3146 meant 75% of mitoses were classified as abnormal, with two distinct 
phenotypes.  A relatively small fraction of cells (13%) appeared to have an anaphase 
bridge-like structure, as shown in montage ii.  However, the principal abnormality in 
AZ3146-treated hTERT-RPE cells was anaphase initiation in the presence of misaligned 
chromosomes (62% of mitoses), ranging in severity as exemplified in montages iii and iv.  
Divisions like these are likely to lead to loss or gain of a few chromosomes, resulting in the 
relatively minor aneuploidy seen by DNA content analysis of these cells when treated with 
2 µM AZ3146 for 24 hours (Figures 4.2 and 4.3).  Taken together, the data in Figure 4.6 
and 4.7 back up the DNA content analysis in Figures 4.2-4.4, providing direct evidence of 
a mitotic phenotype consistent with Mps1 inhibition.  
4.8 | Summary 
In this chapter I tested the effect of AZ3146 on three different human cell lines.  
Whilst this is not a comprehensive examination of the compound’s effects on various cell 
types, it enabled me to gain some insight into the response of both tumour cell lines and 
untransformed cell lines to Mps1 inhibition.  Overall, the results show that hTERT-RPE 
cells, like HeLa and HCT116s, are sensitive to Mps1 inhibition: all cell lines showed signs 
of mitotic checkpoint override and a decrease in viability in the presence of the drug.  
However, it is noteworthy that the mitotic defect exhibited by the hTERT-RPEs was less 
severe than that observed in HeLa cells, which is possibly why the untransformed cells 
appeared to tolerate treatment with 2 µM AZ3146 better then the tumour cell lines in the 
shorter term (Figure 4.3) and seemed slightly more resistant to long term treatment (Figure 
4.2).   
The major aim of this chapter was to characterise AZ3146’s effect in cells by using 
various read-outs of mitotic checkpoint inhibition.  To summarise, the data in this chapter 
provides evidence that AZ3146 treatment (1) decreases viability in both transformed and 
untransformed human cells; (2) abrogates the mitotic checkpoint response induced by 
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 spindle-perturbing agents, and; (3) overrides the mitotic checkpoint in asynchronous cells, 
leading to accelerated passage through mitosis and aneuploidy.  Importantly, these 
observations are all wholly consistent with Mps1 inhibition.  Therefore, I am confident that 
AZ3146 is indeed a useful tool to probe Mps1 biology.  
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 5 | Results Chapter III: AZ3146 leads to loss of Mad2 and 
accumulation of Mps1 at kinetochore 
5.1 | Introduction 
In the previous chapter, I found that AZ3146-mediated Mps1 inhibition abrogated 
mitotic checkpoint signalling.  In order to establish a possible mechanism for this, I 
focused my attention on the origin of the checkpoint signal: the unattached kinetochore 
(Rieder et al., 1995).  Proteins involved in the mitotic checkpoint localise to the fibrous 
corona of unattached kinetochores, and abolishing kinetochore localisation of core 
checkpoint proteins perturbs the checkpoint response (e.g. Taylor and McKeon, 1997; 
Zhao and Chen, 2006).  The work in this chapter focuses on the unattached kinetochore, 
and describes the effect of AZ3146 treatment on its components.  By making these 
observations, I hoped to gain some insight into the function of Mps1 catalytic activity in 
the mitotic checkpoint.  
5.2 | Mad2 localisation is highly sensitive to AZ3146 treatment  
To explore the cellular effects of AZ3146-mediated Mps1 inhibition, I used a simple, 
indirect immunofluorescence-based assay to observe the effect of AZ3146 treatment on 
localisation of several kinetochore proteins.  Briefly, HeLa cells were treated 
simultaneously with nocodazole, MG132 and 2 µM AZ3146 (or DMSO in controls) for 2 
hours before fixation and staining with antibodies to detect kinetochore proteins of interest.  
The addition of nocodazole created unattached kinetochores, and MG132 prevented 
mitotic exit, thereby keeping a proportion of the cells arrested in prometaphase where, 
under normal circumstances, the mitotic checkpoint is active and checkpoint proteins are 
recruited.  In these cells, selected protein levels were qualitatively assessed after fixation 
and staining with appropriate antibodies.  Standard fluorescence microscopy was used to 
view the cells, and levels were assessed by eye then classified as high, medium or low.  I 
intended the categories to correspond roughly to kinetochore staining levels of 100-66%, 
66-33% and 33-0% respectively.   
Loss of Mad2 at the prometaphase kinetochore is a relatively well-established 
indicator of loss of Mps1 function.  Mps1 depletion leads to loss of Mad2 at kinetochores 
in Xenopus egg extracts and in human cells (Abrieu et al., 2001; Fisk et al., 2003; Jelluma 
et al., 2008b; Liu et al., 2003; Martin-Lluesma et al., 2002; Tighe et al., 2008); 
furthermore, the use of kinase-dead and ATP analogue-sensitive mutants, along with the  
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 Kinetochore protein levels after treatment with nocodazole and 2 µM AZ3146 
Protein Level after AZ Protein Level after AZ 
Mad2 Low Bub1 High 
Mad1 Med BubR1 High 
Rod Med Aurora B High 
ZW10 Med Cenp-F Med 
Zwilch Med/Low Cenp-E Med 
Zwint High Cenp-A High 
Table 5.1  Summary of kinetochore protein levels in HeLa cells after treatment with AZ3146, 
nocodazole and MG132, derived from the data presented in Figure 5.1. 
 
recently-published Mps1-IN-1 inhibitor, has revealed that the catalytic activity of the 
kinase is necessary for Mad2 recruitment (Kwiatkowski et al., 2010; Sliedrecht et al., 
2010; Tighe et al., 2008).  Therefore, I would predict decreased levels of Mad2 staining 
after AZ3146 treatment in my immunofluorescence-based assay.  The majority of 
AZ3146-treated, prometaphase-arrested cells (66%) had faint or undetectable kinetochore 
Mad2, in stark contrast to the readily visible kinetochore staining pattern in control cells, 
where 83% of cells had high levels of staining (Figure 5.1A and Table 5.1).  In parallel 
with my analysis, A. Tighe’s quantification of pixel intensities in AZ3146-treated cells 
showed that this equates to an 85% reduction, on average (Hewitt et al., 2010).  
Importantly, these observations fit with previous work and confirm that Mps1 kinase 
activity is required for Mad2 recruitment and/or maintenance at the kinetochore. 
The effect of Mps1 depletion or inhibition on Mad1 localisation is somewhat 
controversial.  Whilst it is established that Mps1 RNAi leads to Mad1 loss (Jelluma et al., 
2008b; Liu et al., 2003; Tighe et al., 2008), there is some conflicting data regarding the 
requirement for Mps1 kinase activity for Mad1 localisation (Jelluma et al., 2008b; Schmidt 
et al., 2005; Tighe et al., 2008).  Therefore, I was particularly interested in finding out 
whether AZ3146 caused loss of Mad1 signal at kinetochores.  Mad1 is clearly affected by 
AZ3146 treatment in this assay: 36% or 42% of prometaphase cells had low or medium 
kinetochore staining levels, respectively (Figure 5.1B and Table 5.1).  Notably, however, 
the effect of AZ3146 on Mad1 is certainly less severe than on Mad2, which had almost 
twice the number of cells with low levels of staining (Figure 5.1A).  Therefore, it seems 
that Mps1 kinase activity is differentially required for Mad2 and Mad1 recruitment.  One 
possible explanation for this difference is that Mad1 kinetochore localisation may require 
less Mps1 activity: perhaps any residual catalytic activity remaining after treatment with 2 
µM AZ3146 is enough to recruit or maintain Mad1 at easily detectable levels in many  
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Figure 5.1 Localisation of kinetochore proteins after Mps1 inhibition with AZ3146
HeLa cells were treated with nocodazole, MG132 and DMSO or AZ3146 (2 µM), fixed after 2 h and pro-
cessed for immunofluorescence. Kinetochore levels of the protein shown in red were assessed by eye and the
results shown as bar graphs. Cells were co-stained with antibodies to phospho-histone H3 (pH3), Bub1, or
anticentromere marker (ACA), shown in green. Representative images are shown for each protein. Values of
n refer to number of cells counted per condition; datasets are combined from 2 experiements. Bars: 5 µm.
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 cells, but not sufficient for detectable Mad2 localisation.  However, this may not be a 
complete explanation, since when higher molarities of AZ3146 are used, presumably 
minimising residual activity, there remains a difference between Mad2 and Mad1 
kinetochore levels: almost all prometaphase cells treated with 4 µM and 8 µM AZ3146 
have low levels of Mad2 staining at kinetochores (83% and 98% respectively, Figure 
5.2A), whereas medium levels of Mad1 staining are observed in ~50% of cells under the 
same conditions (Figure 5.2B).  In agreement with this variability in the population 
assessed in my assays, recent work carried out by A. Tighe suggests that inhibition of 
Mps1 activity can prevent Mad1’s recruitment to unattached kinetochore, but has less 
effect on Mad1 if it has already been recruited prior to Mps1 inhibition (Hewitt et al., 
2010).  This may provide an explanation for the data presented here, since the cells in my 
assay are likely to be a mixture of mitotic cells that had already recruited Mad1 to 
prometaphase kinetochores, and those which were in prophase or metaphase and therefore 
had no Mad1 at the kinetochore at the time of drug treatment.  Overall, my data provides 
evidence that, in mixed cell population, Mad1 localisation is clearly affected by AZ3146 
treatment, but in some cells is less sensitive to loss of Mps1 activity than Mad2, likely 
because of the different mitotic stages at which Mps1 inhibition takes place.   
After establishing the effect of AZ3146-meditated Mps1 inhibition on Mad1 and 
Mad2, I turned my attention to the RZZ complex.  The RZZ complex (Rod, ZW10 and 
Zwilch) is found in the fibrous corona region, interacts with the outer kinetochore plate 
component Zwint, and is required for Mad1-Mad2 recruitment to the kinetochore 
(reviewed in Karess, 2005).  After AZ3146 treatment, I observed a partial decrease in 
kinetochore staining for all three components of the RZZ complex (Figure 5.2C-E and 
Table 5.1).  There are minor differences between the data for the three constituents of the 
complex, possibly due to differences in antibody sensitivity.  Notably however, AZ3146’s 
effect on the RZZ complex closely resembles its effect on Mad1 staining.  This observation 
is corroborated by recently published work using the small molecule inhibitor Reversine, 
which implicates Mps1 activity in Zwilch recruitment (Santaguida et al., 2010).  The 
decrease in RZZ staining cannot be explained by a fall in kinetochore-bound Zwint, since 
treatment with AZ3146 produced only a relatively small fraction of cells with notably 
decreased Zwint signal (Figure 5.1F and Table 5.1).  Taken together, these data suggest a 
role for Mps1 kinase activity in the recruitment of Mad1-Mad2 via the RZZ complex. 
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5.3 | Bub1, BubR1 and Aurora B are relatively unaffected by AZ3146-
mediated Mps1 inhibition 
There are some discrepancies in the literature regarding the requirement of Mps1 for 
the kinetochore localisation of Bub1 (Jelluma et al., 2008b; Liu et al., 2006; Martin-
Lluesma et al., 2002; Santaguida et al., 2010; Sliedrecht et al., 2010; Tighe et al., 2008).  
When cells were treated with nocodazole, MG132 and 2 µM AZ3146, a small increase in 
the frequency of medium levels of kinetochore staining was observed (from 0% in the 
control population to 14% in AZ3146-treated cells).  It should also be noted that many 
cells classified as having high levels exhibited a small reduction in Bub1 levels.  In 
keeping with this, when pixel intensities were quantified by A. Tighe in identically treated 
cells, an average reduction of 25% was seen (Hewitt et al., 2010).  This suggests Bub1 
recruitment and/or maintenance at the kinetochore is largely unaffected by inhibition of 
Mps1 kinase activity.  The relatively mild nature of the defect may be partly due to 
residual Mps1 activity in cells treated with 2 µM AZ3146: when the AZ3146 dosage is 
increased to 8 µM, 52.5% of cells had either low or medium Bub1 levels (Figure 5.2C).  
Overall however, the results presented here do not exclude a role for Mps1 catalytic 
activity in Bub1 localisation, but they suggest a comparatively minor role. 
Like its role in Bub1 localisation, the role for Mps1 in BubR1 localisation has also 
been subject to debate (Jelluma et al., 2008b; Kang et al., 2007; Liu et al., 2006; Martin-
Lluesma et al., 2002; Santaguida et al., 2010; Schmidt et al., 2005; Sliedrecht et al., 2010; 
Tighe et al., 2008).  Several reports have suggested that perturbation of Mps1 kinase 
activity leads to a significant decrease in BubR1 kinetochore staining (Kang et al., 2007; 
Schmidt et al., 2005), however others have reported that the effect of inhibition on 
kinetochore-bound BubR1 is only marginal (Santaguida et al., 2010; Sliedrecht et al., 
2010).  When I analysed BubR1 levels in a population of 2 µM AZ3146-, nocodazole- and 
MG132-treated cells and compared them to control cells, I observed only a small fraction 
with significantly decreased, medium or low levels of BubR1 (26% compared to 1% in the 
control population, Figure 5.1H).  As with Bub1, many cells appeared to have slightly 
reduced BubR1 staining, but were still within the range considered ‘high’.  Whilst I cannot 
exclude the possibility that a more major defect may reveal itself at higher molarities of 
AZ3146, this data suggests at most a small, relatively minor role for Mps1 kinase activity 
in BubR1 recruitment and maintenance at kinetochores.   
Aurora B localises to the centromere/kinetochore region at prometaphase, and its 
kinase activity is known to be required for the recruitment of several other kinetochore 
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 components (Ditchfield et al., 2003; Hauf et al., 2003).  Mps1 RNAi is reported to have 
very little effect on Aurora B’s immunolocalisation pattern (Jelluma et al., 2008b; Tighe et 
al., 2008).  When I analysed Aurora B staining following inhibition of Mps1 with AZ3146, 
I saw virtually no difference between the control and AZ3146-treated populations (Figure 
5.1I).  This data suggests that Mps1 kinase activity has no discernable role in recruitment 
or maintenance of Aurora B at the prometaphase centromere/kinetochore region, in 
agreement with published RNAi-based data. 
5.4 | Cenp-F and Cenp-E are reduced at kinetochores after AZ3146 
treatment 
I also used my immunofluorescence-based assay to look at the localisation of Cenp-
F, a component of the fibrous corona that is required for chromosome alignment (Holt et 
al., 2005; Yang et al., 2005).  After AZ3146-treatment, the population of prometaphase-
arrested cells exhibited noticeably lower levels of Cenp-F kinetochore staining than the 
control population (Figure 5.1J): 75% of cells analysed had medium or low levels.  Mps1 
knockdown by RNAi has been reported to have no effect on Cenp-F localisation (Liu et al., 
2006), or cause a 35% reduction (Tighe et al., 2008); the data presented here is in broad 
agreement with the latter.  This suggests Mps1 kinase activity has at least a partial role in 
recruitment and/or maintenance of Cenp-F at the kinetochore. 
The role of Mps1 in Cenp-E kinetochore localisation is somewhat controversial.  
Work in the Xenopus egg extract model system implicates Mps1 kinase activity in Cenp-E 
kinetochore localisation (Abrieu et al., 2001), and Mps1 RNAi in HeLa cells is reported to 
cause improper Cenp-E localisation during mitosis (Fisk et al., 2003).  However, several 
reports have concluded that Mps1 RNAi has no effect on Cenp-E immunolocalisation 
(Jelluma et al., 2008b; Martin-Lluesma et al., 2002; Tighe et al., 2008), and one recent 
report saw no effect on Cenp-E after inhibition of Mps1 kinase activity (Sliedrecht et al., 
2010).  In my assay, AZ3146-treatment clearly led to a reduction in Cenp-E staining at 
kinetochores: 92% of cells analysed had either medium or low levels (Figure 5.1K).  Thus, 
in contrast to a previous report (Sliedrecht et al., 2010), these data suggest that Mps1 
kinase activity contributes to Cenp-E kinetochore localisation in human cells.  This might 
be mediated via Cenp-F, since Cenp-F has been shown to interact with Cenp-E and 
promote its kinetochore localisation (Chan et al., 1998; Johnson et al., 2004; Yang et al., 
2005; Yao et al., 2000). 
I also wanted to extend my analysis to a structural component of the inner 
kinetochore, so I analysed the effect of AZ3146 on the histone H3 homologue, and 
constitutive centromere-binding protein, Cenp-A (Cheeseman and Desai, 2008).  AZ3146-
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 mediated Mps1 inhibition had no effect on the levels of Cenp-A staining in the majority of 
AZ3146-treated cells, where levels were classified as high (Figure 5.1L and Table 5.1).  
However, a small increase in cells with medium or low Cenp-A staining levels was 
observed (from 20% in controls to 34% in AZ3146-treated cells).  This might indicate a 
small reduction in kinetochore levels in some cells.  However, it is unlikely that a small 
decrease would cause problems with subsequent assembly of other kinetochore 
components, since Cenp-A is thought to be in excess at the human kinetochore (Liu et al., 
2006).  Whilst more detailed analysis would be required to fully confirm the presence of 
other structural kinetochore proteins, this data, along with the near-normal Zwint levels 
described earlier (Figure 5.1F), means I have no evidence to suggest underlying inner and 
outer kinetochore structure is perturbed by AZ3146.   
Taken together, the data presented in the chapter so far show that AZ3146 treatment 
leads to kinetochore recruitment defects that could contribute to mitotic checkpoint 
malfunction (Chapter 4).  Crucially, Mad2 appeared exquisitely sensitive to AZ3146 
treatment; Mad1, while partially mislocalised, was less sensitive.  The requirement for 
Mps1 activity in Mad1 localisation might be indirect, since I also observed a decrease in 
kinetochore levels of the RZZ complex.  Cenp-E and Cenp-F staining levels were notably 
lower at kinetochores following AZ3146 treatment; interestingly, both of these proteins are 
involved in chromosome alignment, a process in which Mps1 is also implicated.  Other 
components of the kinetochore (Bub1, BubR1, Aurora B, Cenp-A, Zwint) were largely 
unaffected by AZ3146 treatment. 
5.5 | Mps1 accumulates at prometaphase kinetochores following AZ3146 
treatment 
Having established at AZ3146’s effect on the above kinetochore components, I 
turned my attention to Mps1 itself.  Mps1 localises to the kinetochore via its N-terminal 
domain (Liu et al., 2003; Stucke et al., 2004), and its interaction with the kinetochore is a 
dynamic one, with a half-life of recovery of 13 s (Howell et al., 2004).  However, the 
mechanism by which this interaction is regulated remains elusive.  I wanted to test the 
effect of loss of kinase activity on the kinetochore localisation of endogenous Mps1, so I 
used my indirect immunofluorescence assay to look at Mps1 localisation in nocodazole, 
MG132 and AZ3146-treated HeLa cells.  In control cells, Mps1 staining is evident at the 
kinetochore region, but the signal is rather weak (Figure 5.3A, top panel).  Strikingly, on 
addition of AZ3146, the signal increases markedly (Figure 5.3A, bottom panel).  
Quantification of pixel intensities revealed that Mps1 staining at the kinetochore increased 
5-fold on average in AZ3146-treated cells, suggesting that Mps1’s kinase activity 
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Figure 5.3 Endogenous Mps1 accumulates at kinetochores after AZ3146 treatment.
(A) HeLa cells were treated with either DMSO (Control) or 2 µM AZ3146 plus nocodazole and MG132 for 2
h, then processed for immunofluorescence with antibodies against Mps1 (red) and ACA (green). DNA was
visualised with Hoechst staining. Representative examples of a control and AZ3146-treated cell are shown.
Images are maximum intensity projections of deconvolved z-section stacks. Enlargements of boxed kineto-
chore pairs show enhanced Mps1 staining with AZ3146 treatment. Scale bar: 5 µm.
(B) Quantification of cells treated as in A. Mps1 pixel intensities at each kinetochore pair were quantified as
a ratio to the ACA signal. The data shown in the bar graph is combined from 3 independent experiments, in
which a total of 19 control cells or 18 AZ3146-treated cells were analysed. Numbers within bars refer to the
total kinetochore pairs in dataset. Ratios were normalised to the mean control value for each experiment.
Error bars represent the standard deviation. (***P < 0.0001, Mann-Whitney U-test.)
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  may be involved in regulating its localisation. 
In the above experiments, I detected endogenous Mps1 using a polyclonal antibody 
raised against an N-terminal 242-amino acid fragment of Mps1 (Tighe et al., 2008).  It is 
possible that the apparent accumulation I observed might be due to changes in the 
antibody’s affinity for kinetochore-bound Mps1 caused by epitope unmasking, perhaps due 
to changes in phosphorylation.  With this in mind, I set out to firmly establish whether the 
increase in signal seen in Figure 5.3 was indeed a consequence of raised levels of 
kinetochore-bound protein.  For this, I used HeLa cells stably expressing tetracycline-
inducible GFP-tagged wild type Mps1 (GFP-Mps1-WT, Tighe et al., 2008). 
 Firstly, I tested the propensity of GFP-Mps1-WT to accumulate after AZ3146 
treatment.  Levels of the exogenous kinase were detected by immunostaining with an anti-
GFP antibody.  In control cells, the kinetochore signal from GFP-Mps1WT staining was 
often so low that it was virtually undetectable after deconvolution (see Figure 5.4A, top 
panel).  Importantly, when cells were cultured with AZ3146, the anti-GFP signal 
increased, and was frequently readily detectable (Figure 5.4A, bottom panel).  When 
quantified, an average ~2-fold increase in GFP-Mps1-WT kinetochore staining was 
observed (Figure 5.4B).  As the standard deviation of the datasets indicates (error bars), 
there was wide variation in GFP-Mps1-WT levels in these experiments.  This was largely 
due to variability in transgene expression levels from cell to cell, a characteristic of the 
HeLa stable cells lines being used (data not shown and A. Tighe, personal 
communication).  In order to exclude any possibility that the ~2-fold increase observed in 
Figure 5.4B was due to sampling differences rather than a real trend towards higher GFP-
Mps1-WT staining after AZ3146 treatment, I assessed the kinetochore levels of the control 
and treated cell populations by eye.  As shown in Figure 5.4C, there was a clear shift 
towards brighter kinetochore staining when cell when AZ3146 was used.  Thus, I was able 
to recapitulate the kinetochore accumulation of inhibitor-treated Mps1 with a second 
antibody against the GFP-tag of stably expressed wild-type Mps1, further supporting the 
idea that AZ3146-treatment leads to Mps1 accumulation at kinetochores. 
As a second way of assessing the effect of AZ3146 on kinetochore levels of GFP-
Mps1-WT, I turned to an antibody-free approach.  GFP-Mps1-WT fluorescence was 
observed directly by standard fluorescence microscopy and levels assessed by eye.  
Control cells stably expressing GFP-Mps1-WT frequently had undetectable kinetochore 
levels, but in some cells, expression was high enough to allow visualisation of GFP-
Mps1WT at the kinetochore, and levels were classified as medium (Figure 5.4D, top panel). 
When cells were treated with AZ3146, cells frequently had intensely fluorescent 
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Figure 5.4 GFP-tagged wild-type Mps1 accumulates at kinetochores after AZ3146 treatment.
(A) HeLa cells expressing tet-inducible GFP-tagged wild-type Mps1 (GFP-Mps1-WT) were treated with
either DMSO (Control) or 2 µM AZ3146 plus nocodazole and MG132 for 2 h, then processed for immuno-
fluorescence with antibodies against GFP (green), Mps1 (red) and ACA (blue). Representative examples of
a control and AZ3146-treated cell are shown. Images are maximum intensity projections of deconvolved z-
section stacks. Enlargements of boxed kinetochore pairs show enhanced GFP and Mps1 staining with
AZ3146 treatment. (B) Quantification of kinetochore GFP-Mps1-WT levels in cells treated as in A. GFP
pixel intensities at each kinetochore pair were quantified as a ratio to the ACA signal. The data shown in the
bar graph is combined from 3 independent experiments, in which a total of 19 control cells and 18 AZ-
treated cells were analysed. Numbers within bars refer to the total kinetochore pairs in each dataset. Ratios
were normalised to the mean control value in each experiment. Error bars represent the standard deviation.
(***P < 0.0001, Mann-Whitney U-test.) (C) Levels of GFP-Mps1-WT were assessed by eye in the same
cells described in A and B. Data from one of the three repeats is shown. Values within the bars refer to the
number of cells counted. (D) GFP-Mps1-WT at kinetochores was visualised directly by virtue of GFP fluo-
rescence, in cells treated as in A, but by standard fluorescence microscopy. Cells were co-stained with ACA
(red). (E) Quantitation of GFP-Mps1-WT levels in cells treated and visualised as in D. Scale bars: 5 µm
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  points of GFP-Mps1-WT at the kinetochore, as in the example shown in Figure 5.4D 
(bottom panel), where levels were classed as high.  There was a clear increase in the 
proportion of cells with either medium or high GFP-Mps1-WT levels at kinetochores after 
AZ3146 treatment (Figure 5.4E).  Importantly, this confirms that the enhanced staining in 
Figure 5.3 and 5.4A-D is not caused by changes in antibody affinity, but by an increase in 
Mps1 protein levels at kinetochores following inhibition. 
5.6 | Kinase-dead Mps1 accumulates at unattached kinetochores following 
AZ3146 treatment 
In parallel with experiments to determine that wild type GFP-Mps1 was enriched at 
kinetochores, I also carried out the same experiments with cells expressing catalytically 
inactive, mutant GFP-Mps1 (GFP-Mps1-KD, Tighe et al., 2008).  Originally, I 
hypothesised that the kinetochore localisation of the catalytically inactive kinase would not 
be enhanced on addition of the inhibitor, since the kinase is already inherently inactive.  If 
lack of catalytic activity caused the kinetochore accumulation observed in Figure 5.3 and 
5.4, the GFP-Mps1-KD would already be maximally enriched at kinetochores before 
inhibitor treatment.  However, like GFP-Mps1-WT, GFP-Mps1-KD was frequently 
virtually undetectable when stained with an anti-GFP antibody in control cells (Figure 
5.5A, top panel).  Furthermore, when cells were treated with AZ3146, the anti-GFP signal 
at the kinetochores became substantially higher than in control cells, with GFP-Mps1-KD 
now readily visible (Figure 5.5A, bottom panel).  Quantification of the GFP signal showed 
an average ~5-fold increase at the kinetochore following AZ3146 treatment (Figure 5.5B), 
though levels were once again highly variable due to cell to cell expression level 
differences.  As with GFP-Mps1-WT, I was able to confirm the increase in kinetochore 
bound GFP-Mps1-KD by analysis of a larger sample of cells from the two populations by 
eye (Figure 5.5C).  Contrary to my original hypothesis, these data indicate that, like GFP-
Mps1-WT, GFP-Mps1-KD accumulates at prometaphase kinetochores after AZ3146 
treatment. 
One possible explanation for this observation is that the kinetochore accumulation of 
Mps1 is not dependent on the intrinsic activity of a single molecule, but instead on the 
level of Mps1 activity in the cell.  Thus, in the presence of endogenous Mps1 activity, 
GFP-Mps1-KD remains at a low level at the kinetochore, and only accumulates following 
AZ3146 treatment, presumably because it can no longer interact with active endogenous 
Mps1.  To further confirm this effect, I turned to an RNAi complementation approach, in 
which I repressed endogenous Mps1 with shRNA, and induced expression of RNAi- 
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Figure 5.5 GFP-tagged kinase-dead Mps1 accumulates at kinetochores after AZ3146 treatment.
(A) HeLa cells expressing tet-inducible GFP-tagged kinase-dead Mps1 (GFP-Mps1-KD) were treated with
either DMSO (Control) or 2 µM AZ3146 plus nocodazole and MG132 for 2 h, then processed for immuno-
fluorescence with antibodies against GFP (green), Mps1 (red) and ACA (blue). Representative examples of
a control and AZ3146-treated cell are shown. Images are maximum intensity projections of deconvolved z-
section stacks. Enlargements of boxed kinetochore pairs show enhanced GFP and Mps1 staining with
AZ3146 treatment. Scale bar: 5 µm (B) Quantification of kinetochore GFP-Mps1-KD levels in cells treated
as in A. GFP pixel intensities at each kinetochore pair were quantified as a ratio to the ACA signal. The data
shown in the bar graph is combined from 3 independent experiments, in which a total of 17 control cells and
16 AZ-treated cells were analysed. Numbers within bars refer to the total kinetochore pairs in dataset.
Ratios were normalised to the mean control value in each experiment. Error bars represent the standard devi-
ation. (***P < 0.0001, Mann-Whitney U-test.) (C) Levels of GFP-Mps1-KD were assessed by eye in the
same cells described in A and B. Data from one of the three repeats is shown. Values within the bars refer to
the number of cells counted.
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 resistant GFP-Mps1-WT or GFP-Mps1-KD (Tighe et al., 2008).  Western blots (Figure 
5.6A) confirmed that transfection with shRNA targeting Mps1 caused a fall in endogenous 
protein levels, whilst levels of resistant GFP-Mps1 were unaffected.  When cells 
transfected with control shRNA were treated with nocodazole and MG132, staining with 
an anti-GFP antibody revealed virtually undetectable kinetochore levels of both WT and 
KD GFP-Mps1 (data not shown), in agreement with data from control cells in Figures 5.4 
and 5.5.  Following repression of endogenous Mps1, GFP-Mps1-WT levels at kinetochores 
remained very low; although the GFP-tagged form was now predominant in the cells, 
accumulation did not occur.  Importantly however, GFP-Mps1-KD levels increased 
markedly in shRNA-transfected cells (Figure 5.6B, C).  Quantification of anti-GFP pixel 
intensities indicated an ~8.5 fold increase in kinetochore-bound GFP-Mps1-KD on average 
(Figure 5.6C).  Again, the datasets had high levels of variability, but additional qualitative 
analysis of kinetochore GFP levels in each cell population showed a clear increase in the 
proportion of cells with high levels in Mps1-depleted, GFP-Mps1-KD expressing cells.  
Taken together, this data confirms that decreasing cellular levels of Mps1 catalytic activity 
leads to its accumulation at the kinetochore, and since kinase dead Mps1 only accumulates 
markedly following Mps1 shRNA, hints at the importance of inter-molecular interactions 
in regulating Mps1 localisation. 
5.7 | Summary 
To summarise, the data in this chapter provide evidence that AZ3146 treatment 
affects the localisation of kinetochore proteins essential for mitotic checkpoint function 
(Mad2, Mad1, RZZ complex).  Conversely, I also show that the levels of Mps1 itself 
increase markedly at kinetochores after ablation of the kinase’s activity: this novel 
observation may reflect an important aspect of the mechanism by which Mps1 inhibition 
causes mitotic checkpoint override.  
AZ3146 treatment also leads to an apparent decrease in kinetochore levels of 
proteins with a role in chromosome alignment (Cenp-E and Cenp-F).  The effect of 
AZ3146 treatment on this aspect of Mps1 function will be explored further in Chapter 6.   
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Figure 5.6 Kinase-dead GFP-Mps1 accumulates at kinetochores after depletion of endogenous Mps1
(A) HeLa cells stably expressing tet-inducible RNAi-resistant GFP-Mps1 wild-type (WT) or kinase-dead
(KD) were transfected with plasmids encoding shRNA targetting Mps1, or a control plasmid. Samples were
processed for western blot and probed with antibodies against Mps1 (top panel) or Aurora A (bottom panel)
as a loading control. (B) After endogenous Mps1 depletion and induction of GFP-Mps1 expression as in A,
cells were treated with nocodazole and MG132 for 2 hours. Cells were then fixed and processed for immun-
ofluorescence, staining with antibodies against GFP (green) and ACA (red). In each cell analysed,
shRNA/control plasmid transfection was confirmed by expression of co-transfected DsRed-histone H2B (not
shown). Representative examples of cells lacking endogenous Mps1, but expressing either wild-type or
kinase-dead GFP-Mps1 are shown. Note the enhanced kinetochore localisation of GFP-Mps1-KD. Scale
bar: 5 µm. (C) Quantification of kinetochore GFP-Mps1 levels in cells treated as in B. GFP pixel intensi-
ties at each kinetochore pair were quantified as a ratio to the ACA signal. The data shown in the bar graph is
combined from 3 independent experiments, in which at least 16 cells were analysed for each condition.
Numbers within bars refer to the total kinetochore pairs in the dataset. WT and KD ratios were normalised to
their respective mean control value in each experiment. Error bars represent the standard deviation. (***P <
0.0001, Mann-Whitney U-test) (D) Levels of GFP-Mps1 WT and KD were assessed by eye in the same
cells described in B and C. Values within the bars refer to the number of cells counted.
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 6 | Results Chapter IV: Inhibition of Mps1 perturbs chromosome 
alignment by inducing mislocalisation of Cenp-E 
6.1 | Introduction 
Over the last few years, a dual role for Mps1 in mitosis has emerged.  Not only does 
it promote mitotic checkpoint signalling to delay anaphase until the appropriate time, but it 
also functions in the mechanics of chromosome alignment.  Some reports have found that 
Mps1’s role in chromosome alignment is mediated via phosphorylation of Borealin, a 
member of the chromosomal passenger complex (Jelluma et al., 2008b; Sliedrecht et al., 
2010).  This phosphorylation is said to be required for full activation of Aurora B, which 
itself has a well-documented role in error correction, promoting the destabilisation of 
erroneous kinetochore-microtubule attachments (reviewed in Ruchaud et al., 2007).  In 
addition, some of the observations documented in the previous chapter, namely Cenp-E 
and Cenp-F reduction, hinted at possible alternative ways in which Mps1 could influence 
alignment by its effect on the mitotic kinetochore.  The work described in this chapter 
focuses on the effect of AZ3146 on the mechanics of chromosome alignment, and the 
relationship between Mps1 and Aurora B. 
6.2 | Mps1 inhibition leads to alignment problems after enrichment for 
errors 
In order to detect problems with alignment, I treated cells with the proteasome 
inhibitor MG132.  Assays I have used in the previous chapters could not distinguish this 
type of defect, since either a spindle toxin was present, or premature mitotic exit was 
induced due to checkpoint malfunction.  By blocking proteolysis, MG132 prevents 
anaphase onset downstream of spindle checkpoint inactivation.  In normal cells, 
chromosomes will align, forming a metaphase plate, but chromatids will not separate.  If 
AZ3146-treated cells have problems with alignment, this will manifest as an inability to 
form a fully aligned metaphase plate, despite the extended time in mitosis afforded by 
MG132 treatment.  I assessed alignment in MG132-treated cell populations by fixing cells, 
staining to visualise DNA, kinetochores and the mitotic spindle to allow classification of 
cells according to their stage of mitosis (prophase, prometaphase, metaphase, or anaphase).  
A cell with one or more unaligned chromosomes was classified as being in prometaphase.  
When I treated either HeLa cells or DLD1 cells with MG132 (Figure 6.1A), a large 
proportion of control cells reached a fully aligned metaphase (39% of HeLa cells and 68% 
of DLD1s).  Surprisingly, this did not significantly decrease when cells were treated with  
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Figure 6.1 Inhibition of Mps1 does not affect alignment in an unperturbed prometaphase
(A) HeLa and DLD1 cells were treated with DMSO (Control) or 2 µM AZ3146 for 2 hours, and then fixed
and stained. The mitotic population was classified according to the phase of mitosis, and the results are rep-
resented in bar graphs. Note the decreased proportion of metaphase cells in when cells are treated with
AZ3146. HeLa data is combined from 2 independent experiments.
(B) HeLa and DLD1 cells were treated with MG132 and DMSO (Control) or 2 µM AZ3146 for 2 hours,
fixed, analysed and represented as in A.
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 MG132 and AZ3146: 40% of HeLa cells and 57% of DLD1s had aligned all 
chromosomes.  Though an alignment defect did not appear to manifest under these 
conditions, Mps1 was inhibited in these cells: the mitotic checkpoint was compromised, as 
shown by analysis of the mitotic population of asynchronous cells (Figure 6.1B).  In both 
cell types, the proportion of cells in metaphase or prometaphase decreased, indicating cells 
rarely achieved alignment and were accelerated through prometaphase, as predicted 
following Mps1 inhibition. 
The lack of alignment defect observed after Mps1 inhibition was somewhat 
surprising.  To see if Mps1 activity really was entirely dispensable for alignment, I used a 
monastrol wash-out approach to enrich for erroneous attachments (Kapoor et al., 2000; 
Mayer et al., 1999). When spindle pole separation is prevented using monastrol, 
kinetochore pairs frequently become attached to the same spindle pole (syntelic 
attachment).  Monastrol can be efficiently washed out of cells, allowing spindle pole 
separation and correction of the erroneous attachments so that alignment can be achieved 
(Kapoor et al., 2000).  The mechanism of alignment after monastrol wash-out has been 
dissected (see Figure 1.6): Aurora B activity mediates the first steps towards alignment by 
promoting K-fibre disassembly, moving the chromosome polewards (Lampson et al., 
2004).  Mono-oriented chromosomes can then congress from the polar region towards the 
spindle equator via the action of the plus-end directed kinesin Cenp-E, and in doing so, 
increase their chances of becoming bioriented (Kapoor et al., 2006).  To detect any 
problems in this process following Mps1 inhibition, HeLa cells were released from 
monastrol into MG132 with or without AZ3146, then fixed and stained to allow 
classification of the mitotic population.  Cells were also released into ZM447439 and 
MG132 to provide examples of the phenotype induced by direct Aurora B inhibition. 
Ninety minutes after monastrol removal, the majority of control cells had formed a bipolar 
spindle and a fully aligned metaphase plate (65.1%; Figure 6.2A, B).  By contrast, 96.9% 
of cells released into ZM447439 were still in prometaphase with many misaligned 
chromosomes spread along the spindle.  Strikingly, AZ3146-treated cells also rarely 
achieved alignment: 85.9% of mitotic cells remained in prometaphase, sometimes with 
numerous unaligned chromosomes in the polar region (e.g. Figure 6.2A, ‘AZ major’) and 
sometimes with just a few unaligned chromosomes (e.g. ‘AZ minor’).  Thus, though 2 µM 
AZ3146 does not elicit an alignment defect in cells treated with MG132 alone (Figure 6.1), 
this level of Mps1 inhibition does lead to an alignment defect in the presence of an 
artificially high number of incorrect attachments.  There are several possible explanations 
for the emergence of the alignment defect following monastrol treatment.  Perhaps residual 
Mps1 activity in cells treated with 2 µM AZ3146 is enough to ensure alignment of any 
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Figure 6.2 Inhibition of Mps1 perturbs alignment after enrichment for errors by monastrol wash-out
(A) HeLa cells were treated with monastrol for 4 hours, then the monastrol was removed by washing and
cells were incubated with media containing MG132 to arrest cells at metaphase, and either DMSO (Control),
AZ3146 or ZM447439 (both at 2 µM) for 90 minutes. Some cells remained in monastrol for the duration of
the experiment (“No wash”). Cells were fixed, stained to detect DNA and with antibodies against α-tubulin
(TAT1; red) to visualise the spindle and Aurora B to mark centromeres (green). Representative images are
shown for each treatment; two examples of AZ3146-treated cells are shown to refect the varying severity of
the misalignments observed. Images are maximum intensity projections of deconvolved z-section stacks.
Scale bar: 5 µm.
(B) Mitotic cells were treated as in A were classified according to their phase of mitosis, and the results are
shown as a bar graph. Cells with any number of unaligned chromosomes were called prometaphase cells.
Data shown reflects the mean derived from 3 independent experiments, error bars show the standard devia-
tion. Values of n refer to the total number of cells classified per treatment. Note that while most control cells
achieve full alignment after monastrol wash-out (metaphase), cells treated with AZ3146 or ZM447439 still
exhibit unaligned chromosomes (prometaphase).
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 erroneous attachments in an unperturbed metaphase, though insufficient to support full 
mitotic checkpoint function (Figure 6.1).  It is also possible that in the cells I used, during a 
normal prometaphase where the spindle poles are allowed to move apart normally, so few 
erroneous attachments actually occur that Mps1 activity may not be required at all.  Arrest 
with a monopolar spindle may be required to increase the number of mono-oriented 
chromosomes in order for the defect to become visible.  Whatever the explanation, it is 
clear that AZ3146-mediated Mps1 inhibition does indeed compromise the alignment 
process, as previously reported (Jelluma et al., 2008b; Sliedrecht et al., 2010). 
6.3 | Aurora B activity remains high after Mps1 inhibition 
The alignment defect exhibited after loss of Mps1 activity was previously explained 
by decreased Aurora B activity (Jelluma et al., 2008b; Sliedrecht et al., 2010).  With this in 
mind, I set out to see if I could detect Aurora B inhibition in AZ3146-treated cells.  My 
first strategy was to treat nocodazole-arrested HeLa cells with AZ3146 or ZM447439, 
along with MG132 to prevent mitotic exit, then harvest cells and probe the lysates with 
phospho-specific antibodies against markers of global Aurora B activity, namely the 
autoactivation site Thr232 (Yasui et al., 2004) and the endogenous Aurora B substrate 
Ser10 of Histone H3 (Fischle et al., 2005; Hirota et al., 2005).  To look at phospho-Thr232, 
I used a phospho-antibody with reactivity against the phosphorylated autoactivation 
residue of Aurora A, B and C.  In control lysates, the antibodies recognised bands at the 
expected sizes for both phospho-Thr232 Aurora B and phospho-Ser10 Histone H3 (Figure 
6.3A).  Direct inhibition of Aurora B with ZM447439 abolished the phospho-T232 signal, 
and significantly reduced the phospho-Ser10 Histone H3 signal.  However, AZ3146 did 
not noticeably affect the signal from either phospho-antibody, even at the highest 
concentration tested (10 µM).  Although this data not absolutely conclusive, Figure 6.3A 
suggests that under these conditions, Mps1 inhibition does not significantly affect Aurora 
B autoactivation or Ser10 Histone H3 phosphorylation in cells.  
To extend my analysis of Aurora B activity in cells with inhibited Mps1, I turned to 
an immunofluorescence-based approach, which allowed me to look specifically at mitotic 
cells in an asynchronous population.  Again, I used reactivity of an antibody against 
phosphorylated Histone H3 as a read-out of Aurora B activity in asynchronous HeLa cells 
treated with either only ZM447439 or AZ3146.  As expected, prometaphase cells stained 
brightly for phospho-Histone H3 around the condensed chromatin (Figure 6.3B); 
ZM447439 effectively abolished this staining.  By contrast, prometaphase cells treated 
with AZ3146 still had high levels of phospho-Histone H3 staining, suggestive of 
comparatively high levels of Aurora B activity.  I also looked at the localisation of the 
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Figure 6.3 Aurora B does not appear significantly inhibited following AZ3146 treatment.
(A) HeLa cells were treated with nocodazole for 14 h, then with nocodazole, MG132 plus the indicated con-
centrations of AZ3146, ZM447439 (5 µM) or DMSO (control) for 2 h. Cells were harvested, lysed in SDS-
PAGE sample buffer and processed for western blotting. A phospho-Aurora A/B/C antibody was used but
only the pT232 Aur B band is shown. The dotted line indicates an excised lane. (B,C) HeLas were treated
with AZ or ZM alone (both 2 µM) for 2 h. Cells were fixed and stained to visualise DNA, and the indicated
proteins by IF. (D-G) HeLas were treated with monastrol (D and F) or nocodazole (E and G) along with
MG132 and either AZ3146 or ZM447439 (both 2 µM) for 2 h. Cells were fixed and processed for IF using
the indicated antibodies. Kinetochore/centromere levels of phospho-Aurora (D,E) or phospho-Ser7 Cenp-A
staining (F,G) were assessed by eye and the data shown as bar graphs, along with representative images. (H)
HeLa cells were treated as in G, but various concentrations of AZ3146 were used. Values of n refer to cells
counted in each dataset. Scale bars: 5 µm.
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 microtubule-depolymerising kinesin MCAK in the centromere/kinetochore region as a 
read-out for Aurora B activity in prometaphase cells (Andrews et al., 2004; Lan et al., 
2004): as shown in Figure 6.3C, while centromeric MCAK staining was much reduced 
after ZM447439 treatment, AZ3146 had no discernable effect, implying the cells had 
sufficient Aurora B activity to support recruitment of the kinesin.   
Although the western blot shown in Figure 6.3A did not show a global decrease in 
phospho-Thr232 Aurora B signal following AZ3146 treatment, it could be argued that the 
western blot analysis might lack the sensitivity to detect changes in Aurora B activation at 
the centromere.  To address this, I used the Aurora autoactivation residue phospho-
antibody described above to stain fixed HeLa cells for immunofluorescence.  This antibody 
detects phospho-Thr232 Aurora B at the centromere, as well as the active forms of the 
other Aurora family members.  Cells were arrested in prometaphase, either with normal 
microtubule dynamics but erroneous, unstable kinetochore-microtubule attachments 
(monastrol) or with depolymerised microtubules and unattached kinetochores 
(nocodazole).  Levels of centromeric staining were assessed by eye as previously described 
(Chapter 5).  In both monastrol (Figure 6.3D) and nocodazole (Figure 6.3E), the majority 
of control cells exhibited high levels of staining in the centromeric region, reflecting the 
expected localisation of active, phospho-Thr232 Aurora B.  As predicted, most 
ZM447439-treated cells had low levels of centromeric staining in both monastrol and 
nocodazole, pointing to loss of phospho-Thr232 and inactivation of Aurora B.  By contrast, 
the majority of AZ3146-treated cells had high levels of centromeric phospho-Aurora 
staining, suggesting Aurora B was phosphorylated at Thr232 and therefore active.  It is 
worth noting that I cannot rule out the contribution of phospho-Thr198 on Aurora C to the 
centromeric staining pattern: while the lesser-studied Aurora family member is usually 
associated with male meiosis (e.g. Tang et al., 2006), it is also expressed in several human 
cancer cell lines derived from different tissues, including HeLa cells (Kimura et al., 1999) 
and is reported to localise to centromeres (Li et al., 2004; Sasai et al., 2004).  However, I 
saw little effect on the centromeric phospho-threonine pattern after AZ3146 treatment.  
I also carried out a similar analysis using another read-out of Aurora B activity at the 
centromere: phosphorylation of the Ser7 of the Histone H3 variant, Cenp-A (Zeitlin et al., 
2001).  In monastrol (Figure 6.3F) and nocodazole (Figure 6.3G), brightly stained 
kinetochores were evident in control cells; this staining largely disappeared on treatment 
with ZM447439, but was still present at high levels in cells treated with AZ3146.  In 
keeping with the data presented above, this suggests Aurora B is relatively active at 
centromeres when Mps1 is inhibited.   
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 Taken together, the data in Figure 6.3 suggest that, contrary to previous reports 
(Jelluma et al., 2008b; Kwiatkowski et al., 2010; Sliedrecht et al., 2010), Aurora B activity 
remains relatively high after Mps1 inhibition.  One possible explanation for this is that 
residual Mps1 activity in cells treated with 2 µM AZ3146 is enough to promote sufficient 
Borealin phosphorylation which, in turn, supports relatively normal levels of Aurora B 
catalytic activity towards the substrates I looked at.  However, phospho-Ser7 Cenp-A 
levels at kinetochores were still high in most nocodazole-treated HeLa cells at 
concentrations of AZ3146 up to 8 µM (Figure 6.3H), and phospho-Thr232 Aurora B levels 
by western blot remain high in nocodazole-treated cells at 10 µM AZ3146 (Figure 6.3A).  
While I have not been able to look directly at the phosphorylation of Borealin itself, and 
cannot rule out effects on specific Aurora B substrates that I have not examined, I have no 
evidence to suggest Aurora B’s kinase activity is decreased after Mps1 inhibition.  
6.4 | Aurora B inhibition affects Mps1 phosphorylation in cells and its 
kinetochore localisation 
To extend my investigations into the relationship between Mps1 and Aurora B, I 
used Phos-tag gels to look at the phosphorylation status of both kinases in nocodazole-
arrested mitotic HeLa cells following treatment with AZ3146 and ZM447439.  Both Mps1 
and Aurora B appeared as a ladder of multiple bands after immunoblotting of mitotic 
samples run on Phos-tag gel, likely representing differentially phosphorylated forms 
(Figure 6.4A).  As previously described in Chapter 3 (Figure 3.5), treatment of mitotic 
cells with the Mps1 inhibitor AZ3146 led to the loss of the slowest-mobility band on the 
Mps1 blot (compare lanes 2 and 3); most Mps1 migrates as a major, faster-mobility band 
in samples treated with AZ3146, which suggests a decrease in phosphorylation.  Similarly, 
treatment with the Aurora B inhibitor ZM447439 led to a marked decrease in intensity of 
the two slowest-mobility Aurora B bands (compare lanes 2 and 4), leaving the majority of 
protein as two faster-migrating bands, and suggesting the kinase becomes 
dephosphorylated following direct inhibition.  AZ3146 had little effect on the Aurora B 
banding pattern (lane 3), which agrees with data presented above (Figure 6.3A) and 
supports the notion that Aurora B activity remains high after Mps1 inhibition.   
Surprisingly, direct inhibition of Aurora B caused a clear loss of the uppermost Mps1 
band; this suggests Aurora B inhibition affects the phosphorylation of Mps1 in cells 
(Figure 6.4A, lane 4).  It is not possible to determine whether Aurora B itself influences 
Mps1 phosphorylation directly or indirectly from this data; however, it strongly suggests 
that Aurora B is positioned upstream from Mps1 in a mitotic signalling cascade.  
Furthermore, while Aurora B’s localisation in nocodazole-treated cells is unaffected by  
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Figure 6.4 Aurora B inhibition leads to a decrease in Mps1 phosphorylation and mislocalisation of
kinetochore-bound Mps1
(A) HeLa cells were treated with nocodazole for 12 hours. Mitotic cells were collected and replated into the
indicated drug combinations (plus MG132 to prevent mitotic exit) for 2 hours. Adherent cells left behind
after mitotic shake-off were harvested and constituted the interphase sample (lane 1). AZ3146 and
ZM447439 was used at 2 µM and DMSO was used in controls to account for the solvent. Harvested cells
were lysed directly in SDS-PAGE sample buffer and run on gels containing Phos-tag. Proteins were trans-
ferred to a PVDF membrane and probed with anti-Mps1 or anti-Aurora B antibodies. Several bands were
visible for both proteins in mitotic lysates. Bands decreased in mitotic samples following direct inhibition of
the respective kinases are marked by open arrowheads. Faster-migrating bands remaining after inhibition are
marked by closed arrowheads. Note than the slowest-migrating species on the Mps1 blot disappears after
inhibition of Aurora B with ZM447439, as well as after direct inhibition with AZ3146. Part of the anti-Mps1
blot was also presented in Figure 3.5.
(B) HeLa cells were treated with nocodazole, MG132 and DMSO (control) or 2 µM ZM447439 for 2 h, then
fixed and processed for IF using antibodies against the indicated proteins. Mps1 kinetochore staining levels
were assessed by eye in prometaphase-arrested cells; data is represented as a bar graph. Scale bar: 5 µm.
Contributions to part A of this figure:
Cells were treated with drugs and harvested by Anthony Tighe. Samples were run on Phos-tag gels and
immunoblotted by Laura Hewitt.
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 Mps1 inhibition (see Figure 6.3B, also Jelluma et al., 2008b; Tighe et al., 2008), Mps1 
kinetochore staining is reduced when cells are treated with ZM447439 (Figure 6.4B): only 
12% of cells assessed had high levels Mps1 at kinetochores after ZM447439 treatment, 
compared to 86% of control cells.  This data implicates Aurora B activity in Mps1 
recruitment and/or maintenance at unattached kinetochores, possibly through a direct or 
indirect effect on its phosphorylation. 
Taken together, the data presented in this Chapter so far point to a model where 
Mps1 inhibition compromises chromosome alignment, as previously reported (Jelluma et 
al., 2008b), but I have seen no evidence that this is mediated via reduced Aurora B activity.  
It is not immediately clear why this discrepancy should exist, though other groups have 
recently published similar findings using different methods of Mps1 inhibition 
(Maciejowski et al., 2010; Santaguida et al., 2010).  With Aurora B inhibition not apparent, 
I sought alternative explanations for the alignment problem seen in Figure 6.2. 
6.5 | Mps1 inhibition reduces Cenp-E levels at unaligned chromosomes  
The alignment defect seen after monastrol wash-out (Figure 6.2) shared some 
characteristics with the defect seen after Cenp-E depletion (Kapoor et al., 2006; Weaver et 
al., 2003; Wood et al., 1997; Yao et al., 2000), and Mps1 activity has been shown to be 
required for maximal Cenp-E localisation in Xenopus egg extracts (Abrieu et al., 2001).  
This, along with the reduction in Cenp-E staining in AZ3146 and nocodazole-treated cells 
(Figure 5.1K), prompted me to investigate Cenp-E localisation in AZ3146-treated 
unaligned chromosomes.  To do this, I performed monastrol wash-outs as described earlier, 
and released cells into MG132 with or without 2 µM AZ3146 for 1 hour before fixation 
and staining to detect Cenp-E (Figure 6.5A).  Control cells still in the process of aligning 
their chromosomes had kinetochores with bright staining for Cenp-E; however, in AZ3146 
cells, despite the presence of numerous unaligned chromosomes, very little Cenp-E was 
apparent at kinetochores.  To compare levels in control and Mps1-inhibited cells, I 
quantified Cenp-E pixel intensities at unaligned kinetochores judged to be in the polar 
region of the spindle (see inset schematic in Figure 6.5B).  Strikingly, in AZ3146-treated 
cells, kinetochore Cenp-E levels fell dramatically, to an average 7% of control levels.  This 
decrease in Cenp-E is more drastic than that which I observed in nocodazole (Figure 
5.1K): this may, at least in part, be due to the presence of polymerised microtubules, which 
have been shown to facilitate loss of microtubule motors from kinetochores (Murata-Hori 
and Wang, 2002).  In support of this, I observed near-disappearance of Cenp-E at 
kinetochores in monastrol- and AZ3146-treated cells (Figure 6.5C).  Cenp-E could  
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Figure 6.5 Cenp-E is absent from unaligned chromosomes when Mps1 is inhibited
(A) HeLa cells were treated with monastrol for 4 hours, followed by wash-out and incubation with MG132
and DMSO (control) or 2 µM AZ3146 for 1 h. Cells were fixed and stained to detect DNA and with antibod-
ies against the proteins indicated. Representative examples of a control and AZ3146-treated cell are shown.
Images are maximum intensity projections of deconvolved z-section stacks. Enlargements of boxed polar
kinetochore pairs show absence of Cenp-E following AZ3146 treatment.
(B) Quantification of polar kinetochore Cenp-E levels in cells treated as in A. Polar kinetochores were
defined as those situated in the approximate equivalent of the shaded region on the schematic diagram.
Cenp-E pixel intensities at each kinetochore pair were quantified as a ratio to the ACA signal. The data
shown in the box-and-whiskers plot is combined from 3 independent experiments, in which a total of 23 con-
trol cells (315 kinetochores) and 23 AZ-treated cells (308 kinetochores) were analysed. Ratios were
normalised to the mean control value in each experiment. Whiskers represent the full range; boxes the
interquartile range, and the line shows the median. (***P < 0.0001, Mann-Whitney U-test.)
(C) HeLa cells were treated with monastrol, MG132 and DMSO (control) or 2 µM AZ3146 for 2 h, then
fixed and processed for IF using antibodies against the indicated proteins. Cenp-E kinetochore staining lev-
els were assessed by eye in monopolar cells; data is represented as a bar graph. Values of n refer to the num-
ber of cells counted. Scale bars: 5 µm.
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 sometimes be seen decorating what appear to be microtubules instead (Figure 6.5C, lower 
panel).  Taken together, this implicates Mps1 activity in the promotion of proper Cenp-E 
localisation. 
Cenp-E binds kinetochores via a region within its carboxyl-terminus tail domain 
(Chan et al., 1998).  To investigate whether this interaction might be perturbed after Mps1 
inhibition, and so help to confirm the requirement for Mps1 activity in Cenp-E localisation, 
I used a DLD1 stable cell line expressing a GFP- and Myc-tagged ~122 kDa Cenp-E tail 
fusion protein which has been described previously (Gurden et al., 2010).  This tool 
allowed me visualise Cenp-E tail’s subcellular localisation directly via the GFP tag, and 
therefore potentially exclude the contribution of epitope masking following Mps1 
inhibition.  After fixation of the cells and visualisation of the GFP, I could clearly see 
Cenp-E tail at kinetochores in nocodazole-treated cells (Figure 6.6A).  Importantly, when 
AZ3146 was present, the GFP tagged protein was markedly decreased at kinetochores.  
When GFP-Cenp-E tail levels were assessed by eye, the vast majority of AZ3146-treated 
cells had either low or medium levels (70%), compared to only 12 % of control cells 
(Figure 6.6B).  This strongly suggests that Mps1 inhibition does indeed result in a loss of 
Cenp-E protein from unattached kinetochores.  Importantly, work carried out by my 
colleague Anthony Tighe shows that perturbation of Mps1 activity by replacement of the 
endogenous kinase with an inhibitable, ATP analogue-sensitive mutant also causes loss of 
Cenp-E at unaligned kinetochores (Hewitt et al., 2010).  This is consistent with Cenp-E 
loss being an on-target effect of AZ3146, and supports the existence of a link between 
Mps1 kinase activity and Cenp-E localisation in human cells.   
6.6 | Summary 
This chapter has focused on the role of Mps1 catalytic activity in chromosome 
alignment.  Using AZ3146, I have confirmed that inhibition of Mps1 leads to an alignment 
defect after enrichment for mono-oriented chromosomes using a monastrol wash-out 
protocol.  Previously, reduced Aurora B activity has been shown to be the cause of this 
defect; however, I was unable to detect any decrease in Aurora B activity levels in cells 
treated with AZ3146.  In fact, it appeared that Aurora B was upstream of Mps1, since 
direct inhibition of Aurora B affected both Mps1’s phosphorylation status and its 
kinetochore localisation.  Interestingly, as a possible alternative explanation for the 
alignment problem observed after Mps1 inhibition, I found that Cenp-E levels were 
drastically reduced at unaligned kinetochores when Mps1 was inhibited.  This might 
indicate either an indirect link between the two, or a direct phosphorylation event, as has 
been shown in vitro for Xenopus Cenp-E and Mps1  (Espeut et al., 2008).  Loss of  
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Figure 6.6 Exogenous Cenp-E tail is displaced from kinetochores when Mps1 is inhibited
(A) DLD1 cells expressing GFP-tagged Cenp-E tail were treated with nocodazole, MG132 and either
DMSO (control) or 2 µM AZ3146, then fixed and processed for immunofluorescence, staining to visualise
centromeres (ACA, blue). Cenp-E tail was detected directly via GFP fluorescence, and chromatin was
visualised by DsRed-histone H2B fluorescence. Representative examples of a control and AZ3146-treated
cell are shown. Images are maximum intensity projections of deconvolved z-section stacks. (B) In cells
treated as in A, Cenp-E tail levels at kinetochores were assessed by eye and the results depicted as bar
graphs; n values refer to the number of cells counted.
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 Cenp-E from unaligned kinetochores may, at least in part, explain the inability of Mps1 
treated cells to achieve a fully aligned metaphase. 
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 7 | Discussion 
The ultimate aim of this study was to investigate the role of Mps1 in mitotic 
checkpoint signalling and the process of chromosome alignment, two key aspects of 
mitotic control that contribute towards the fidelity of genome propagation.  To achieve 
this, I used the small molecule inhibitor AZ3146, a novel compound originally developed 
by AstraZeneca.  Initial characterisation of the compound gave me confidence that 
AZ3146 was a useful tool with which to dissect the role of Mps1’s kinase activity in cells: 
the compound appeared relatively selective and potent in in vitro assays, and affected the 
phosphorylation status of Mps1 in HeLa cells (Chapter 3).  Furthermore, the compound 
decreased the viability of cultured human cell lines, and perturbed the mitotic checkpoint 
(Chapter 4).  I turned to an immunofluorescence-based approach to assess the effect of 
Mps1 inhibition on various components of the kinetochore.  In agreement with previous 
studies, the localisation of the checkpoint effector molecule Mad2 was exquisitely 
sensitive to Mps1 inhibition (Chapter 5).  Interestingly, Mps1 abundance at unattached 
kinetochores markedly increased following AZ3146 treatment.  This novel finding implied 
that Mps1’s release from kinetochores might be regulated by its activity.  Additionally, 
kinase-dead Mps1 accumulated at kinetochores, but only after removal of endogenous 
Mps1 activity, suggesting inter-molecular interactions may regulate Mps1’s release from 
the kinetochore (Chapter 5).  Finally, I used AZ3146 to investigate the role of Mps1 kinase 
activity in chromosome alignment: an alignment defect was apparent, but in contrast to 
other studies (Jelluma et al., 2008b; Sliedrecht et al., 2010) I was unable to detect Aurora B 
inhibition (Chapter 6).  Mps1 inhibition also caused levels of the plus-end directed kinesin 
Cenp-E to decrease markedly at kinetochores of unaligned chromosomes, providing a 
novel possible alternative cause of the chromosome alignment defects in human cells. 
In this chapter, I will discuss: firstly, the merits of AZ3146 as a tool to investigate 
Mps1 function; secondly, my findings with respect to checkpoint regulation in human 
cells; thirdly, my observations pertaining to Mps1’s role in chromosome alignment and the 
link between Mps1 and Aurora B; fourthly, and lastly, data relating to Mps1 and cell 
viability.   
7.1 | AZ3146: a novel tool to probe Mps1 function 
In this study, I present AZ3146, a novel Mps1 inhibitor originally developed at 
AstraZeneca.  AZ3146 has proved a useful tool, and enabled me to make several novel 
observations relating to Mps1’s role in the regulation of mitosis (see above). Small 
molecule kinase inhibitors are desirable tools: they are a favourable alternative to RNAi-
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 based strategies, since they avoid variability and technical challenges associated with these 
approaches, and offer exquisite temporal control over target inhibition.  Ideally, small 
molecule inhibitors should be both potent and selective, to enable complete inhibition of 
the target kinase and minimise the potential for confusing off-target effects in cells.  
AZ3146 is potent enough to be useful in cells: in vitro, the compound perturbed Mps1CAT 
dependent phosphorylation with an IC50 of ~35 nM (Figure 3.2), and elicited effects in 
cells consistent with Mps1 inhibition at 2 µM (Figures 3.5-5.1).  There may be some 
residual activity in cells treated with 2 µM AZ3146, as implied by the increase in the 
severity of the phenotype when cells were treated with higher molarities (see Figure 4.2 
and 5.2).  A reliable biomarker for Mps1 activity would facilitate accurate assessment of 
Mps1 activity levels.  
In vitro selectivity screens are commonly used to gain some insight into the ability of 
a compound to inhibit a wide range of kinases, and can help to predict selectivity in cells 
(Knight and Shokat, 2005; Smyth and Collins, 2009).  The Invitrogen SelectScreen™ data 
(Figure 3.4) indicated that 1 µM AZ3146 was capable of partially inhibiting several 
kinases out of a diverse panel of 50 in vitro: Fak, Kit, and the two JNK isoforms were 
inhibited by more that 40%, and several other kinases were inhibited by more than 20% 
(Figure 3.4). However, it was encouraging that none of the kinases tested in the panel were 
inhibited to the same degree as Mps1, which is almost completely inactive in the presence 
of 1 µM AZ3146 under my assay conditions (Figure 3.4).  To place this data in context, 
although some kinase inhibitors have been described with a higher degree of selectivity 
[e.g. the Plk inhibitors BI 2536 (Steegmaier et al., 2007) or Cyclapolin 9 (McInnes et al., 
2006) which have minimal activity against a kinase panel at 10 or 100 µM, and very 
potently inhibit Plks], AZ3146 can be considered a reasonably selective Mps1 inhibitor.  
While I cannot rule out AZ3146-mediated inhibition of kinases other than the fifty I 
included in my panel, the screen gave me confidence that the cellular phenotypes I 
observed were likely to be due to Mps1 inhibition. 
Further support for AZ3146’s validity as an Mps1 inhibitor comes from the 
observation that AZ3146-treated cells behaved similarly to cells in which endogenous 
Mps1 was replaced with an exogenous kinase-dead mutant form of the kinase (Jelluma et 
al., 2008b; Tighe et al., 2008) in several important respects.  As well as abrogating the 
mitotic checkpoint and leading to errors in chromosome segregation (see Chapter 4), 
AZ3146 led to the loss of anti-Mad2 staining at the kinetochore (Figure 5.1).  This has 
been observed following Mps1 inhibition in our laboratory and others (Jelluma et al., 
2008b; Tighe et al., 2008).  By comparing the results of AZ3146 treatment with Mps1 
RNAi followed by kinase-dead mutant add-back, I have also been able to support the idea 
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 that the accumulation of Mps1 at kinetochores is an on-target effect (Figure 5.6).  
Additionally, my colleague A. Tighe has shown that Cenp-E loss at unaligned kinetochores 
is common to both AZ3146-treated cells and those in which analogue-sensitive Mps1 is 
inhibited using the ATP-analogue 1NM-PP1 (Hewitt et al., 2010), suggesting that this too 
is an on-target effect.   
Whilst these approaches have proved helpful, an AZ3146-resistant Mps1 mutant 
would aid confirmation that the effects in cells are caused by on-target Mps1 inhibition.  
Mutation of the Mps1 active site gatekeeper residue from methionine to glutamine 
(M602Q) imparts a degree of resistance to both SP600125 (Schmidt et al., 2005) and 
Mps1-IN-1 (Kwiatkowski et al., 2010); expression of the mutant kinase was shown to 
lessen the severity of some of the drug-induced effects.  However, expression of Mps1 
M602Q in HeLa cells did not lessen the severity of the mitotic defects caused by 2 µM 
AZ3146 treatment when cells were observed by timelapse microscopy (data not shown).  
Future efforts might include a search for an AZ3146-resistant mutant form of Mps1, 
perhaps by conducting a screen for resistance in hypermutagenic HCT116 cells (e.g. 
Girdler et al., 2008), or by a systematic mutation of residues in the active site, where the 
inhibitor is likely to bind (e.g. Scutt et al., 2009).  The crystal structure of the Mps1 kinase 
domain in complex with AZ3146 should be informative for the latter approach.   
Whilst further work could help to firmly establish the degree of inhibition in cells, 
and strengthen the case for selectivity, as it stands AZ3146 is an important part of the 
newly-expanded toolbox for investigation of Mps1’s role in cells.  Until very recently, only 
the relatively nonspecific compound SP600125 (Schmidt et al., 2005) was available for 
inhibition of endogenous Mps1 in human cells; now, AZ3146 (this study and Hewitt et al., 
2010), Reversine (Santaguida et al., 2010), and Mps-IN-1 (Kwiatkowski et al., 2010) have 
been introduced.  Reversine also directly inhibits Aurora B (D'Alise et al., 2008), albeit 
less potently than Mps1 (Santaguida et al., 2010).  This may have the potential to cause 
problems with the dissection of the two kinases’ roles.  AZ3146 and Mps1-IN-1 do not 
appear to target Aurora B (this study and Kwiatkowski et al., 2010).  The existence of 
several small molecule inhibitors targeting Mps1, as well as cell lines engineered to 
express ATP-analogue sensitive Mps1 alleles, (Maciejowski et al., 2010; Sliedrecht et al., 
2010) means data can be corroborated and off-target effects are more likely to be 
recognised as such.  However, this does not entirely preclude discrepancies between 
groups, such as those discussed in Section 7.8. 
Much of the data I present in this study has been built upon and extended by further 
work using AZ3146 in the Taylor laboratory.  Along with data presented in this thesis, 
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 some of this work is published in the appended journal article (Hewitt et al., 2010).  
Discussion of data presented in this study will be followed by reference to, and discussion 
of, relevant data obtained by my colleague Anthony Tighe and published in Hewitt et al 
(2010).   
7.2 | Mps1 and checkpoint signalling 
Mps1 is an established member of the signalling network governing mitotic 
checkpoint activation (Abrieu et al., 2001; Stucke et al., 2002; Weiss and Winey, 1996).  
Recently published work has implicated Mps1 kinase activity in the establishment and 
maintenance of the mitotic checkpoint (Hewitt et al., 2010; Jelluma et al., 2008a; 
Kwiatkowski et al., 2010; Santaguida et al., 2010; Sliedrecht et al., 2010; Tighe et al., 
2008), and the data I presented in Chapter 4 is consistent with the notion that Mps1 activity 
is required for checkpoint function.  
The kinetochore has long been understood play a critical role in mitotic checkpoint 
signalling (Rieder et al., 1995).  Kinetochore protein recruitment is known to be crucial for 
the mitotic checkpoint to restrain anaphase in the presence of unaligned chromosomes 
(Meraldi et al., 2004).  However, evidence exists for a preformed APC/C inhibitor, which 
acts as a kinetochore independent ‘timer’, preventing anaphase onset in early mitosis, 
before kinetochores have reached maturity (Meraldi et al., 2004; Sudakin et al., 2001).  
Reports suggest cytosolic MCC-like complexes containing Cdc20, Mad2 and/or BubR1 
(Kulukian et al., 2009; Sudakin et al., 2001) exist in interphase and determine the 
minimum length of mitosis, independently of kinetochore-derived checkpoint signalling.  
Perturbing solely kinetochore-based checkpoint signalling (e.g. by depletion of Mad1) 
does not cause a significant shortening of an unperturbed mitosis comparative to controls; 
however, depletion of components of the proposed timer does drastically reduce mitotic 
timing (Meraldi et al., 2004).  Interestingly, Mps1 inhibition by via AZ3146 hastens 
mitotic exit in an unperturbed mitosis, in both HeLa and hTERT-RPE cells (Figure 4.6), 
consistent with a role in formation of the cytosolic timer.  This study has not examined this 
aspect of Mps1 function, but a recent publication has: Maciejowski and colleagues (2010) 
report that cells in which Mps1 is potently inhibited have reduced levels of cytosolic 
Cdc20-bound Mad2 and BubR1 in interphase and mitotic cell extracts, implicating Mps1 
activity in the creation of an APC/C inhibitory complex both outside and within mitosis.  
Furthermore, a mutant form of Mps1 lacking its kinetochore targeting region (Mps1ΔN) 
could restore formation of Cdc20-Mad2, mitotic timing, and partially rescue the mitotic 
checkpoint defect in response to nocodazole, though not the alignment defect caused by 
Mps1 inhibition (Maciejowski et al., 2010).  The apparent functionality of the 
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 predominantly cytosolic Mps1ΔN mutant seems to contradict earlier work, which found the 
kinetochore localisation of Mps1 was important for spindle checkpoint function (Liu et al., 
2003; Zhao and Chen, 2006).  However, Mps1ΔN was only partially competent to restore 
checkpoint function when challenged with nocodazole, implying that active Mps1 at the 
kinetochore is necessary for sustained checkpoint signalling (Maciejowski et al., 2010).  It 
will be interesting to see if this new data implicating cytosolic Mps1 activity in mitotic 
timing can be replicated with other Mps1 inhibitors.   
7.2.1 | Mps1 regulates Mad1 and Mad2 levels at the kinetochore 
Although the newly-emerging cytosolic role of Mps1 may contribute to mitotic 
timing, evidence suggests the recruitment of the checkpoint effectors molecules Mad1 and 
Mad2 to unattached kinetochores is a critical step in the amplification and maintenance of 
the checkpoint signal (Musacchio and Salmon, 2007), and one that Mps1 has been 
proposed to regulate in human cells (Jelluma et al., 2008b; Liu et al., 2003; Martin-
Lluesma et al., 2002; Sliedrecht et al., 2010; Xu et al., 2009).  Previous work from our 
laboratory using an RNAi complementation approach had observed a difference between 
Mad1 and Mad2 localisation in terms of the requirement for Mps1 kinase activity: while 
Mad2 was exquisitely sensitive to loss of Mps1 activity, Mad1 localisation was only 
partially decreased (Tighe et al., 2008).  This implied that either Mps1’s role in Mad1 
recruitment was predominantly structural, or that a far lower level of enzymatic activity 
was necessary for Mad1 recruitment than for Mad2 recruitment.  In keeping with this, I 
saw a similar effect with AZ3146 treatment: with 2 µM AZ3146, most cells had low levels 
of Mad2 staining at kinetochores, whereas Mad1 levels were less severely affected (Figure 
5.1).  However, while both Mad1 and Mad2 are decreased after treatment with AZ3146, 
the apparent difference between Mad1 and Mad2 sensitivity to Mps1 inhibition is 
maintained even when higher molarities of AZ3146 are used in cells (Figure 5.2), 
indicating that the difference is unlikely to be solely attributable to residual Mps1 activity.  
The data I present in this study confirms a role for Mps1 kinase activity in both Mad1 and 
Mad2 kinetochore localisation, and points to a more critical role for Mps1 activity in Mad2 
recruitment.  The implications of this data, along with recent work extending the analysis 
of Mad1 and Mad2 recruitment after Mps1 inhibition, are discussed below. 
The apparent difference in requirement for Mps1 catalytic activity in Mad1 and 
Mad2 recruitment (Figure 5.1 and Hewitt et al., 2010) is at odds with data from other 
laboratories, where both Mad1 and Mad2 were lost from kinetochores following Mps1 
inhibition (Santaguida et al., 2010).  However, this difference might be explained by 
differences between assay designs, affecting the timing of Mps1 inhibition.  The 
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 immunofluorescence-based assay I used to assess kinetochore protein localisation involved 
simultaneous treatment with AZ3146, nocodazole and MG132.  All cells undergo 
microtubule depolymerisation via nocodazole, and proteasome inhibition via MG132 
prevents cells from either leaving or entering mitosis.  As a result, a mixed population of 
mitotic cells, undistinguishable from one another, is created for analysis: some were 
already in prometaphase at the time of treatment, some were at metaphase with 
kinetochores stripped of Mad1/2 (DeLuca et al., 2003), and some were in early mitosis, 
prior to recruitment of checkpoint proteins to kinetochores.  The question arises: could the 
reason for the variability in Mad1 levels following AZ3146 treatment (Figure 5.1), which 
leads to the partial effect when staining levels are quantified (Hewitt et al., 2010), stem 
from differences between the sub-populations of mitotic cells?  Work carried out by A. 
Tighe and published in Hewitt et al (2010) suggests that this is indeed the case.  When 
cells were pre-treated with nocodazole to trigger recruitment of checkpoint protein to 
unattached kinetochores, then incubated with AZ3146 and MG132 to inhibit Mps1 and 
prevent mitotic entry/exit respectively, Mad1 levels remained high.  By contrast, when 
cells were treated first with MG132 to arrest cells at metaphase (with Mad1 gone from 
kinetochores), then with nocodazole to destroy the spindle, control cells re-recruited Mad1 
to newly unattached kinetochores, whereas Mps1-inhibited cells did not.  Thus, it appears 
that high levels of Mps1 activity are required to recruit (or re-recruit) Mad1 to unattached 
kinetochores, but Mps1 activity is less important for the maintenance of Mad1 at 
kinetochores at which it is already established.  Notably, Mad2 levels were always 
predominantly low when Mps1 was inhibited; implying sustained Mps1 activity is critical 
for both recruitment (via Mad1) and maintenance of Mad2 at unattached kinetochores. 
When this data is placed in the context of the currently favoured Mad2 template 
model (see Intro Figure 1.5 and De Antoni et al., 2005a; Musacchio and Salmon, 2007), 
further questions arise.  As discussed in detail in the Chapter 1, Mad2 is capable of 
forming two very different conformations, which can dimerise: an open conformation (O-
Mad2) and a closed conformation (C-Mad2).  At the unattached kinetochore, Mad1 and C-
Mad2 form a stable core complex consisting of Mad1 and C-Mad2, which then acts as a 
receptor for soluble O-Mad2, facilitating its conversion to C-Mad2 bound to Cdc20, and 
consequently APC/CCdc20 inhibition (De Antoni et al., 2005a; Fang et al., 1998; Luo et al., 
2004; Mapelli et al., 2007; Yang et al., 2008).  Importantly, the Mad1-C-Mad2 core 
complex is highly stable (Howell et al., 2004; Shah et al., 2004; Vink et al., 2006), and 
exists at the nuclear pore in interphase (Campbell et al., 2001; Shah et al., 2004), 
suggesting it might be recruited to the kinetochore pre-complexed.  Thus, biochemical and 
cell-based data implies that the interaction between Mad1 and C-Mad2 is an improbable 
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 candidate for regulation by Mps1 activity.  Rather, it seemed more likely that the 
recruitment of O-Mad2 might be the step at which Mps1 acts.  So, why does the Mad2 
signal at kinetochores largely disappear after AZ3146 treatment, when Mad1 remains 
relatively high (this study and Hewitt et al., 2010)?  One possible explanation is that the 
antibody with which Mad2 was detected in these assays (SM2.2, Tighe et al., 2008) may 
only detect Mad2 in cells when it is in the open conformation.  C-Mad2 may either be 
masked in cells, or have no affinity for the antibody.  If this is indeed the case, C-Mad2 
might be present at the kinetochore when Mps1 is inhibited, but remain undetectable by 
immunofluorescence with SM2.2, reconciling the immunofluorescence data with current 
knowledge regarding the biochemical behaviour of the Mad1-Mad2 complex (see Figure 
7.1).  
Work carried out by A. Tighe and described in Hewitt et al (2010) has provided 
substantial data to support this hypothesis.  Using stable cell lines expressing Myc-tagged 
Mad2 fusion proteins, it was found that anti-Myc antibodies could readily detect Myc-
Mad2 at the nuclear envelope in interphase cells, in contrast to SM2.2.  This supports the 
notion that SM2.2 has low affinity for C-Mad2, the conformer present at the nuclear pore 
(Shah et al., 2004), and suggests the anti-Myc antibody recognises C-Mad2.  Both SM2.2 
and anti-Myc antibodies yielded a kinetochore staining pattern in mitotic cells; crucially, 
however, AZ3146 treatment only partially ablated the anti-Myc signal, while the SM2.2 
signal disappeared almost completely.  Thus, unlike SM2.2, the anti-Myc antibody 
recognises both conformers formed by the exogenous Myc-Mad2 pool:  the anti-Myc 
kinetochore signal decreases as Myc-O-Mad2 is absent, but Mad1-bound Myc-C-Mad2 
remains at readily detectable, relatively high levels (Hewitt et al., 2010).   
The hypothesis was further confirmed by examining the kinetochore localisation of 
two Myc-Mad2 mutants initially characterised by Mapelli et al (2007): Mad2ΔC, which 
cannot form the closed conformation or bind to Mad1, represents an ‘open only’ form of 
Mad2; and Mad2RQ, which cannot dimerise, only binds kinetochores via Mad1, therefore 
only adopts the closed conformation (Mapelli et al., 2007).  As predicted, AZ3146 
treatment severely compromised Myc-Mad2ΔC kinetochore localisation, decreasing it to 
levels comparable to that seen when SM2.2 was used.  Conversely, Myc-Mad2RQ showed 
only a slight decrease after AZ3146 treatment (Hewitt et al., 2010).  Taken together, this 
data indicates that C-Mad2, presumably as part of the core complex with Mad1, is not 
severely affected by AZ3146-mediated Mps1 inhibition (unless Mps1 is inhibited prior to 
mitotic entry); however, O-Mad2 is exquisitely sensitive to Mps1 inhibition, and requires 
sustained Mps1 activity to both recruit and maintain it at unattached kinetochores.  
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Figure 7.1 Schematic describing the role of Mps1 in Mad1 and Mad2 recruitment at the kinetochore
(A) Mps1 activity recruits and maintains the stable Mad1-C-Mad2 core complex and O-Mad2 at unattached
kinetochores during mitosis. O-Mad2 at the kinetochore is recognised by the anti-Mad2 antibody SM2.2
(Hewitt et al, 2010), which I used in this study (Figure 5.3).
(B) Mps1 activity is required to recruit Mad1-C-Mad2 to unattached kinetochores in early mitosis. This can
be inferred from data showing that when unattached kinetochores are created in cells where Mad1 and Mad2
have been stripped from kinetochores, Mps1 inhibition via AZ3146 prevents re-recruitment of the proteins to
unattached kinetochores (Hewitt et al, 2010). When Mad1-C-Mad2 cannot be recruited, O-Mad2 cannot
dimerise at the kinetochore, and the SM2.2 does not stain kinetochores.
(C) Mps1 activity is required to maintain O-Mad2 levels at unattached kinetochores during mitosis. When
cells are arrested with nocodazole to induce Mad1 and Mad2 recruitment to unattached kinetochores, then
treated with AZ3146 to inhibit Mps1, Mad1-C-Mad2 levels remain relatively high, whereas O-Mad2 levels
(and consequently SM2.2 kinetochore staining) are very low (Hewitt et al, 2010). The specificity of SM2.2
for O-Mad2 in cells explains the low levels of SM2.2 staining compared to Mad1 staining, and the difference
in effect of Mps1 inhibition depending on the point of inhibition contributes to the variability in Mad1 levels
in the mixed mitotic population analysed in Figure 5.3.
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7.2.2 | Mps1 appears to have an indirect role in Mad1-Mad2 core complex 
recruitment 
The data discussed above, along with work from other groups highlighting the 
importance of Mps1 kinase activity in recruiting Mad1 and Mad2 to kinetochores (Jelluma 
et al., 2008b; Kwiatkowski et al., 2010; Liu et al., 2003; Maciejowski et al., 2010; Martin-
Lluesma et al., 2002; Santaguida et al., 2010; Sliedrecht et al., 2010; Tighe et al., 2008; Xu 
et al., 2009), provides a mechanistic explanation for the spindle checkpoint malfunction in 
Mps1-inhibited cells.  How exactly Mps1 might promote initial recruitment of the Mad1-
C-Mad2 core complex to the kinetochore in prometaphase is unknown; notably, however, 
data in this study (Figure 5.1) and concurrently from others (Maciejowski et al., 2010; 
Santaguida et al., 2010) indicated that kinetochore levels of the RZZ complex, which is 
necessary for full Mad1 recruitment (Buffin et al., 2005; Kops et al., 2005), are also 
lowered following Mps1 inhibition.  Therefore, Mps1’s role in Mad1 recruitment might be 
indirect, perhaps by mediating the interaction between RZZ and Zwint: along with other 
members of the outer kinetochore KMN network, Zwint remains at kinetochores following 
Mps1 inhibition (this study, Figure 5.1 and Santaguida et al., 2010).  The kinetochore 
binding sites for the RZZ complex are not fully understood (Civril et al., 2010), and further 
understanding of specific requirements for kinetochore assembly could help clarify any 
role for Mps1. 
7.2.3 | Regulation of Mad2 dimerisation – the “cap” hypothesis 
As well as it’s role in initial recruitment of the core Mad1-C-Mad2 complex to 
kinetochores, likely via mediation of RZZ localisation, Mps1 kinase activity seems to be 
important in both the recruitment and subsequent maintenance of soluble O-Mad2 levels at 
the kinetochore (Hewitt et al., 2010).  How O-Mad2 recruitment is promoted remains a key 
question.  The fact that the dynamics of Mad1-Mad2 binding can be recreated in vitro 
(Vink et al., 2006) suggests that promotion of Mad2 dimerisation in cells likely involves 
removal of some inhibitory element that is not present in the in vitro experiments.  
Structural and biochemical data have led to the hypothesis that p31comet acts as a kind of 
“cap” on the core complex, inactivating the checkpoint (Mapelli et al., 2006; Vink et al., 
2006; Yang et al., 2007a).  It is hypothesised that some factor(s) at kinetochores might 
regulate p31comet, perhaps via post-translational modification, to allow Mad2 dimerisation 
and checkpoint signalling when unattached kinetochores are present.  The subsequent 
reactivation of p31comet might contribute to the cessation of checkpoint signalling when all 
chromosomes have aligned (Musacchio and Salmon, 2007).  Mps1 is a candidate p31comet 
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 regulator: conceivably, its sustained activity could prevent association of p31comet with C-
Mad2, allowing Mad2 dimerisation.  Currently, this remains speculation, but work is 
underway to elucidate the mechanism by which p31comet regulates the checkpoint.   
A striking novel observation described in this study suggests a possible alternative 
mechanism controlling O-Mad2’s association with C-Mad2.  When Mps1 activity was 
decreased in nocodazole-arrested cells, either by inhibition of Mps1 with AZ3146 or by 
expressing a kinase-dead mutant and depleting the endogenous kinase by RNAi, Mps1 
increases in abundance at the kinetochores (Figure 5.3-5.6).  As FRAP-based experiments 
have shown, Mps1 is not a stable resident at unattached kinetochores: it cycles with an 
apparent half-life of recovery of 13 seconds (Howell et al., 2004).  Therefore, the increased 
levels of Mps1 at kinetochores I observed by immunofluorescence might reflect a decrease 
in the rate at which Mps1 cycles on and off the kinetochore. In the future, FRAP 
experiments might prove useful to determine whether or not Mps1’s residency at 
kinetochores is extended after inhibition of its kinase activity. 
One important implication of this data is that Mps1 activity might regulate its own 
kinetochore localisation, and that this may relate to checkpoint signalling.  Since Mps1 
activity levels peak as cells enter mitosis (Liu et al., 2003; Stucke et al., 2002), it is 
plausible that Mps1 itself might act as the inhibitory cap on the Mad1-C-Mad2 core 
complex: its activation on mitotic entry could trigger its release from kinetochores, 
enabling Mad2 dimerisation and activating checkpoint signalling (see schematic diagram 
in Figure 7.2).  Following checkpoint satisfaction, Mps1 levels at kinetochores decrease 
(Howell et al., 2004; Liu et al., 2003; Stucke et al., 2002), as do levels of Mad1 and Mad2 
at kinetochores due to Dynein-dependent stripping (Howell et al., 2001).  Perhaps Mps1 
reprises its role as a cap on the core complex as the proteins are stripped from aligned 
kinetochores, as has been suggested for p31comet (Musacchio and Salmon, 2007).  There is 
currently a lack of biochemical data to support the Mps1 cap hypothesis: no physical 
interactions between Mps1 and members of the core complex have been reported.  Indeed, 
none were detected in immunoprecipitations performed in this laboratory (A. Tighe, 
unpublished results).  Nevertheless, it is possible that such interactions may exist despite 
these negative results, since they may be relatively weak and difficult to detect by 
immunoprecipitation.   
7.2.4 | Mps1 molecules interact with each other in cells 
The increase in Mps1 levels at kinetochores also pointed to important aspects of 
Mps1 regulation.  Specifically, the fact that the exogenous kinase-dead GFP-Mps1 levels 
did not increase significantly relative to wild-type levels at kinetochores, unless 
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autophosphorylates, triggering its own auto-release, and allowing O-Mad2 to dimerise with C-Mad2 in the
core complex. This facilitates downstream checkpoint signalling. Note that Mps1 activity is required for the
initial recruitment of both Mad1-C-Mad2 core complex and O-Mad2 to unattached kinetochores, but its sus-
tained activity is a critical requirement for continued O-Mad2 recruitment (Hewitt et al, 2010). Mps1's auto-
release also exposes the Cenp-E tail’s kinetochore binding site, allowing Cenp-E to be recruited and contrib-
uting to proper alignment of chromosomes at the metaphase plate.
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 endogenous activity was removed by RNAi (Figure 5.6), or ablated by AZ3146 treatment 
(Figure 5.5), was intriguing.  The inactive transgene was apparently prevented from 
accumulating when active, endogenous Mps1 was present, which hinted at some 
interaction between the two pools of Mps1 in the cell.  Evidence from several laboratories 
implies that Mps1 molecules do indeed interact with each other: the kinase is capable of 
trans-molecular autophosphorylation, and this autophosphorylation is required for full 
kinase activity (Jelluma et al., 2008a; Kang et al., 2007; Mattison et al., 2007; Tyler et al., 
2009).  Artificially induced dimerisation leads to hyperactivity of immunoprecipitated 
Mps1 (Kang et al., 2007).  A hypothesis presents itself based on these findings: perhaps 
Mps1 functions as a dimer, which comes together at the kinetochore, trans-
autophosphorylates, activates and also triggers its own release from kinetochores.  One 
might therefore predict that dimers in which both Mps1 molecules are inactive fail to trans-
autophosphorylate and are retained at the kinetochore.  
Work published in Hewitt et al (2010) supports this hypothesis.  Importantly, my 
colleague A. Tighe found the first evidence of Mps1 dimers in mitotic cells, observing an 
interaction between immunoprecipitated Myc- and GFP-tagged Mps1.  If at least one of 
the members of the immunoprecipitated dimer was active, wild type Mps1, the 
immunoprecipitated kinase appeared to be phosphorylated, as measured by band-shift on 
an SDS-PAGE gel.  However, when both members of the dimer were inactive kinase dead 
mutants, this apparent phosphorylation was markedly reduced.  This work supports Mps1 
dimerisation and trans-phosphorylation in cells, but the significance of these findings with 
regard to regulation of Mps1 kinetochore localisation is as yet unknown.  The identity of 
the Mps1 target phosphorylation site(s), whether autophosphorylation or otherwise, will be 
important in helping to understand the regulation of its localisation.   
7.3 | Mps1 and chromosome alignment 
As detailed in Chapter 1, Mps1 has a dual role in mitosis, regulating the mitotic 
checkpoint via Mad1/Mad2, and also facilitating chromosome alignment (Jelluma et al., 
2008b; Maciejowski et al., 2010; Santaguida et al., 2010; Sliedrecht et al., 2010).  In 
agreement with this, AZ3146-treated cells failed to reach metaphase after removal of 
monastrol (Figure 6.2).  However, in contrast to some previous reports (Jelluma et al., 
2008b; Kwiatkowski et al., 2010; Sliedrecht et al., 2010), I did not see any evidence of 
Aurora B inhibition in Mps1 inhibited cells (Figure 6.3; discussed below), but I did see a 
significant decrease in Cenp-E levels at kinetochores in both nocodazole- and monastrol-
treated cells, and at unaligned chromosomes after monastrol wash-out.  Previous reports 
indicate Cenp-E is relatively unaffected after RNAi of Mps1 (Jelluma et al., 2008b; Tighe 
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 et al., 2008), raising the possibility that Cenp-E loss after AZ3146 treatment may be caused 
by Mps1 accumulation at the kinetochore.  Cenp-E and Mps1 may occupy mutually 
exclusive binding sites at kinetochores, meaning Cenp-E can localise via its tail domain 
relatively normally when Mps1 is active and rapidly cycling, but is prevented from binding 
when inactive Mps1 does not auto-release from kinetochores (see Figure 7.2). 
The above hypothesis is speculative, but if true, suggests that Mps1’s role in Cenp-E 
recruitment is not through direct protein-protein interaction.  However, evidence does exist 
to support a direct substrate-kinase interaction between Xenopus Mps1 and the Cenp-E tail 
domain, at least in vitro (Espeut et al., 2008).  In this system, Mps1 phosphorylation of the 
Cenp-E tail is proposed to relieve autoinhibition of the kinesin, thereby presumably 
activating it at the kinetochore (Espeut et al., 2008).  Cdk1 is also known to phosphorylate 
the Cenp-E tail domain (Espeut et al., 2008; Liao et al., 1994), and out of the 4 mitotic 
phospho-sites identified in the Cenp-E tail by phosphoprotemic methods (Dephoure et al., 
2008; Nousiainen et al., 2006), 2 match the consensus site for proline-directed kinases 
(Cdk1 or MAPKs).  The fact that 2 of these sites are not in proline-directed motifs suggests 
Cenp-E’s kinetochore localisation domain is phosphorylated by other kinase(s) in mitotic 
human cells: Mps1 is a possible candidate.  However, to date there is no evidence that 
Mps1 phosphorylates Cenp-E in cells.  Preliminary data I obtained from mass spectrometry 
on Cenp-E tail from mitotic cells identified one of these non-Cdk1 sites (S2651 in the full-
length protein), and saw no change in its phosphorylation level after AZ3146 treatment, 
though the level of phosphorylation at a Cdk1 consensus site (S2654) was increased 
slightly (data not shown).  This preliminary data requires both repetition and consolidation 
before any conclusions can be confidently drawn from it, however it is tempting to 
speculate that the increase in phosphorylation at S2654 might be a consequence of Cenp-E 
tail’s mislocalisation from kinetochores into the cytoplasm where Cdk1 has access to the 
substrate.  Further analysis of Cenp-E phosphorylation in both Mps1-inhibited and Cdk1-
inhibited cells will be required to determine whether or not this holds true. 
Whether or not it is regulated by phosphorylation, Cenp-E’s disappearance from 
kinetochores may at least partly explain the problems with alignment in Mps1 inhibitor-
treated cells.  Notably, Mps1 activity is a requirement for efficient Cenp-E recruitment to 
kinetochores in X. laevis egg extracts (Abrieu et al., 2001), and my observations have 
recently been corroborated in hTERT-RPE cells expressing analogue-sensitive Mps1as 
(Maciejowski et al., 2010).  Lack of Cenp-E at kinetochores would prevent chromosomes 
from congressing from the poles toward the metaphase plate.  It is likely, however, that 
Mps1-deficient cells might have multiple problems with the mechanism of alignment.  
Kinetochores in AZ3146-treated cells also have lowered levels of Cenp-F (Figure 5.1), 
137
 which, in addition to binding Cenp-E (Chan et al., 1998; Johnson et al., 2004; Yang et al., 
2005; Yao et al., 2000), has also been linked to Dynein-dynactin recruitment via Nde1 
(Vergnolle and Taylor, 2007).  This may mean AZ3146-treated cells have a reduced ability 
to move chromosomes polewards prior to biorientation, a process that is thought to 
contribute to the efficiency of alignment (Yang et al., 2007b).  More detailed analysis of 
AZ3146-treated cells could shed light on the contributions of these proteins to the 
alignment defect. 
7.3.1 | Mps1 and Aurora B – who regulates whom? 
As previously mentioned, Mps1 has previously been placed upstream of Aurora B in 
a signalling network controlling the correction of erroneous kinetochore-microtubule 
attachments, thereby facilitating alignment (Jelluma et al., 2008b; Sliedrecht et al., 2010).  
In the process of conducting this study, I found no evidence that Aurora B activity is 
diminished in cells treated with an Mps1 inhibitor (Figure 6.3).  On the contrary, both 
Mps1’s phosphorylation status and its kinetochore localisation were affected by treatment 
with the Aurora B inhibitor ZM447439, positioning Aurora B upstream of Mps1 (Figure 
6.4).  It remains to be determined whether Mps1 is a direct substrate for Aurora B, or 
whether the decrease in phosphorylation is linked to the lowered kinetochore levels of 
Mps1.  This, in turn, might reflect an increase in the rate of cycling Mps1, or a lower level 
of Mps1 cycling normally: FRAP experiments would be necessary to distinguish between 
these two possibilities.    
The apparent lack of Aurora B inhibition after AZ3146 treatment was surprising in 
light of previous publications (Jelluma et al., 2008b; Kwiatkowski et al., 2010; Sliedrecht 
et al., 2010).  However, concurrent with the publication of our report (Hewitt et al., 2010), 
two other laboratories published similar findings, arrived at by different means: Santaguida 
and colleagues (2010) used another small molecule, Reversine; Maciejowski et al (2010) 
used targeted gene deletion followed by replacement with bulky purine analogue-sensitive 
Mps1as.  Both reports show that potent Mps1 inhibition had no appreciable effect on 
Aurora B activation levels, meaning the lack of Aurora B inhibition I observed is unlikely 
to be due to be solely attributable to residual Mps1 activity.  The contrasting conclusions 
concerning who regulates whom might point to a non-linear signalling network involving 
the kinases, maybe involving cross-talk between the two.  But why would different labs 
produce such divergent results?  The answer is currently unclear, but one possibility is that 
differences between cells lines may be important.  Aurora B appears to be regulated by 
Mps1 in U2OS and HCT116-derived cell lines (Sliedrecht et al., 2010), but not in HeLa 
cells (Hewitt et al., 2010, and this study; Santaguida et al., 2010) or in untransformed 
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 hTERT-RPE cells (Maciejowski et al., 2010).  This suggests the differences are not simply 
due to use of transformed versus untransformed cell lines.  However, it is still conceivable 
that other differences between cell lines might explain these results.  Perhaps Aurora B 
activity is regulated in RPE and HeLa cells by Mps1-independent mechanism(s) that are 
non-functional in U2OS and HCT116 cells.  Another possible explanation is that 
expression, or regulation of Aurora C, the third, lesser-studied member of the Aurora 
family, might differ between cells lines, potentially masking Aurora B inhibition in Mps1 
treated cells.  Aurora C might be able to compensate for loss of Aurora B activity in Mps1-
inhibited cells (Li et al., 2004; Sasai et al., 2004; Slattery et al., 2008), meaning Aurora B 
appears active, but is not.  Aurora C expression has been reported in an untransformed 
human fibroblast cell line (WI-38 cells), plus several cancer cell lines including both HeLa 
and HCT116 cells (Sasai et al., 2004), suggesting the explanation may not be as simple as 
presence or absence of the kinase.  The situation is further complicated by the fact that, 
like Aurora B, Aurora C can also form a complex with the apparent Mps1 substrate 
Borealin, along with other members of the CPC (Li et al., 2004; Slattery et al., 2008), but it 
is not known whether these complexes are regulated identically, or whether Aurora C only 
functions as part of the CPC.  This situation certainly warrants further exploration: it would 
be interesting to find out if Aurora C expression or activation levels might differ between 
cell lines, and whether these correlate with Aurora B activity levels following Mps1 
inhibition.  Whilst the relationship between Mps1 and Aurora B is far from completely 
understood, newly described tools for Mps1 inhibition, including AZ3146, should facilitate 
further investigation into the function of the two kinases in mitosis.  
7.4 | Mps1 inhibition and cell viability 
The discovery that inactivation of the mitotic checkpoint cause cell death due to 
catastrophic errors in segregation (Kops et al., 2004; Michel et al., 2004) gave rise to the 
idea that inhibition of the mitotic checkpoint could represent a useful anti-cancer strategy.  
However, evidence suggests that Mps1 inhibition kills both cancer cells lines and “normal” 
untransformed cell lines (Figure 4.1 and Kwiatkowski et al., 2010; Maciejowski et al., 
2010), making it less than ideal for therapeutic use, where drugs that are selective for 
tumour cells are desirable.  Another important caveat is that effective checkpoint inhibition 
might be difficult to achieve in vivo without a more potent drug than those currently 
available.   
Prior publications have shown that a low level of Mps1 activity (~10-40%) is 
sufficient to maintain viability of cultured cells (Janssen et al., 2009; Jelluma et al., 2008a; 
Maciejowski et al., 2010).  My data appears to conflict with this: colony formation assays 
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 showed that treatment with 1 µM AZ3146, a concentration that does not cause significant 
aneuploidy after 24 hour treatment (as measured by the appearance of the DNA content 
profile of treated cells, Figure 4.2) significantly affected the long-term viability of HeLa, 
HCT116 and hTERT-RPE cells (Figure 4.1).  In the absence of a more detailed analysis of 
the level of inhibition caused by 1 µM AZ3146 in cells, and a more sensitive measurement 
of chromosome missegregations it may cause, it is difficult to compare my data with 
earlier publications. However, it has been shown that even relatively severe chromosome 
missegregations can take several doublings to cause widespread death in a population 
(Kops et al., 2004), so if 1 µM AZ3146 causes loss or gain of a few chromosomes with 
each division (which may not be visible by the relatively insensitive DNA content profiling 
I used in Figure 4.2) it seems reasonable that this may have a detrimental effect on cell 
survival over 9-10 days (Figure 4.1).  While the contribution of off-target effects to the 
decrease in viability in AZ3146-treated cells cannot be excluded, taking together my data 
and that from other laboratories, (Janssen et al., 2009; Jelluma et al., 2008a; Kwiatkowski 
et al., 2010; Maciejowski et al., 2010) it is clear that Mps1 activity is necessary for the 
survival of both transformed and untransformed cell lines.   
Although current data casts doubt upon its selectivity for cancer cell lines, AZ3146 
and other new Mps1 inhibitors will allow further evaluation of Mps1 targeting as an anti-
cancer strategy by assessing its effect in more tumour cell lines and in tumour models.  It 
has been suggested that Mps1’s dual role in chromosome alignment and checkpoint 
signalling can be exploited to selectively kill cancer cells: RNAi-based studies indicate that 
partial Mps1 depletion combined with a low, sub-lethal dose of Taxol leads to an increased 
rate of chromosome missegregation, providing selective toxicity towards cultured cancer 
cell lines (Janssen et al., 2009). The fact that partial depletion of Mps1 was enough to 
synergise with Taxol treatment in cancer cells is encouraging, since partial inhibition is 
likely to be easier to achieve in vivo than complete inhibition.  It remains to be seen 
whether AZ3146 or other Mps1 inhibitors will also have a selective synergy with Taxol, 
and more importantly whether this strategy of enhancing the rate of chromosome 
missegregation will prove selective for tumour cells in in vivo models.   
7.5 | Perspectives and future directions 
Mps1 activity has a dual role in the maintenance of genomic stability and cell 
viability: it is involved in both the mechanism of chromosome alignment and control of 
mitotic timing in human cells.  The dynamic nature of Mps1’s interaction with the 
kinetochore may prove critical in the regulation of both of these processes.  Further 
dissection of the relationship between Mps1 and Aurora B is a key challenge for the future: 
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 it has become apparent that the two kinases are closely linked and converge upon some of 
the same substrates: for example, Ndc80 and BubR1 are targets of both kinases 
(Cheeseman et al., 2002; Ditchfield et al., 2003; Hauf et al., 2003; Huang et al., 2008; 
Kemmler et al., 2009).  Interestingly, a key Mps1 substrate appears to be Mps1 itself: a 
role for dimerisation and trans-autophosphorylation in regulation of Mps1 activity has 
emerged (Hewitt et al., 2010; Kang et al., 2007), and might also be involved in regulation 
of Mps1’s kinetochore localisation (see speculative model in Figure 7.2).  It seems likely 
that further Mps1 substrates remain to be discovered, and AZ3146, along with other Mps1 
inhibitors, should prove valuable in this endeavour and help to further understanding of the 
processes of mitotic checkpoint regulation and chromosome alignment. 
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Introduction
The Mps1 protein kinase plays an essential role in the spindle as-
sembly checkpoint (SAC; Weiss and Winey, 1996), an inhibitory 
network that restrains anaphase until all kinetochores are stably 
attached to spindle microtubules (Musacchio and Salmon, 2007). 
Recent efforts have revealed that its catalytic activity is required 
for SAC function and chromosome alignment (Jelluma et al., 
2008a,b; Tighe et al., 2008; Kwiatkowski et al., 2010; Sliedrecht 
et al., 2010; see Santaguida et al. in this issue). Exactly how Mps1 
does this is unclear; although its SAC function is linked to kineto-
chore recruitment of Mad1 and Mad2 (Martin-Lluesma et al., 
2002; Liu et al., 2003), Mps1 has also been implicated in aurora B 
regulation (Jelluma et al., 2008b), possibly explaining its role in 
chromosome alignment.
Previously, when we used an RNAi complementation 
assay to inhibit Mps1’s catalytic activity, Mad2 was largely un-
detectable at kinetochores (Tighe et al., 2008). However, Mad1 
recruitment was only partially affected, suggesting two possi-
bilities: either Mps1 recruits Mad1 via a noncatalytic role or 
only low level Mps1 activity is required for Mad1 recruitment. 
Either way, because Mad1 directly recruits Mad2 to the kineto-
chore (Chung and Chen, 2002), the simplest explanation was 
that Mps1 activity promotes the Mad1–Mad2 interaction.
This notion is at odds with current views of Mad2 function 
(Mapelli et al., 2007). The Mad2 template model posits that a Mad1 
dimer acts as the kinetochore receptor for Mad2, which can adopt 
two conformations, open (O-Mad2) and closed (C-Mad2). When 
Mad2 binds Mad1, it adopts the closed conformation, forming the 
Mad1–C-Mad2 core complex. Because Mad2 can dimerize, this 
core complex in turn recruits two O-Mad2 molecules. These are 
handed over to Cdc20, and in doing so, Mad2 closes, generating 
two Cdc20–C-Mad2 complexes. Because the Mad1–C-Mad2 
complex is very stable (Howell et al., 2004; Shah et al., 2004; Vink 
et al., 2006) and probably present in interphase where it binds the 
Mps1 is an essential component of the spindle assembly checkpoint. In this study, we describe a novel Mps1 inhibitor, AZ3146, and use it to 
probe the role of Mps1’s catalytic activity during mitosis. 
When Mps1 is inhibited before mitotic entry, subsequent 
recruitment of Mad1 and Mad2 to kinetochores is abol-
ished. However, if Mps1 is inhibited after mitotic entry, 
the Mad1–C-Mad2 core complex remains kinetochore 
bound, but O-Mad2 is not recruited to the core. Although 
inhibiting Mps1 also interferes with chromosome align-
ment, we see no obvious effect on aurora B activity. 
In contrast, kinetochore recruitment of centromere protein E 
(CENP-E), a kinesin-related motor protein, is severely 
impaired. Strikingly, inhibition of Mps1 significantly in-
creases its own abundance at kinetochores. Furthermore, 
we show that Mps1 can dimerize and transphosphory-
late in cells. We propose a model whereby Mps1 trans-
phosphorylation results in its release from kinetochores, 
thus facilitating recruitment of O-Mad2 and CENP-E and 
thereby simultaneously promoting checkpoint signaling 
and chromosome congression.
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inhibitor that was modified to enhance potency and selectiv-
ity, resulting in AZ3146 (Fig. 1 A). In in vitro kinase assays, 
AZ3146 inhibited human Mps1Cat with an IC50 (50% inhibi-
tory concentration) of 35 nM (Fig. 1, B and D). AZ3146 
also efficiently inhibited autophosphorylation of full-length 
Mps1 immunoprecipitated from human cells (Fig. 1 C). 
Screening a panel of 50 other kinases demonstrated minimal 
activity against 46 enzymes (Fig. 1 E). Only four kinases 
were inhibited by >40%, namely FAK, JNK1, JNK2, and 
KIT. Together, these data suggest that AZ3146 is a reasonably 
potent and selective Mps1 inhibitor. To measure the effect 
on Mps1 in cells, we used Phos tag gels to resolve phos-
phorylated isoforms (Kinoshita et al., 2006). When isolated 
from mitotic cells, Mps1 appeared as a major band and a 
minor, slower-migrating band (Fig. 1 F). Upon exposure to 
AZ3146, the minor band largely disappeared, demonstrating 
that it clearly inhibits phosphorylation of Mps1 in cells 
(Fig. 1 F and Fig. S1 B). Mitotic-specific phospho forms of 
aurora B and BubR1 were not affected by AZ3146 (Fig. S1 C), 
and AZ3146 did not inhibit Cdk1 or aurora B in mitotic cells 
(Fig. S1, A and D).
nuclear envelope (Campbell et al., 2001), it seems unlikely that 
Mps1 promotes binding of Mad2 to Mad1.
An alternative explanation comes from the fact that our ob-
servations were derived using an antibody against Mad2, called 
SM2.2 (Tighe et al., 2008). Because kinetochore-bound Mad2 
effectively represents two different species, we reasoned that the 
effect observed in Mps1-deficient cells was not necessarily caused 
by a complete inability to recruit Mad2, but may reflect an inability 
to detect it using SM2.2 either because the antibody is conforma-
tion specific (i.e., it cannot bind C-Mad2) or possibly because 
C-Mad2 is masked. If either possibility is true, an attractive hypoth-
esis emerges; if SM2.2 only detects O-Mad2 at kinetochores for 
whatever reason, perhaps Mps1 kinase activity is required to recruit 
O-Mad2 to the Mad1–C-Mad2 core complex. In this study, we test 
this hypothesis using a novel small molecule Mps1 inhibitor.
Results and discussion
AZ3146, a novel Mps1 inhibitor
To identify Mps1 inhibitors, we used a high throughput in vitro 
kinase assay to screen a compound collection, yielding an 
Figure 1. AZ3146, a novel Mps1 inhibitor. 
(A) AZ3146 (AZ) is shown. (B) In vitro kinase 
assay measuring the ability of Mps1Cat to 
phosphorylate myelin basic protein (MBP). 
(C) In vitro kinase assays measuring the activity 
of Mps1 immunoprecipitated from nocodazole-
arrested HeLa cells. (D) Dose–response curve 
showing inhibition of Mps1Cat by AZ3146. 
(E) Activity of AZ3146 against a kinase panel. 
(F) Phos tag immunoblot of Mps1 isolated from 
interphase cells or nocodazole-arrested cells 
treated with MG132 ± 2 µM AZ3146 for 
2 h. Arrowhead, major band; asterisk, minor 
band. Error bars indicate SEM derived from 
three experiments.
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Although AZ3146 had a dramatic effect on kinetochore localiza-
tion of Mad2, reducing its levels to 15%, its effect on Mad1 was 
less pronounced, with levels remaining at 60% (Fig. 2, C and D). 
These data are entirely consistent with our prior observations, 
namely a dramatic inhibition of Mad2 and a partial effect on 
Mad1 (Tighe et al., 2008). Thus, taking together the enzyme 
data, the SAC override phenotype, and the effect on Mad1 
and Mad2 localization, these data show that AZ3146 behaves as 
one would predict for an Mps1 inhibitor, strongly arguing that it 
is a useful tool for probing Mps1 function.
Mps1 plays two roles when recruiting 
Mad1 and Mad2 to kinetochores
We were puzzled why inhibiting Mps1 had a dramatic effect on 
kinetochore localization of Mad2 but only partially effected 
Mad1. Indeed, other studies suggest that Mps1 inhibition does 
AZ3146 overrides the spindle checkpoint
Cell cycle analysis showed that HeLa cells treated with no-
codazole and 2 µM AZ3146 only delayed mitosis briefly and 
then rereplicated their genomes (Fig. S2, A–C), demonstrating 
that the drug overrides the SAC. AZ3146 also silenced an al-
ready established SAC signal; after release from a nocodazole 
block, AZ3146 dramatically accelerated mitotic exit (Fig. S2 D). 
This was blocked by MG132, a proteasome inhibitor (Fig. S2 E), 
ruling out direct inhibition of Cdk1 activity. Time-lapse analysis 
of HeLa cells expressing a GFP-tagged histone showed that 
during an otherwise unperturbed mitosis, AZ3146 reduced the 
time to complete mitosis from 90 min in controls to 32 min 
(Fig. 2 A). Strikingly, 90% of AZ3146-treated cells underwent 
abnormal mitoses; although 50% entered anaphase without 
aligning all of their chromosomes, 30% exited mitosis with-
out undergoing obvious chromosome segregation (Fig. 2 B). 
Figure 2. AZ3146 compromises SAC function 
and inhibits Mad2 localization. (A) Box and 
whisker plot of HeLa GFP-H2B cells treated 
with or without AZ3146 (AZ) and analyzed 
by time-lapse microscopy, showing the time 
from nuclear envelope breakdown to chromo-
some decondensation. Values were derived 
from ≥75 cells. (B) Bar graph quantifying mi-
totic phenotypes. Values were derived from 
≥115 cells. (C) Images of HeLa cells treated 
with nocodazole and MG132 for 2 h with or 
without AZ3146, fixed, and stained to detect 
centromeres (ACA) and either Bub1, Mad1, 
or Mad2. Insets show higher magnification 
views of individual kinetochore pairs (boxed 
regions). (D) Bar graph quantifying pixel in-
tensities at kinetochores normalized to ACA 
in mitotic HeLa cells treated with or without 
AZ3146. Values were derived from ≥228 
kinetochores. (E) Bar graphs scoring kineto-
chore staining of Mad1/2 as high, medium, 
or low after exposure to nocodazole (Noc) or 
MG132 (MG) plus either AZ3146 or reversine 
(Rev). Data were derived from a two experi-
ments in which at least 50 cells were counted 
per condition. (F) Images of HeLa cells stained 
to detect Zwilch and centromeres after expo-
sure to nocodazole, reversine, and MG132 in 
the sequences indicated. AZ3146 was used at 
2 µM and reversine at 500 nM. Ctrl, control. 
Error bars indicate SEM. Bars: (C and F) 5 µm; 
(C, insets) 0.5 µm.
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data showing that the Mad1–C-Mad2 interaction is very stable 
(Howell et al., 2004; Shah et al., 2004; Vink et al., 2006). 
Because a key step in checkpoint activation is recruitment of 
O-Mad2 to kinetochore-bound Mad1–C-Mad2 (Musacchio 
and Salmon, 2007), we hypothesized that perhaps Mps1 activ-
ity is required to recruit O-Mad2 to Mad1–C-Mad2 complexes 
already at kinetochores. In that case, upon Mps1 inhibition, 
kinetochore-bound Mad2 should only fall to 50% (Fig. 3 A), 
yet AZ3146 abolishes Mad2 localization (Fig. 2, C–E). There-
fore, we speculated that the Mad2 antibody SM2.2 does not ef-
ficiently detect C-Mad2 at the kinetochore either because the 
antibody cannot bind C-Mad2 or because the relevant epitopes 
are masked.
To test this, we generated cells expressing Myc-tagged 
Mad2 (Fig. 3 B and Fig. S3 B), reasoning that anti-Myc antibodies 
might detect it regardless of conformation or cellular context. 
Interestingly, Mad1 and Mad2 localize to the nuclear envelope in 
interphase (Campbell et al., 2001; Shah et al., 2004), and although 
we could readily detect Mad2 there using anti-Myc antibodies, 
SM2.2 did not decorate the envelope (Fig. 3 C), suggesting that it 
does not recognize C-Mad2 when bound to Mad1. In mitosis, 
both anti-Myc antibodies and SM2.2 decorated kinetochores 
(Fig. 3 D). Significantly, although AZ3146 reduced SM2.2 signal 
to background levels, anti-Myc antibodies still gave obvious 
kinetochore staining (Fig. 3, D and E). Importantly, however, quan-
titation showed that anti-Myc staining was reduced to 45 ± 5% 
(Fig. 3 E), i.e., approaching the 50% value predicted by 
our hypothesis.
To test the hypothesis further, we analyzed two Mad2 mu-
tants. Mad2C cannot adopt the closed conformation (Mapelli 
et al., 2007) or bind Mad1 and, thus, can only bind kinetochores 
via dimerizing with endogenous C-Mad2 (Fig. 3 A). Mad2RQ 
can bind Mad1 but cannot dimerize (Mapelli et al., 2007) and, 
thus, can only target kinetochores by binding Mad1 (Fig. 3 A). 
If Mps1 is required to recruit O-Mad2 to the core, upon exposure to 
AZ3146, Mad2C should be absent from kinetochores, whereas 
Mad2RQ should be unaffected (Fig. 3 A). We generated stable 
cell lines expressing Myc-Mad2C and Myc-Mad2RQ (Fig. 3 B 
and Fig. S3 B). Although both mutants localized to kinetochores 
in mitosis (Fig. 3 D), Myc-Mad2C did not bind the nuclear en-
velope (Fig. S3 C). However, consistent with our hypothesis in 
response to AZ3146, Mad2C was no longer abundant at kineto-
chores, whereas Mad2RQ appeared unaffected (Fig. 3 D). Indeed, 
quantitation showed that Myc-Mad2C was reduced to a back-
ground level, whereas Myc-Mad2RQ remained at 90% 
(Fig. 3 E). Thus, these observations strongly support the notion 
that during mitosis, Mps1 kinase activity is required to recruit 
O-Mad2 to kinetochore-bound Mad1–C-Mad2.
Mps1 is required for  
chromosome alignment
To confirm and further probe the role of Mps1 in chromosome 
alignment (Maure et al., 2007; Jelluma et al., 2008b), we ana-
lyzed the effect of AZ3146 after a monastrol washout (Mayer 
et al., 1999; Kapoor et al., 2006). Note that cells were also treated 
with MG132 to prevent mitotic exit caused by SAC override. 
Under these conditions, AZ3146 inhibited chromosome alignment 
dramatically affect Mad1 (Jelluma et al., 2008b; Kwiatkowski 
et al., 2010; Sliedrecht et al., 2010); e.g., inhibition of Mps1 using 
another small molecule, reversine, blocked recruitment of Mad1 
and its kinetochore receptor, the Rod–Zw10–Zwilch (RZZ) 
complex (Santaguida et al., 2010). We reasoned that these dif-
ferences may be a result of when Mps1 was first inhibited either 
before or during mitosis. To test this, we designed three experi-
ments, exposing cells to nocodazole, MG132, and AZ3146, but 
in different orders. After treatment, cells were fixed, stained, and 
the intensity of Mad1 at kinetochores was scored as high, me-
dium, or low (Fig. S3 A).
First, we treated cells with nocodazole and AZ3146 for 
2 h, adding MG132 for the last hour. Like our previous experi-
ments, in this regimen, some cells should enter mitosis in the 
presence of AZ3146, whereas others would already be in mito-
sis. This yielded a mixed effect on Mad1: although some cells 
still had high levels of Mad1 at kinetochores, others had low 
levels (Fig. 2 E, Expt. 1). Thus, the aforementioned partial ef-
fect on Mad1 (Fig. 2 D) appears to arise from the fact that when 
we quantitate pixel intensities in a small population of cells, 
some have relatively normal levels of Mad1 at kinetochores, 
whereas in others, it is markedly reduced (Fig. S3 A). Next, 
we treated cells with nocodazole and MG132 for 2 h, adding 
AZ3146 for the last hour. Because MG132 blocks entry into and 
exit out of mitosis, in this regimen, all mitotic cells should have 
entered mitosis before AZ3146 exposure. Under these condi-
tions, Mad1 was now largely unaffected (Fig. 2 E, Expt. 2). 
Finally, we treated cells with MG132 for 2 h, adding nocodazole 
and AZ3146 for the last hour. In this regimen, before AZ3146 
treatment, all mitotic cells should have aligned chromosomes 
with kinetochores stripped of Mad1/2 (DeLuca et al., 2003). 
Therefore, adding nocodazole to destabilize microtubules 
should lead to rerecruitment of Mad1. Significantly, although 
Mad1 was present at kinetochores in controls, kinetochores in 
cells treated with nocodazole plus AZ3146 were devoid of 
Mad1 (Fig. 2 E, Expt. 3). Note that AZ3146 inhibited kineto-
chore localization of Mad2 regardless of the experimental 
regimen (Fig. 2 E).
The simplest explanation for these data is that Mps1 is in-
volved in two distinct steps. First, it is required upon mitotic 
entry to get Mad1 to kinetochores (or, in the case of experiment 3, 
it is required in mitosis to rerecruit Mad1 when microtubules 
are removed from attached kinetochores). Although Mps1 activ-
ity is no longer needed to maintain Mad1 localization, it is 
continuously required during mitosis to promote Mad2 recruit-
ment. Importantly, reversine yielded virtually identical pheno-
types (Fig. 2 E). Furthermore, when cells were treated with 
reversine before mitotic entry, the RZZ component Zwilch was 
largely absent from kinetochores (Fig. 2 F). However, when 
cells accumulated in mitosis before exposure to reversine, 
Zwilch localization was normal.
Mps1 activity is required to recruit  
O-Mad2 to the Mad1–C-Mad2 core
The aforementioned data suggest that during mitosis, Mps1 activ-
ity is required continuously to recruit Mad2 to kinetochore-
bound Mad1 (Fig. 2 E, Expt. 2). However, this notion contradicts 
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efficient chromosome alignment, whereas the severe phenotype, 
at least in some cells, may be a consequence of the prolonged 
mitotic arrest.
Mps1 activity is required for centromere 
protein E (CENP-E) localization
In light of Mps1 regulating aurora B via borealin phosphoryla-
tion (Jelluma et al., 2008b), we were surprised that the alignment 
in >85% of cells (Fig. 4, A and B), yielding either a mild pheno-
type with few unaligned chromosomes or a severe phenotype with 
most chromosomes near the poles (Fig. 4 A). Time-lapse micros-
copy showed that AZ3146-treated cells typically aligned all 
but a few chromosomes (Fig. 4 C, 96 min). However, sometime 
later, sister chromatids appeared to separate followed by rather 
chaotic attempts to realign (Fig. 4 C, 184 min; and Fig. S2 F). 
Thus, the mild phenotype appears to reflect Mps1’s role in 
Figure 3. AZ3146 inhibits kinetochore recruitment of O-Mad2. (A) A scheme is shown predicting the behavior of endogenous Mad2 and Myc-tagged 
mutants in cells after inhibition of Mps1 activity. (B) Immunoblots of Tet-induced HeLa lines probed to detect Mad2. (C) Images of an interphase HeLa cell 
expressing Myc-Mad2 wild type stained to detect Mad1, Mad2 using SM2.2, and an anti-Myc antibody. (D) Images of nocodazole-treated cells stained to 
detect the Myc tag (red), Mad2 (green), and centromeres (ACA; blue) after a 2-h exposure to 2 µM AZ3146 (AZ) and MG132. Insets show higher magnifi-
cation views of individual kinetochore pairs (boxed regions). (E) Bar graph quantitating either Mad2 (red) or Myc tag (blue) pixel intensities at kinetochores 
normalized to ACA. WT, wild type; RQ, Mad2RQ. Values indicate SEM derived from ≥245 kinetochores. Bars: (C and D) 5 µm; (C, insets) 0.5 µm.
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Figure 4. AZ3146 inhibits chromosome alignment. (A) Images of HeLa cells stained to detect the chromosomes (blue), tubulin (red), and aurora B (green) 
after monastrol washout into 2 µM AZ3146 (AZ) and MG132 for 90 min. (B) Bar graph quantitating the mitotic phenotypes observed after monastrol 
washout into AZ3146 or ZM447439 (ZM). Values were derived from ≥115 cells in three independent experiments. Ctrl, control. (C) Time-lapse sequences 
of GFP-H2B HeLa cells after monastrol washout into AZ3146 and MG132. Numbers represent minutes after monastrol washout. (D) Images of HeLa cells 
stained to detect the chromosomes (red), aurora A (green/blue), CENP-E (red), and centromeres (ACA; green) after monastrol washout into AZ3146 and 
MG132 for 60 min. Insets show higher magnification views of individual kinetochore pairs (boxed regions). (E) Bar graph quantitating CENP-E staining 
normalized to ACA at polar kinetochores in AZ3146-treated cells. The mean control value is normalized to 100%. At least 300 polar kinetochores were 
analyzed in ≥23 cells. Error bars indicate SEM. Bars: (A, C, and D) 5 µm; (D, insets) 0.5 µm.
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inactive, the Myc-Mps1 band shift was absent (Fig. 5 F, lane 4). 
Together, these observations support the notion that Mps1 does 
dimerize and transphosphorylate in mitotic cells. Whether this 
regulates its localization requires further investigation.
Coupling SAC signaling with  
chromosome congression
Our observations suggest a two-step role for Mps1. Around the 
onset of mitosis, Mps1 activity is required to first recruit the 
Mad1–C-Mad2 core to kinetochores, possibly indirectly by pro-
moting RZZ recruitment. During mitosis, Mps1 activity is con-
tinuously required to recruit O-Mad2 to the Mad1–C-Mad2 core. 
Although Mps1 may achieve this directly, e.g., by phosphorylat-
ing the core or O-Mad2, this seems unlikely because the Mad2 
template mechanism can be recapitulated in vitro without Mps1 
activity (Vink et al., 2006). Therefore, perhaps Mps1 kinase 
activity counters a cellular inhibitor not present in these in vitro 
assays. Interestingly, p31comet may act as an inhibitory “cap” on the 
Mad1–C-Mad2 core (Musacchio and Salmon, 2007). Thus, an 
attractive hypothesis is that Mps1 phosphorylates and inactivates 
p31comet, removing the inhibitory cap to allow recruitment of 
O-Mad2 and thereby kick starting the Mad2 template reaction. 
However, we presently have no evidence linking Mps1 and 
p31comet. As Mps1 levels at kinetochores increase when its activ-
ity is blocked, perhaps Mps1 is itself an inhibitory cap that must 
be released for checkpoint signaling. Having first recruited the 
Mad1–C-Mad2 core, perhaps Mps1 transphosphorylation pro-
motes an autorelease mechanism that allows recruitment of 
O-Mad2, kick starting the Mad2 template mechanism.
We confirm a role for Mps1 activity in chromosome align-
ment. Although we observe no obvious effect on aurora B func-
tion, Mps1 activity is clearly required for CENP-E recruitment after 
monastrol washout. Interestingly, however, Mps1-RNAi did not 
prevent CENP-E recruitment (Jelluma et al., 2008b; Tighe et al., 
2008). Because inactive Mps1 accumulates at kinetochores, perhaps 
Mps1 and CENP-E occupy mutually exclusive binding sites. In this 
scenario, Mps1 autorelease would normally expose the CENP-E–
binding site. However, when its catalytic activity is inhibited, Mps1 
blocks CENP-E recruitment by remaining bound to the kinetochore. 
In contrast, when the entire Mps1 protein is depleted by RNAi, the 
CENP-E–binding site is vacant, allowing its recruitment. Consistent 
with this notion, the levels of kinetochore-bound CENP-E have been 
observed to increase after Mps1 depletion (Jelluma et al., 2008b). 
Although speculative, these ideas warrant further exploration and 
should provide interesting insights into how Mps1 coordinates spin-
dle checkpoint signaling and chromosome congression.
Materials and methods
Inhibitor screen
N-terminal GST-tagged full-length human Mps1 kinase (GenBank accession 
no. NM_003318) was expressed in insect cells and purified via the GST epi-
tope tag. A 12 µl mixture of recombinant enzyme, an FITC-labeled peptide 
substrate (FITC-DHTGFLTEYVATR-CONH2), 12 µM ATP, and a buffer solution 
(50 mM Hepes, pH 7.5, 0.015% vol/vol Brij-35, 1 mM DTT, and 10 mM 
MgCl2) were incubated with test compounds at room temperature for 
25 min. Test compounds were prepared and further diluted in DMSO and 
placed into 384-well low volume white polystyrene plates (Greiner) using an 
acoustic liquid handler (Echo; Labcyte, Inc.). Reactions were stopped by the 
defect was not typical of that observed after aurora B inhibition 
(Ditchfield et al., 2003). Indeed, AZ3146 had no obvious effect 
on several bona fide aurora B substrates (Fig. S1, D–F). There-
fore, we turned our attention to other factors to explain the 
chromosome alignment defect. The phenotype observed in 
AZ3146-treated cells is quite exquisite; most chromosomes align, 
K-fibers are evident (Fig. 4 A), and only a few chromosomes re-
main near the spindle poles (Fig. 4, A–C). This reminded us of the 
phenotype typical of CENP-E inhibition (Wood et al., 1997; 
Weaver et al., 2003; Kapoor et al., 2006). Strikingly, 1 h after 
monastrol washout, the level of CENP-E at kinetochores was re-
duced to 10% (Fig. 4, D and E). Consistent with this being an 
on-target effect of AZ3146, when Mps1-RNAi cells were recon-
stituted with the Mps1M602A allele, 1NM-PP1 inhibited kineto-
chore localization of CENP-E (Fig. S3 D). Thus, CENP-E appears 
to be an important downstream effector of Mps1 kinase activity. 
Note that this is entirely consistent with a previous study analyz-
ing Xenopus laevis egg extracts (Abrieu et al., 2001).
Inhibition of Mps1 increases its abundance 
at kinetochores
These data indicate that Mps1 contributes to mitotic fidelity by 
promoting kinetochore recruitment of O-Mad2 and Cenp-E. 
Although detailing the exact molecular mechanisms will require 
further experimentation, one observation may prove informative. 
In the presence of AZ3146, Mps1 staining at kinetochores 
increased by about sixfold (Fig. 5, A and B). This is not simply 
caused by increasing epitope accessibility, as direct fluorescence 
from a GFP-Mps1 fusion was also more evident at kinetochores 
in AZ3146-treated cells (Fig. 5 E).
To confirm that this reflected an on-target effect of AZ3146, 
we compared kinetochore localization of wild-type and kinase-
dead GFP-Mps1 fusions after repression of the endogenous ki-
nase by RNAi (Tighe et al., 2008). Strikingly, the kinase-dead 
mutant was about eightfold more abundant at kinetochores 
compared with wild-type (Fig. 5, C and D), supporting the notion 
that inhibiting Mps1’s activity does indeed increase its levels at 
kinetochores. Because FRAP experiments have shown that 
GFP-Mps1 has a relatively short residency time at kinetochores 
(Howell et al., 2004), one explanation is that inhibiting Mps1 activ-
ity reduces its turnover at kinetochores.
Mps1 dimerizes and transphosphorylates
Importantly, the GFP-Mps1 kinase-dead fusion only increased at 
kinetochores when we repressed the endogenous kinase (Fig. 5 C). 
Therefore, we wondered whether Mps1 functions as a dimer that 
requires transphosphorylation to be released from the kinetochore. 
Interestingly, Mps1 transphosphorylation has been demonstrated 
in vitro, but there is no evidence to support dimerization in cells 
(Kang et al., 2007). Therefore, we transiently transfected GFP-
tagged Mps1 into cells stably expressing Myc-tagged Mps1. Myc-
tagged proteins were immunoprecipitated and blotted to detect 
GFP. When we immunoprecipitated Myc-Mps1, GFP-Mps1 was 
readily detectable (Fig. 5 F and Fig. S3 E), which is consistent 
with dimerization. Interestingly, when either fusion was catalyti-
cally active, a portion of the Myc-tagged protein was phosphory-
lated (Fig. 5 F). In contrast, when both fusions were catalytically 
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addition of 40 mM, 0.1% coating reagent (Caliper Life Sciences), 100 mM 
Hepes, pH 7.5, 0.015% vol/vol Brij-35, and 5% DMSO. Inhibitors of Mps1 
activity were identified using a microfluidic chip and laser-induced fluores-
cence (LabChip LC3000; Caliper Life Sciences) to measure the conversion of 
the fluorescent-labeled peptide to a phosphorylated product.
In vitro kinase assays
His-tagged human Mps1Cat encoding amino acids 510–857 was gener-
ated as described previously (Chu et al., 2008). For kinase assays, 500 ng 
was added to buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 50 µg/ml 
BSA, 0.1 mM EGTA, 0.1% -mercaptoethanol, 10 mM MgCl2, and 0.5 µg/ml 
Figure 5. AZ3146 enhances kinetochore localization of Mps1. (A) Images of HeLa stained to detect Mps1 (red), centromeres (ACA; green), and the 
chromosomes after treatment with nocodazole and MG132 for 2 h ± 2 µM AZ3146 (AZ). (B) Bar graph quantitating Mps1 at kinetochores normal-
ized to ACA. Values were derived from ≥345 kinetochores in ≥18 cells with the mean in control cells normalized to 100%. (C) Images of HeLa cells 
expressing GFP-Mps1, either wild type (WT) or kinase dead (KD), stained to detect GFP-Mps1 (green), centromeres (ACA; red), and chromosomes. Note 
that endogenous Mps1 was first repressed by RNAi. Before fixation, cells were treated with nocodazole and MG132 for 2 h with or without AZ3146. 
(D) Bar graph quantitating GFP pixel intensities at kinetochores normalized to ACA. Values were derived from ≥240 kinetochores in ≥17 cells with the 
mean in controls cells normalized to 100%. (E) Images of HeLa cells expressing GFP-Mps1 treated with or without AZ3146 and a bar graph scoring direct 
GFP fluorescence from kinetochores as high, medium, or low are shown. Data are representative of two independent experiments in which ≥50 cells 
were counted. Ctrl, control. (F) Immunoblots of anti-Myc immune complexes isolated from HEK293 cells stably expressing Myc-tagged Mps1 transgenes 
and transiently transfected with vectors encoding GFP-tagged Mps1 transgenes, either wild type or kinase dead. Membranes were blotted as indicated. 
IP, immunoprecipitation. (A and C) Insets show higher magnification views of individual kinetochore pairs (boxed regions). Error bars indicate SEM. 
Bars: (A, C, and E) 5 µm; (A and C, insets) 0.5 µm.
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(Millipore), blocked in 5% milk, and primary antibodies were added over-
night. After washing and incubation with appropriate secondary anti-
bodies, proteins were visualized using chemiluminescence (SuperSignal; 
Thermo Fisher Scientific) and imaged on film (Biomax MR; Kodak). For 
immunofluorescence, cells grown on coverslips were fixed in 1% formalde-
hyde, quenched in glycine, pH 8.5, permeabilized using PBS plus 0.1% 
Triton X-100 (PBST), and incubated with primary antibodies. After washes 
in PBST and incubation with appropriate secondary antibodies, cells were 
counterstained with 1 µg/ml Hoechst 33358 in PBST and mounting in 90% 
glycerol and 20 mM Tris-HCl, pH 8.0. To visualize microtubules, cells were 
preextracted in 100 mM Pipes, 1 mM MgCl2, 0.1 mM CaCl2, and 0.1% 
Triton X-100 for 90 s before fixation in 4% formaldehyde in the same buffer 
for 10 min. To stain for CENP-E, cells were preextracted with a buffer con-
taining 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% BSA, and 0.2% 
Triton X-100 for 2 min before fixation with 4% formaldehyde in PBS (Chan 
et al., 2000). Phos tag (Wako Chemicals USA, Inc.) was used according 
to the manufacturer’s instructions. In brief, 25 µM Phos tag and 50 µM 
MnCl2 were added to standard SDS-PAGE gels containing 6% acrylamide 
and visualized by immunoblotting.
Image acquisition and processing
Immunofluorescence images were acquired at room temperature on a resto-
ration microscope (Delta Vision RT; Applied Precision) using a 100× 1.40 NA 
Plan Apo objective and a filter set (Sedat Quad; Chroma Technology 
Corp.). The images were collected at room temperature using a charge- 
coupled device camera (CoolSNAP HQ; Photometrics) with a z-optical spac-
ing of 0.2 µm. Raw images were deconvolved using the SoftWorx software 
(Applied Precision), and maximum intensity projections of these deconvolved 
images are described in Results and discussion. Time-lapse microscopy was 
performed on a manual microscope (Axiovert 200; Carl Zeiss, Inc.) equipped 
with an automated stage (PZ-2000; Applied Biosystems) and an environmen-
tal control chamber (Solent Scientific), which maintained the cells at 37°C in 
a humidified stream of 5% CO2. Imaging was performed using either a 32× 
0.40 NA long-distance A-Plan or a 40× 0.75 NA Neo Fluor objective. Shut-
ters, filter wheels, and point visiting were driven by MetaMorph software 
(Universal Imaging). Images were taken using a camera (CoolSNAP HQ; 
Photometrics), and individual tagged image file format files were imported 
into PhotoShop (Adobe) for printing or into QuickTime (Apple) for videos.
Online supplemental material
Fig. S1 shows that AZ3146 does not inhibit Cdk1 or aurora B. Fig. S2 
shows that AZ3146 overrides the spindle checkpoint. Fig. S3 shows that 
Mps1 activity is required for kinetochore localization of CENP-E. Table S1 
lists the PCR primers used in this study. Table S2 lists the antibodies used in 
this study. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201002133/DC1.
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Figure S1.  AZ3146 does not inhibit Cdk1 or aurora B. (A) Immunoblot of mitotic-arrested HeLa cells treated for 2 h with MG132 and either AZ3146 (AZ; 
Mps1 inhibitor), ZM447439 (ZM; aurora B inhibitor; Ditchfield et al., 2003), or RO-31-8220 (RO; Cdk1 inhibitor; Tighe et al., 2007) and blotted with an 
antibody to detect phosphonucleolin. Bub3 is used as a loading control. AZ3146 does not inhibit phosphorylation of nucleolin, suggesting that it does not 
target Cdk1. (B) Phos tag immunoblot of cell extracts isolated from interphase cells or nocodazole (Noc)-arrested cells treated with -phosphatase (P) ± 10 
mM sodium orthovanadate (P + I), demonstrating that the super-shifted species are Mps1 phospho forms. (C) Phos tag immunoblot of extracts isolated from 
interphase cells or nocodazole-arrested cells treated with MG132 (MG) and either AZ3146 or ZM447439 for 2 h. When isolated from mitotic cells, Mps1 
appeared as a major band (arrowhead) and a minor slower-migrating band (asterisk). The super-shifted isoform of Mps1 (asterisk) is reduced upon treat-
ment with either AZ3146 or ZM447439. The faint super-shifted aurora B isoform (arrow) is absent in the presence of ZM447439. Short and long expo-
sures of the aurora B blot are shown. Collectively, these data are consistent with aurora B being upstream of Mps1. The super-shifted forms of BubR1 are 
not affected by either drug. (D) Immunoblots of nocodazole-arrested HeLa cells treated with MG132 and increasing concentrations of AZ3146 for 2 h, then 
blotted to detect aurora B, aurora B when phosphorylated on threonine 232 in the T loop, and pHistone H3Ser10. Note that although ZM447439 inhibits 
phosphorylation of aurora B and histone H3, AZ3146 does not. Black lines indicate that intervening lanes have been spliced out. (E) Immunofluorescence 
images of cells treated with ZM447439 or AZ3146 for 2 h and stained to detect aurora B, pHistone H3Ser10, and DNA (left); pCENP-ASer7, ACA, and au-
rora A (middle); and pAurora A/B, ACA, and aurora A (right). The cells were also treated with nocodazole (left) or monastrol (middle and right) and 
MG132. Note that ZM447439 inhibits phosphorylation of histone H3Ser10 and CENP-ASer7 as well as the centromere signal revealed by the pan pAurora 
antibody. In contrast, AZ3146 inhibits none of these markers of aurora B activity. (F) Bar graphs scoring pCENP-ASer7 and centromeric pAurora staining as 
either high, medium, or low in cells treated with spindle toxins and MG132 plus either AZ3146 or ZM447439 (as in E), confirming that although 
ZM447439 inhibits CENP-ASer7 and aurora B phosphorylation, AZ3146 does not. Data are representative of two independent experiments in which ≥50 
cells were counted per condition. (G) Projections of deconvolved image stacks showing HeLa cells treated with nocodazole and MG132 plus AZ3146 
and/or ZM447439 and stained to detect Mps1 (red) and centromeres (ACA; green). Insets show magnified views of kinetochore pairs (boxed regions). 
Consistent with data in Fig. 5, kinetochore localization of Mps1 is more apparent in AZ3146-treated cells. However, this is reversed in cells treated with 
ZM447439, suggesting that kinetochore localization of Mps1 requires aurora B activity. AZ3146 was used at 2 µM in all experiments except that shown 
in D. Bars: (E and G) 5 µm; (G, insets) 0.5 µm.
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Figure S2.  AZ3146 overrides the spindle checkpoint. (A) DNA content histograms of HeLa cells treated with either nocodazole (Noc), AZ3146 (AZ), or 
nocodazole plus AZ3146 for 24 h. (B) DNA content histograms of HeLa cells synchronized at G1/S using a double-thymidine block and released into no-
codazole or nocodazole plus AZ3146. (C) Line graph showing mitotic index determined by MPM-2 staining of drug-treated HeLa cells after release from 
a G1/S block. (D) Line graph showing mitotic index determined by MPM-2 staining of drug-treated HeLa cells after release from a nocodazole block. Sym-
bols in D are the same as those in C. (E) Line graph showing mitotic index determined by MPM-2 staining of nocodazole-blocked HeLa cells released into 
taxol or taxol plus AZ3146 ± MG132. (F) Bar graph quantitating cells with separated sister chromatids after release from a 2-h monastrol block into 
MG132 ± AZ3146 (MG + AZ) for 3 h. Images show examples of paired (MG) and separated chromatids (MG + AZ). AZ3146 was used at 2 µM in all 
cases. Bar, 1 µm.
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Figure S3.  Mps1  activity  is  required  for  kinetochore 
localization of CENP-E. (A) Images of HeLa cells treated 
simultaneously with nocodazole, MG132, and AZ3146 
and stained to detect Mad1 and ACA. Mad1 levels are 
scored as low and high in cells 1 and 2, respectively. In 
this protocol, although some cells will already be in mi-
tosis when exposed to the AZ3146, others will enter mi-
tosis in the presence of the Mps1 inhibitor. (B) Immunoblot 
of HeLa cells expressing Myc-tagged Mad2 proteins 
blotted with antibodies to detect the Myc tag. WT, wild 
type; RQ, Mad2RQ; C, Mad2C. (C) Immunofluores-
cence images of interphase HeLa cells expressing Myc-
tagged Mad2C and Mad2RQ proteins stained with 
antibodies to the Myc tag. (D) HeLa cells harboring an 
RNAi-resistant and tetracycline-inducible Myc-tagged 
Mps1M602A transgene were transfected with an shRNA 
designed to repress endogenous Mps1 (Tighe et al., 
2008). Tetracycline was used to induce Mps1M602A, thus 
restoring Mps1 function (Tighe et al., 2008). The cells 
were treated with monastrol for 2 h to inhibit bipolar 
spindle assembly. After monastrol washout, the ATP ana-
logue 1NM-PP1 was added for 1 h to inhibit the enzy-
matic activity of Mps1M602A. The cells were fixed and 
stained to detect CENP-E (red), centromeres (ACA; 
green), and DNA. Insets show magnified views of indi-
vidual kinetochore pairs (boxed regions). In controls, 
i.e., cells retaining endogenous Mps1 activity, CENP-E 
is readily apparent at kinetochores. In contrast, in cells 
in which Mps1 activity is inhibited, kinetochore localiza-
tion of CENP-E is severely affected; note that although 
background spindle staining is apparent, kinetochores 
are not. (E) Immunoblots of anti-Myc immune complexes 
isolated from HEK293 cells stably expressing Myc-
tagged Mps1 transgenes and transiently transfected 
with vectors encoding GFP-tagged Mps1 transgenes, ei-
ther wild-type or a kinase-dead mutant. Membranes 
were blotted as indicated.
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Table S1. PCR primers used in this study
Oligo Sequence Purpose
1 5-CACGGATCCGCGCTGCAGCTCTCCCGG-3 Forward primer for amplification of Mad2
2 5-CACGCGGCCGCTCAGCTATTTACTTTGTGGATTGTAG-3 Reverse primer for Mad2C (196–205)
3 5-GAAATCCGTTCAGTGATCGAAGCGATCACAGCTACGGTGAC-3 Forward mutagenic primer for Mad2 R133E, Q134A
4 5-GTCACCGTAGCTGTGATCGCTTCGATCACTGAACGGATTTC-3 Reverse mutagenic primer for Mad2 R133E, Q134A
Table S2. Antibodies used in this study
Antibody Description Dilution Source
SAA.1 Sheep anti–aurora A 1:5,000 Girdler et al., 2006
SAB.1 Sheep anti–aurora B 1:1,000 Girdler et al., 2006
SB1.3 Sheep anti-Bub1 1:1,000 Taylor et al., 2001
SB3.2 Sheep anti-Bub3 1:500 Gurden, 2010
SMP1.1 Sheep anti-Mps1 1:1,000 Tighe et al., 2008
ACA Human anticentromere 1:500 B. Earnshawa
9B10 Mouse anti-Mad1 1:500 Abcam
SM2.2 Sheep anti-Mad2 1:500 Johnson et al., 2004
4A6 Mouse anti-Myc 1:5,000 Millipore
CENP-E Rabbit anti–CENP-E 1:2,000 D. Clevelandb
GFP Rabbit anti-GFP 1:5,000 Abcam
TAT1 Mouse antitubulin 1:100 K. Gullc
pAurora Rabbit anti–pAurora A (Thr288)/ 
B (Thr232)/C (Thr198)
1:2,000 Cell Signaling Technology
CENP-A Rabbit anti–CENP-A 1:200 Millipore
Phospho–CENP-A Rabbit anti–phospho (Ser7) CENP-A 1:1,000 Millipore
PH3 Rabbit anti–phospho (Ser10) histone H3 1:500 
(WB, 1:10,000)
Millipore
MPM-2 Mouse anti–MPM-2 1:2,000 Millipore
TG3 Mouse anti-phosphonucleolin 1:25 P. Daviesd
Cy2-, Cy3-, and Cy5-anti–  
 sheep/mouse/rabbit/human
Conjugated secondaries 1:500 Jackson ImmunoResearch Laboratories, Inc.
HRP anti–sheep/mouse/rabbit Conjugated secondaries 1:2,000 Invitrogen
FITC-anti–mouse Conjugated secondary 1:1,000 Jackson ImmunoResearch Laboratories, Inc.
WB, western blot.
aUniversity of Edinburgh, Edinburgh, Scotland, UK.
bUniversity of California, San Diego, La Jolla, CA.
cOxford University, Oxford, England, UK.
dAlbert Einstein College of Medicine, Yeshiva University, New York, NY.
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